🇺🇸 USA — Schedule III takes effect 28 April as §280E relief and the expedited DEA pathway recast the federal cannabis stack

🔭 On the radar: DEA Schedule III hearings open 29 June (60-day applications, ~6-month review). November 12 2026 hemp-THC ban (P.L. 119-37, 0.4 mg/container) still scheduled — House delay amendment (to Nov 2027) and Senate state/tribal opt-out competing.

🏛️ Regulation — Schedule III becomes federal reality: §280E relief, expedited DEA pathway and the post-rescheduling implementation cycle

Schedule III became federal reality on 28 April (DEA hearings 29 June); the 12 November 2026 hemp-THC ban held as state containment accelerated; Massachusetts modernised state-level governance ahead of Virginia, California and Pennsylvania; and federal research access plus wellness-payer integration extended the policy frontier around the new schedule.

Schedule III delivers §280E relief and the expedited DEA pathway as the federal pillar shifts. FDA-approved and state-licensed medical marijuana moved to Schedule III via DOJ Order No. 6754-2026, signed 23 April by Acting AG Todd Blanche; the Federal Register final rule is effective 28 April and DEA hearings open 29 June — converting §280E tax relief from policy abstraction into operator-level reality.

• The federal scheduling cycle moves from political deadlock to expedited rulemaking.
  • DOJ/DEA’s order followed Trump‘s 18 April public push on the AG and the Bondi → Blanche rotation, with a Reuters lead framing scope and limits; investor framings cite tax cut ~70% → ~21%, NYSE/Nasdaq uplisting and ETF eligibility.
    • Parallel coverage in Bloomberg, BBC and Newsweed confirms the framing as historic federal reform.
  • The Federal Register Final Rule (AG Order No. 6754-2026) confirms 28 April effective date with a 60-day application window and ‘deemed approved’ status absent contrary notice.
  • Patient-rights agenda sharpens: an organ-transplant discrimination case prompted ASA to respond; D.C.‘s self-certification programme faces re-papering as practitioner same-day signatures become required.

Hemp-THC sector navigates the 12 November 2026 cliff-edge as state containment accelerates. House passed the 2026 Farm Bill (H.R. 7567, 224–200) without delaying the 12 November 2026 hemp-THC product ban (P.L. 119-37, 0.4 mg/container); ATACH mapped the total-THC framework and six state archetypes — leaving operators with a six-month reformulation runway against an accelerating state-containment patchwork.

• Federal cliff-edge holds while lawmakers float opt-outs and state pre-emption accelerates.
  • Lawmakers moved to delay or sidestep the November ban: Rep. Andy Barr‘s Lawful Hemp Protection Act tightens synthetic intoxicants while preserving wellness CBD, with House delay-to-Nov-2027 and Senate state/tribal opt-out amendments competing.
  • Texas hemp businesses sued over total-THC testing rules and won a TRO blocking the smokeable-hemp ban ahead of the 23 April hearing.
  • New Jersey restricted intoxicating hemp sales to licensed dispensaries; Ohio (Franklin County) issued a TRO partially blocking SB 56 for two retailers; Tennessee HB 1376 capped hemp-derived cannabinoids at 0.3% and tightened age rules.

Massachusetts modernisation leads state-level reform as Virginia, California and Pennsylvania recalibrate. Governor Healey signed H.5350 — restructuring the CCC 5 → 3 commissioners, doubling the adult-use possession limit to 2 oz, capping operators at six licences and codifying statewide delivery — while Virginia‘s legislature rejected Spanberger’s amended substitute and California‘s AB 2532 beverage-cap proposal drew operator pushback.

• State governance bifurcates between modernisation, retail-launch delays and tax-revenue defence.
  • Massachusetts implementation: an administrative order sets the 2 oz daily limit with equivalency (10 g concentrates; 1,000 mg edibles), with parallel bill text codifying purchase limits and equivalency guidance.
  • New York CCB approved 27 new adult-use licences and adopted Cannabis Showcase Event regulations as the market crossed US$3bn.
  • California AB 2532 beverage THC-cap proposal faces operator pushback; AB 8 took effect banning THC in hemp extracts for foods.
  • Pennsylvania governor framed adult-use legalisation as worth US$1.3bn over five years.
  • Virginia Senate rejected Spanberger’s amendments 21–18 on adult-use sales (HB642/SB542), delaying retail launch; the governor signed parental-rights and hospital-medical-cannabis bills.
  • Colorado HB 26-1409 advances to eliminate the 3.5% local marijuana tax kickback amid a 40% sales decline; Tennessee lawmakers moved to require legislative approval for state rescheduling; Missouri regulators are seeking alternatives to Metrc.

Research access and wellness-payer integration expand around the new schedule. Federal research barriers loosen as Reps. Titus & Omar introduced the Higher Education Marijuana Research Act on 20 April and Medicare launched a CBD pilot covering up to US$500/patient/year for seniors — extending the Schedule III pivot into research and payer infrastructure.

• Research access and wellness-payer expansion advance in parallel with the schedule change.
  • The Higher Education Marijuana Research Act (20 Apr) seeks to lift Schedule I barriers for academic research.
  • CMS BEI Substance Access programme: FloraWorks TruCBN 50mg softgels positioned as implementation-ready; a cannabis biopharma firm is seeking to join the SAM lawsuit over the CMS hemp/CBD pilot.
  • D.C. Mayor proposed the Medical Cannabis Beverage Product Amendment Act to allow medical cannabis and alcohol companies to partner on THC drinks.

💼 Market — Schedule III ignites operator repositioning as Trulieve, Vireo/FLUENT and LEEF/Himalaya turn §280E relief into M&A

Schedule III‘s 28 April effective date triggered immediate operator repositioning and deal logic (Trulieve, Vireo/FLUENT, LEEF/Himalaya); mature-state demand bifurcated between Michigan‘s −7.8% YoY price compression and New York‘s ~2 m adult consumers crossing US$3 bn; and consumer trust, functional cannabinoids and GLP-1 substitution forced a product-architecture reset.

Trulieve files first DEA registrations as Vireo/FLUENT and LEEF/Himalaya kick off the Schedule III deal cycle. US cannabis operators began repositioning around Schedule III’s 28 April effective date as Trulieve filed first DEA registrations for 200+ medical dispensaries and Vireo Growth announced an all-stock acquisition of FLUENT (~74 Florida stores, US$71.5m FY25 revenue, close expected Q4 2026) — turning §280E tax relief into immediate operator-level deal logic.

• Medical platforms move first as Schedule III unlocks §280E relief and triggers cross-border supply moves.
  • Trulieve filed under the DEA’s expedited pathway covering manufacture, distribution and dispensing of Schedule III products; applications must be lodged within 60 days, with licensure deemed approved unless notified.
    • Village Farms flagged its 7M sq ft of US cultivation assets as ready for activation once regulators permit, citing its 2025 administrative-process advocacy as a contributing factor to the order.
  • Vireo Growth / FLUENT consolidates Florida scale at ~144,000 sq ft of combined canopy and ~74 stores at an exchange ratio of 0.0705359 Vireo shares per FLUENT share; pending court, shareholder and regulatory approval, close expected Q4 2026.
    • LEEF Brands agreed to acquire Himalaya Vapor (Standard Holdings) for ~US$2.5m (13.69M shares + US$100k warrants at C$0.25), extending the cycle into California concentrates and vertical integration via Salisbury Canyon Ranch.
  • Cresco Labs was conditionally awarded a Texas Compassionate Use licence — a vertically integrated permit (cultivate, process, dispense) opening organic entry into the second-most populous US state (~30M population).
  • Doja Pak, partnering with CP Medical, entered Germany (via Bloomwell) and the UK (via Mamedica) with Doja Z, Permanent Marker, CP Z and CP Super Lemon Haze — sourced via Thai GACP cultivation and Portuguese GMP processing through Blossom Pharma.

Mature-state pricing compression persists as disciplined operators reset guidance against normalised demand. Michigan‘s adult-use market posted March sales of US$255.5m (−7.8% YoY, +8.9% sequential) with wholesale flower at US$987/lb, while Grown Rogue introduced multi-year guidance through 2027 (FY25 revenue US$32.4m, +22%; adj. EBITDA US$5.4m, 16.5% margin) — framing April’s reality as margin defence under price normalisation, not growth.

• Demand bifurcates between mature-state compression and normalisation in scaled adult-use markets.
  • Michigan March sales (−7.8% YoY) extend a multi-quarter pricing slide; the state’s 1 January wholesale tax pulled December orders forward and flattened January, with February–March recovering — a pattern Grown Rogue cited as the source of MI’s −22% revenue contribution to its FY25 P&L.
  • New York‘s recreational market reached ~2 million adult consumers five years after legalisation, with cultivation brand Sacci now in ~250 dispensaries and THC beverage brand Dirty Lemonade (Canna-House) signalling category broadening beyond flower; CCB cleared 27 new adult-use licences in April as the market crossed US$3bn.
  • Grown Rogue guided 2026 revenue US$32–35m / adj. EBITDA US$6–8m and 2027 US$50–58m / US$14–18m, with flowering canopy expanding 37,000 → 58,000 sq ft (+55%) across five states by end-2026 (Illinois turnkey lease, Minnesota new-build) at indoor biomass cost <US$225/lb.
    • LEEF Brands posted Q4 2025 revenue US$8.3m (+38.9%) and gross margin 45.5% (+23.5pp YoY), closing an initial US$4.5m of a potential US$8m raise (Mindset Capital, Aaron Edelheit) to scale Salisbury Canyon Ranch 65 → 180 acres — biomass at ~US$8/lb vs US$20–50/lb externally.

Purity, functional cannabinoids and GLP-1 substitution rewrite the consumer-product playbook. Consumer trust displaced potency as the dominant April signal: a Royal Queen Seeds survey found 74% of US adults very concerned about pesticides in cannabis (vs alcohol) while California‘s CBN edibles category grew from 4% to ~25% share (2020–2025), framing a market increasingly sorted by functional outcome and clean-label positioning rather than THC%.

• Trust, functional cannabinoids and GLP-1 substitution converge to reshape April’s product mix.
  • Royal Queen Seeds survey (with 68% of Gen Z viewing cannabis positively vs alcohol) corroborates the wellness-substitution thesis already visible in dispensary purchasing patterns and Forbes‘ framing of cannabis as the cleaner-label alcohol alternative for younger cohorts.
  • Minor cannabinoids (CBN, THCv) commercialise around sleep, focus and metabolic-health positioning; Grand View Research projects the US minor-cannabinoid market US$11.5bn (2023) → US$33.3bn (2030) at ~15% CAGR, with CA retail data already showing CBN edibles +525% share gain over five years.
  • Hemp-THC beverage brands begin reformulating ahead of the 12 November 2026 federal cap: Nowadays launched Extra Light low-dose drinks explicitly designed to clear the anticipated 0.4 mg/container threshold, signalling a sector-wide product-architecture reset rather than a wait-and-see posture.
  • GLP-1 medications are reshaping dispensary product guidance: Stoop’s NYC and Curio Wellness are steering GLP-1 patients toward lower-dose edibles, vapes and tinctures as slowed gastric emptying delays edible onset and raises re-dosing risk; NIDA is funding a tirzepatide trial for cannabis use disorder, with a Brigham and Women’s Hospital trial to follow later in 2026.

🔬 Science — Schedule III rescheduled-era evidence base: Epidiolex read-out, stable population-health signals and measurement R&D

Population-health evidence stabilises around moderating youth use and stable CUD-suicidality. A Lancet Psychiatry systematic review framed cannabinoid therapy for mental disorders and SUDs as offering limited benefits and higher odds of adverse events, while a 2014–2023 NSDUH analysis found CUD-associated suicidal-ideation odds elevated but stable across the decade — anchoring the evidence base for the post-Schedule III clinical pathway.

• Adolescent and youth-cohort data trend toward moderation, while paediatric CUD signals psychiatric risk.
  • JAMA Network Open mapped Northern California adolescent cannabis use rising after legalisation passage and falling after COVID-19 (2011–2024), and the Minnesota Department of Health confirmed continued declines in youth use post state-legalisation.
  • A longitudinal youth-cohort study (Neuropsychopharmacology) combined self-report and toxicology to characterise neurocognitive trajectories among young cannabis users, refining the framework used in regulatory and parental-rights debates.
  • An American Journal of Psychiatry propensity-matched cohort linked paediatric CUD to higher psychiatric-diagnosis risk while adult CUD showed lower relative risks — a bifurcation that aligns with the 0.3% hemp-cannabinoid cap and youth-access tightening across Tennessee and New Jersey.
  • A parallel AJP review on co-occurring psychiatric and substance-use disorders flagged unmet needs as the schedule change exposes the medical system to expanded therapeutic referrals.

Pharma pipeline consolidates around the Epidiolex AAN read-out as real-world oncology data temper the opioid-sparing narrative. Jazz Pharmaceuticals presented six Epidiolex® and Xywav® papers at AAN 2026 (18–22 Apr, Chicago) including the EpiCom TSC interim, while Epic’s COSMOS dataset found early cannabinoid prescribing in GI-cancer patients was not associated with reduced opioid use — tempering the opioid-sparing narrative as Schedule III opens registered-medicine pathways.

• Therapeutic-motive and behavioural-trial research extends beyond the FDA-approved indications.
  • An ADHD-and-therapeutic-cannabis-use-motives study characterised symptom-management motivations among adult patients, informing how Schedule III medical-cannabis programmes will frame off-label use.
  • An AJP trial found approach-bias modification was not superior to sham or usual care in smoking cessation at six-month follow-up, narrowing the evidence base for adjacent behavioural-addiction interventions.

Product safety, measurement and discovery R&D build the infrastructure for the rescheduled era. A Journal of Pediatrics study linked paediatric hemp-cannabinoid poisonings to higher US admissions00141-1/abstract), and a federally funded team unveiled a low-cost 3D-printed colourimetric THC breathalyser concept — a roadside-detection step-change arriving as state hemp regulations and DUI enforcement frameworks tighten.

• Measurement, harm-reduction and discovery-pipeline tools advance in parallel.
  • A US mobile breathalyser self-monitoring study (AJP) found BAC self-estimation accuracy improved and heavy drinkers’ average BAC declined — relevant to the cross-substance policy frame as alcohol/cannabis substitution accelerates.
  • PAX‘s research paper reported vapourisation cuts harmful combustion byproducts versus joints by up to 99%, providing harm-reduction evidence that will shape post-Schedule III product framing alongside CBN/THCv functional positioning.
  • A Plant Direct paper characterised the structure of the chemotype-determining locus in Cannabis sativa (29 Apr), and an Expert Opinion on Drug Discovery review on machine-learning-driven selective cannabinoid-ligand discovery signal the upstream genetics and drug-discovery pipelines feeding Schedule III’s pharma-grade product roadmap.

🇩🇪 Germany — GKV flower cut formalised as Referentenentwurf, BGH closes telemedicine ad channels and EKOCAN 2nd interim documents 413 clubs

🔭 On the radar: GKV-Beitragssatzstabilisierungsgesetz cabinet decision (target 29 Apr 2026) and 2027 effective date; BGH I ZR 118/24 ECJ referral on §9 HWG telemedicine ad-ban (≤3-year timeline); HHC 27th Ordinance (draft 23 Apr) and Bundestag draft 21/2116 on Rauschklausel deletion pending enactment; Curaleaf–Four 20 Pharma integration into Curaleaf International from Q2 2026; Dietrich Bonhoeffer Clinic 30 June closure unless reimbursement reform intervenes.

🏛️ Regulation — GKV flower-delisting bill formalised as Referentenentwurf, BGH closes telemedicine ad channels and EKOCAN 2nd interim logs 413 clubs

Three regulatory developments in April 2026: (1) a draft GKV cost-containment bill removes cannabis flower from statutory reimbursement (cabinet target 29 Apr; effective 2027); (2) BGH I ZR 74/25 (26 Mar; coverage through April) confirms §10 HWG applies in full to prescription medical cannabis; (3) EKOCAN’s second interim report (1 Apr, 222 pp.) reports total demand at 670–823 t/yr, no consumption surge, and 366 approved clubs by Oct 2025.

Draft GKV cost-containment bill: cannabis flower removed from statutory reimbursement; extracts, dronabinol drops and nabilone retained. The draft bill was published mid-April as a Referentenentwurf; comment window closed 20 Apr; cabinet target 29 Apr; effective 2027. BMG projects €130–180 m/yr savings (2027–2030), cumulative ≈€625 m by 2030; AOK methodology assumes flower dispensing of 15–100 g/patient/month without THC normalisation, while association figures put per-1,000 mg THC costs at €40–90 for flower (≈22% THC), ~€380 for Sativex and ~€400 for oily dronabinol drops — the cost paradox at the heart of the bill.

• Pharmacy and supply-chain pushback frames the bill as clinically and economically misjudged.
  • VCA (Verband Cannabisversorgender Apotheken) warns the substitution premise is unsound — flower and extracts are not pharmacokinetically substitutable; patients face out-of-pocket costs many cannot bear.
    • Pharmazeutische Zeitung (Dölger, 21 Apr) ties AOK figures to the savings trajectory and surfaces the cost-per-1,000 mg THC arithmetic that contradicts BMG framing.
      • krautinvest argues that better use of existing AOK data would expose flower as the cheapest reimbursed THC delivery form.
• Patient and consumer associations form a joint front against the delisting.
  • BDCan (Bundesverband der Cannabis-Patienten) opposes deletion outright on patient-care grounds.
    • DHV files a position paper framing the bill as a back-door push toward extracts that mostly benefits pharma incumbents.
• Academic and macro critique converges from a different angle.
  • Heino Stöver (Frankfurt UAS) calls the cut medically questionable and economically negligible — €0.1 bn against a multi-billion GKV deficit.

BGH I ZR 74/25 (26 Mar 2026; coverage 14 Apr): §10 HWG advertising ban applies in full to prescription medical cannabis; questionnaire-only online platforms become non-compliant. König’s Hanf Magazin deep-dive (14 Apr) covers implications for telemedicine and B2C marketing.

• BGH I ZR 118/24 (26 Mar) refers a parallel §9 HWG question to the ECJ — questionnaire-only telemedicine consultations against the EU Services Directive (≤3-year timeline); KFN+ Niermann’s krautinvest synthesis (27 Apr) flags enforcement-proceeding fines up to €250 k.
• Düsseldorf LG (23 Apr, Az 37 O 55/25, not yet final) holds pharmacies co-liable for filling Dr. Ansay questionnaire prescriptions under §17(8) ApoBetrO; AKNR press release confirms the judgment, obtained by Hoffmann/Mecking/Douglas; LG Berlin II preliminary injunction (4 Mar, 101 O 47/23) sits in the same line.
• Cansativa‘s ICBC Berlin recap (16 Apr) frames case-law as a de facto MedCanG-reform substitute: BMG draft “probably not realistic”; compliance-grade operators outlast telehealth-only models.

Prescribing-quality and patient-rights items, April 2026: evidence-based THC ceilings on Rx flower (Ärzteblatt / ZIS Hamburg), industry compliance brochures (BPC, BvCW), the OVG NRW patient-privilege ruling, and the LAKT-led TI e-prescription proposal.

• Ärzteblatt (1 Apr) on the EKOCAN-aligned KCanG 2nd interim (ZIS Hamburg, Manthey): prescribed flower averages ~25% THC vs evidence base ≤10%; risks rise above 15%; recommends MedCanG amendment routing high-potency flower to BtMG annex.
• BPC’s “Information on Recourse” brochure (9 Apr, DocCheck-gated) and BvCW ELEMENTE Vol. 26 update prescribing safety and the track-and-trace position (GACP, QR codes, 2019 US vape-crisis precedent).
• OVG NRW (25 Mar, Az 16 B 101/25) defines patient-privilege loss — 500 g possession vs 30 g/month script, growtent, THC 33.2–50.8 ng/ml vs 3.5 ng/ml threshold; “misuse” defined as more-than-sporadic non-prescribed use; §11(7) FeV — no MPU.
  • Counter: DHV (Klimpel, 23 Apr) — Herford authority dropped Dominik B.’s revocation case after Eisenmann’s 7-page submission.
• Thuringia LAKT + KV + Barmer + pharmacists’ association push BMG for mandatory TI e-prescriptions for cannabis and other BtM scripts, citing ~€100 m/yr forgery damages.

EKOCAN second interim report (1 Apr, 222 pp.): total demand 670–823 t/yr; informal “social supply” 35.2%; home cultivation 5.4% (H1 2024) → 21.4% (H2 2025); 366 clubs approved by Oct 2025 (BvCW says >400 since), supplying ≤3.5% of users. Five recommendations: club-framework reform, a THC cap on freely prescribable flower, stronger LE on organised crime, better youth early-intervention, and HWG §10 enforcement against telemedicine.

• Coalition pushback frames the report as ammunition for tightening: CDU/CSU ministers call for amendments citing the +198% YoY surge in medical-cannabis imports; Interior Minister Alexander Dobrindt accuses EKOCAN of presenting a “distorted picture of reality”; project lead Jörg Kinzig (Tübingen) rebuts as “completely unfounded”, citing 2,000+ police interviews and US/Thai oversupply behind seizure records.
• Clinical pushback from DGPPN, DG-Sucht and DGKJP (joint statement, reinforced in DIE ZEIT 10 Apr) brands the evidence base thin: observation window 5–10 years short; harmful-use share rising as totals stay flat; the old police-to-counselling referral pathway is gone with no replacement; high-potency medical flower blurs the medical/recreational line.
• Greens drug-policy spokesperson Linda Heitmann (1 Apr) frames the same data oppositely — black market visibly retreating for the first time — and presses Länder to actively support club approvals and the CDU/SPD coalition to authorise controlled-sale pilot projects as the missing displacement lever.
• BKA President Holger Münch (7 Apr) calls the black market “unbroken”: the “25-gram problem” (25 g public / 50 g home) makes street-dealer prosecution near-impossible; ≈293 fully licensed clubs against thousands of pending applications; new US- and Canada-origin cannabis appears in seizures alongside the traditional Spain/Morocco supply.
• The first statistically clean PKS post-CanG cuts the other way: DHV’s read of PKS 2025 (BKA, 20 Apr) shows 42,823 KCanG offences, −64% YoY; for the first time consumption-related cases are no longer the majority; illicit trade (17,727) plus smuggling (7,366) make up 58% of the remaining caseload — the structural shift the law was designed to produce.
• NRW Interior Minister Herbert Reul (WAZ, 31 Mar) builds a counter-narrative around road safety and clinical risk: NRW cannabis-related road accidents 506 (+23%), an all-time state record; ≈25,000 drug-driving stops (vs 19,800 in 2024); LVR-Klinik Langenfeld data showing cannabis-related psychoses +40%; police pre-tests still uncalibrated to the new 3.5 ng/ml THC blood-serum threshold (up from 1.0 ng/ml).
• Collateral damage hits youth-prevention infrastructure: Germany’s largest youth addiction rehab clinic (Dietrich Bonhoeffer Clinic, Ahlhorn, 60 beds) announces 30 June closure — pension-insurance reimbursement runs ~70% short of cost, deficit climbing to €3 m from 2027; if it closes only 20 youth rehab beds remain nationally against ~1,100 needing a place each year. The FRED early-intervention programme (>230 sites) is effectively defunct because police lost the sub-25 g referral trigger — exactly the care-gap mechanism DGKJP flags.

Club rollout: 413 approved clubs against 864 applications. RND survey via DIE ZEIT (9 Apr): NRW leads in absolute terms (118 approvals, 219 applications); Niedersachsen leads per capita (85 clubs, 1.06 per 100k inhabitants), Hamburg 0.91, Brandenburg 0.82; Bayern last at 0.07 per 100k (9 approved, 3 already abandoned cultivation).

• Niedersachsen Chamber of Agriculture (Apr, Hanf Magazin 25 Apr) becomes the first approval authority to publish a public list of approved clubs — Minister Miriam Staudte treats transparency as part of the law’s black-market-displacement objective; Bayern and several other states still refuse to publish, undermining the same goal.
• Thuringia‘s State Office for Agriculture goes the opposite way: it imposes mandatory batch testing on every single harvest; Erfurt and Weimar clubs have suspended distribution and announced legal action on proportionality grounds. The structural problem: KCanG delegated club implementation to the Länder without binding minimum standards, producing comparable clubs operating under fundamentally different conditions.
• The Würzburg administrative court (judgment 4 Feb 2026, W 6 K 25.797, published 22 Apr) cuts Bayern’s “special path” sharply: state-set pollutant-residue maxima are struck down (federal competence, no implementing federal regulation in place); mandatory ID-copying of all members is rejected on data-minimisation grounds (PAuswG + GDPR); only the active-participation requirement (minimum hours, documentation) is upheld as a legitimate condition.
• OLG Dresden (second-instance ruling, 1 Apr) fully dismisses a lawsuit against Grünhorn — small in isolation, but stacks with the BGH advertising-ban ruling and the AG Amberg hemp acquittal below into a coherent line of pro-compliant-operator jurisprudence, materially compressing investor-perceived legal risk.

Hemp/CBD: HHC draft 27th Ordinance (23 Apr) and AG Amberg industrial-hemp acquittal (27 Apr). The draft 27th Ordinance amends the Narcotics Act schedules to add HHC to Schedule II, transposing the UN CND 2025–26 resolutions; only synthetic, isolated or enriched HHC (plus stereoisomers and esters) is controlled — naturally occurring trace HHC in the cannabis plant stays under the recreational or medical-cannabis acts.

• On 27 Apr AG Amberg acquitted an industrial-hemp trader of unlawful trade in product below 0.3% THC, and the prosecutor withdrew the appeal — making the judgment final. The reasoning is structural: with adult legal access under KCanG, the BGH 2021 “theoretical misuse for intoxication” rationale that underpinned the Rauschklausel prosecutions collapses.
• Sector damage was already locked in before the ruling: −1,842 ha of industrial-hemp acreage in 2025, 127 farmers exited, and museums and research institutions lost cultivation permits because the legal uncertainty became unmanageable.
• Bundestag draft 21/2116 (referred to committees in March; plenary date unset) would delete the Rauschklausel outright, lift the industrial-hemp THC threshold to 1%, and permit indoor cultivation — the first structural fix in years and a direct test of whether the new coalition will follow the courts’ lead.

💼 Market — Bloomwell barometer shows 84.5% prescription cuts as PHAGRO maps 1,300 strains across 58 suppliers and Curaleaf completes Four 20 Pharma buyout

Three market-side data points in April 2026: (1) Bloomwell Q1 2026 Cannabis Barometer (n=3,528) reports an 84.5% average prescription reduction and 58.9% full discontinuation across conventional drugs; (2) PHAGRO’s strain map counts 1,300 strains across 58 suppliers, average €6.81/g, 78% of SKUs in the €5–10/g band, and calls for wholesale price regulation; (3) König’s Hanf Magazin coverage (16 Apr) reports Germany absorbing ≈66% of Canadian flower exports — see for the Statistics Canada CIMT primary export-flow data.

Bloomwell Q1 2026 Cannabis Barometer (n=3,528 patients). Bloomwell reports an 84.5% average reduction in prescription medication and 58.9% full discontinuation of opioids, sleep aids, antidepressants and anti-inflammatories. Hanf Magazin’s deep dive (25 Apr) reframes the GKV cost debate by quantifying the offsets — 61% drop in opioid use, 75.5% drop in sleeping pills — and notes flower SKUs expanded from ~40 to ~900 while average pharmacy prices fell from €9.30/g to €4.20/g over 24 months.

• SKU proliferation has produced genuine price discovery, but at margins that make the existing operating model untenable.
  • PHAGRO + KrautInvest 2 Apr puts the catalogue at 1,300 strains across 58 suppliers, average €6.81/g with 78% of SKUs in the €5–10/g band; PHAGRO calls for wholesale price regulation as supply outpaces demand.
    • Porstner (KrautInvest, 2 Apr) frames pharmacy economics: efficiency over per-gram margin; fewer than 500 specialised pharmacies handle the bulk of dispensing.
    • 420 Pharma (DLF, 19 Apr) sizes 2025: imports doubled to ~200 t; pharmacy prices €2.99–4.99/g; total market ~€2 bn.
• TAM math from ICBC Berlin sets the ceiling.
  • Whitney (ICBC, 5 Apr) puts current penetration at 200–300 k Rx patients + 500–600 k self-pay against a TAM of 6.2 m (≈9% penetration) — leaving long runway, but only for operators that survive the price reset.

Canada→Germany flower corridor: König (Hanf Magazin, 16 Apr) reports Germany absorbing ≈66% of Canadian flower exports against the ≈€1bn 2026 revenue projection; domestic EU-GMP cultivation “not on the horizon”. König’s Hanf Magazin read (16 Apr) notes Anbauvereinigungen under CanG Pillar 1 serve members only. See for the Statistics Canada CIMT primary export-flow data.

• Aurora’s hybrid Canada-Leuna model is the canonical playbook.
  • Aurora EVP Alex Miller (KrautInvest, 13 Apr) frames the strategic logic: Canada offers scale, Germany takes time, EU-GMP is the competitive moat that determines who serves the European Rx channel.
    • Aurora’s $26.5 M acquisition of Safari Flower (Ontario, EU-GMP) extends international supply capacity; positive Adjusted EBITDA contribution expected from FY2027.
• Alt-origin EU-GMP entrants are scaling into Germany on the same compliance moat.
  • Jersey / Northern Leaf supplied 3,590 kg flower to Germany in 2025; capacity utilisation up from 25% to 75%.
  • Bioxyne (AU) wins Aurora oils/vapes contract for AU/UK/DE.
  • InterCure’s The Flowery Israel targets DE/UK with elite-genetics positioning.
• M&A logic has shifted from cultivation assets to data and patient-flow platforms.
  • Hyde “buy data, not greenhouses” — valuations compressing across five distinct buyer cohorts; cultivation alone no longer commands a premium.
    • KrautInvest summary: prescriptions +3,300% since Apr 2024; data-driven platforms lead.
    • Heimbürger (gunnercooke) — German market trades at a risk discount; earn-out structures rising as buyers price regulatory uncertainty.
    • BoC “Green shoots” recap: Curaleaf Poland integration, Synbiotic stabilises, Aurora-Bioxyne.

Operator results, April 2026. Cantourage preliminary FY2025: revenue €92.8 M (+82.3% YoY), EBITDA €5.7 M (asset-light pan-European medical model).

• Cantourage strategy detail.
  • SdK strategy meeting 7 Apr: asset-light model, ~€100 M FY25 revenue target, 100 k+ patients/month through partner pharmacies.
  • 4investors interview 17 Apr: IFRS conversion saves ~€3.9 M/yr in goodwill amortisation; FR/ES entry monitored, no commitment yet.
• Curaleaf closes its German vertical-integration arc.
  • Full buyout of Four 20 Pharma — integration into Curaleaf International from Q2 2026.
    • Becanex + Curaleaf QMID/PIEX inhalation partnership extends product reach.
    • Vayamed becomes exclusive German wholesale partner for Bedrocan.
    • Canify / IhreApotheken launch CATHAROS marketplace across 7,500 pharmacies.
• Distributor and exporter activity rounds out the operator picture.
  • German distributors: Remexian Pharma ~€67 M revenue and >2.5 t/month dispensing flow (MAZ); Fette Pharma restructured under the Löser/Dobiey investor consortium and pivots to product expansion.
  • ANZ exporters with Germany lines: LGP A$5.5 M Germany sales; Cann Group AMRadV licences + first UK export; ECS Botanics imminent DE shipment.
  • Aurora new product launches — 12 SKUs by Jun 2026 across CA/EU/AU.

Cultivation-association commercial activity, April 2026. Greens spokespeople in Lower Saxony and Bremen report clubs as a lever curbing the local black market. Berlin’s Gourmet Greens Royal one-year operational review (Reinickendorf) reports standardised processes and member-supply structures.

🔬 Science — VER-01 phase 3 (n=820) meets primary endpoint in chronic low back pain as EUDA wastewater ranks Nürnberg 4th in Germany

April 2026 German science outputs: VER-01 phase 3 in chronic low back pain (n=820; reviewed by Kuhn in European Archives of Psychiatry and Clinical Neuroscience, 2 Apr); EUDA 2025 wastewater cycle (Nürnberg 4th in Germany, 6th in Europe for THC-COOH); Fraunhofer IGB HanAkku bio-based fertiliser; and a possible Lower Eocene cannabis fossil re-classified at the Museum für Naturkunde. EKOCAN consumption, pharmacy-pricing and darknet-monitoring data sits in the Regulation and Recreational sections.

VER-01 phase 3 in chronic low back pain (Karst et al; n=820, 12 weeks). Karst et al’s Nature Medicine trial (reviewed by Kuhn in European Archives, 2 Apr) tested VER-01 — a full-spectrum C. sativa DKJ127 extract (2.5 mg THC, 0.02 mg CBD, 0.1 mg CBG plus terpenes/flavonoids per dose) — across a four-phase design. Phase A (n=820, 12 weeks, double-blind vs placebo) met its primary endpoint: pain-intensity MD −0.6 on the 11-point NRS (P<0.001), strengthening to MD −1.5 (P<0.001) in patients with a neuropathic component. NNTB 6.8 for ≥30% pain reduction.

• The phase D randomised-withdrawal arm did not meet its primary endpoint.
  • Time-to-treatment-failure HR 0.75 (P=0.288); the placebo arm did show a significantly greater pain increase (MD −0.5, P=0.034), giving a directional durability signal even without formal significance.
• Tolerability — not dependence — is the binding constraint.
  • Discontinuations 17.3% vs 3.5% placebo; nausea and fatigue significantly more common (P<0.001); 94% of AEs mild-to-moderate.
  • Across up to 12 months, no signals of misuse, dependence or withdrawal — a distinct contrast with the opioid comparator the trial is implicitly benchmarked against.
• Methodological caveats apply.
  • No formal blinding assessment; phase D included only prior-phase responders (selection bias); prior cannabis use beyond the 30-day exclusion window not characterised; external validity limited by product-composition heterogeneity across the cannabis category.

EUDA 2025 wastewater cycle: 115 European cities; Nürnberg 4th in Germany, 6th in Europe for THC-COOH. The EUDA 2025 results (Nord Bayern, 9 Apr) — RKI / Umweltbundesamt cooperation — rank Nürnberg 4th in Germany (behind Erfurt, Berlin, Hamburg) and 6th in Europe; the Netherlands, Germany and Slovenia hold the highest cluster. Cannabis loads were stable 2024 → 2025 against cocaine BE +22%, ketamine +41% and MDMA −16%; clean post-CanG German YoY only becomes available from 2026 because most German cities lack a 2024 baseline.

Fraunhofer IGB HanAkku project: bio-based slow-release fertiliser from hemp shives (1 Apr). The Fraunhofer IGB release (1 Apr) reports the Straubing team (Iwanow, Richter, Roth) using hemp shives — which absorb ~4× their own weight in water — as carriers for nutrients dissolved in Deep Eutectic Solvents, achieving release profiles comparable to conventional 14-month long-term fertilisers without leaving microplastics in the soil. The project concludes 2026; agricultural and horticultural transfer is the next-step milestone, presented at Hannover Messe 2026.

Museum für Naturkunde Berlin: possible Lower Eocene cannabis fossil from Eisleben (Saxony-Anhalt), 17 Apr. The Berlin museum’s press release (17 Apr) revisits a leaf-imprint fossil from Eisleben (Saxony-Anhalt), originally described as Cannabis oligocaenica by Paul Friedrich (1883); newer age classifications place it in the Lower Eocene (~56–48 Mya) — older than Miocene pollen evidence (~20 Mya) and molecular dating of living Cannabis (~28 Mya). Identification is not definitive — diagnostic leaf-surface hairs are not preserved; investigation ongoing.

🇦🇺 Australia — TGA Schedule 9 rescheduling advances as Penington records −28.5% H2 2025 medical-sales fall and Cannatrek/LGP scheme vote slips to 22 May

🔭 On the radar: TGA Schedule 9 rescheduling — ACMS interim decision targeted June 2026, final ~August. NSW roadside drug-testing reform expected May 2026 sitting; Farrer (NSW) federal byelection 9 May. LGP shareholder vote 22 May; LGP–Cannatrek implementation target 1 June 2026 (slipping from 1 May). ODC plant-growth-regulator regulatory review at examination stage; Senate hemp inquiry recommendations pending; Dr Justin Welsh formal reinstatement decision pending.

🏛️ Regulation — Penington logs −28.5% H2 2025 unit-sales fall under TGA-Ahpra enforcement as Schedule 9 rescheduling advances and ODC tightens import quota

Penington Institute documented a 28.5% H2 2025 unit-sales fall in medicinal cannabis (3.70m → 2.65m units) — the first significant decline since 2016 — attributing it to TGA/Ahpra enforcement against 50+ high-volume prescribers. The contraction lands as the TGA’s Schedule 9 rescheduling for THC is ‘already in motion’ ahead of an ACMS interim decision targeted June 2026, and as the Office of Drug Control has adjusted 2026 import forecasts for 89% of importers to free locked-up quota.

TGA confirms its Schedule 9 rescheduling process for THC moved past the consultation phase as the only concrete action tabled after the 2025 medicinal-cannabis review; a separate psychosis safety report is being finalised to feed the same ACMS pipeline.

• ACMS interim scheduling decision is targeted June 2026 with a final decision ~August 2026; regulatory experts urged industry to prepare submissions, since rescheduling is the “only concrete action” on the table.
• TGA is finalising a psychosis safety assessment flagged in the March ACMS discussion paper; the report is expected to shape upcoming reform proposals alongside the rescheduling track.

ODC tightened supply-side oversight on two fronts: 89% of 2026 importer forecasts adjusted to free quota and a regulatory review opened on plant growth regulators (PGRs) in imported flower.

• Office of Drug Control (ODC) told Cannabiz the forecast adjustments were calibrated “by varying amounts” based on 2025 unused permits and forecast accuracy, to prevent the national medicinal-cannabis quota being locked up by inactive permits.
• Domestic cultivators allege widespread use of untested PGRs (paclobutrazol, daminozide) in imported flower; ODC review at examination stage, no enforcement action yet.

Penington’s FOI dataset ties the H2 2025 sales fall to TGA-Ahpra enforcement against 50+ practitioners, while state reforms diverge between Victoria’s blocked anti-discrimination bill and NSW’s pending driving-law reform.

• Penington’s Department of Health FOI dataset attributes the 3.70m → 2.65m unit-sales fall to enforcement against high-volume prescribers and clinics; six infringement notices totalled A$118,800 plus a direction notice to Dispensed Pty Ltd; imports rose from ~45,000 kg (2023) to >77,000 kg (2024), ~80% from Canada.
  • Medical Board of Australia signalled Dr Justin Welsh may return to medicinal-cannabis prescribing under strict conditions, after the November 2025 Ahpra-driven ban on his nationwide telehealth clinic; next step: formal reinstatement decision pending.
• Victoria‘s Legislative Council rejected the Medical Treatment Bill 2026 on 2 April, blocking workplace, tenancy and service-provider protections for prescribed-medication users (including medicinal-cannabis patients) tabled by Legalise Cannabis Victoria on 10 March.
• New South Wales roadside drug-testing reform for prescription holders is delayed but expected in the May 2026 sitting after Premier Chris Minns indicated the government would draft its own legislation.
  • Legalise Cannabis Party named Albury pharmacist Aimee Pearson as Farrer byelection candidate for the 9 May 2026 federal vote, with cannabis driving laws among her top platform priorities.

Legalise Cannabis political slate posted a state-level setback in South Australia and a tactical retreat on 4/20 enforcement risk in Victoria.

• Legalise Cannabis SA polled 2.4% in the Legislative Council (against the 8.3% quota) and 0.9% in the House of Assembly at the 23 March state election, winning no seats; sister parties retain upper-house representation in NSW, Victoria and Western Australia.
• Legalise Cannabis Victoria scaled back 4/20 events to localised gatherings including a “420 High Tea” in Melbourne’s west, citing 2024 enforcement (60 officers, ~40 possession arrests at a ~300-person crowd).

Australian Industrial Hemp Alliance pressed the Senate Rural and Regional Affairs and Transport Committee to remove “unnecessary impediments” as it opened public hearings on industrial hemp.

• AIHA president Charles Kovess told the Senate inquiry “hemp’s time is here”, urging removal of overregulation; next step: committee recommendations pending.

💼 Market — Cannatrek/LGP scheme vote slips to 22 May as Aurora–Bioxyne deal anchors GMP supply across AU/UK/DE and Penington logs −28.5% H2 2025 sales fall

Cannatrek shareholders cleared the LGP scheme of arrangement with 98.44% support (pro-forma US$112 m revenue) while LGP delayed its own share-issuance vote to 22 May and full implementation slipped to 1 June 2026; Aurora anchored an Australia-centric supply rebuild via a 12-month Bioxyne GMP manufacturing deal (oils now, vapes for AU/UK/DE), a US$26.5 M Safari Flower Co. acquisition and a 12-SKU global product roll-out by June; and Penington Institute‘s −28.5% H2 2025 medical-sales fall (3.70 m → 2.65 m) was triangulated by Statistics Canada’s CA$1.06/g landed flower price (−59.6% over two years) and a flat 905-prescriber SAS-B base, testing earnings (record A$21.3 m at Bioxyne) and surfacing capital stress at Cannim and Nexalis.

• Consolidation moved unevenly — Cannatrek cleared the LGP scheme 98.44% but LGP delayed its own share-issuance vote to 22 May, with full implementation now targeted 1 June.
  • Cannatrek shareholders overwhelmingly approved the LGP scheme of arrangement on pro-forma US$112m revenue, US$13m adj. EBITDA and US$15m cash; Cannatrek shareholders to hold ~62.6%–70% of the merged entity (Cannabiz secondary: 98% in favour, ~4% opposed).
  • LGP delayed its share-issuance vote to 22 May and sought adjournment of the 24 April second court hearing.
  • LGP Q4 FY26 record A$12.5m revenue (annual A$42.4m, +15% YoY, four-year 30% CAGR); Europe A$6.4m (+70% QoQ; Germany A$5.5m); A$1.1m operating cash flow (vs −A$1.0m); A$5.6m unused debt facilities.
  • Vitura Health Q3 FY26 transformation: A$2.7m annualised cost savings (A$2.0m personnel + A$0.7m discretionary); MedReleaf distribution worth up to A$15m incremental revenue; ~A$1m gross profit lift; Candor patient acquisition tracking ~25% above H1; next step: Stage 2 transformation flagged for FY2027.
    • Justin James appointed CEO on a A$500k contract (former Health Insurance Fund of Australia chief; five-year tenure to 2025).
  • Tasmanian Botanics: Chinese investors (Y Cannabis Holdings, Guizhou Yongji, Phytoca) near full ownership; CEO Craig Knight warns price-driven pressure raises questions over the viability of domestic cultivation at scale.
• Aurora anchored an AU-centric GMP supply rebuild on two legs — a 12-month Bioxyne manufacturing deal and a global SKU rollout — with Herbal Dispatch opening a parallel BC→AU lane.
  • Aurora–Bioxyne 12-month rolling deal: GMP-certified medicinal oils to AU (initial deliveries completed); expansion to GMP vapes for AU/UK/DE; six-month termination notice; A$3–5m revenue uplift expected for Bioxyne over 12 months.
  • Aurora global medical portfolio: 12 SKUs by June 2026 including AU pastilles (Black Raspberry THC 20mg/CBD 20mg/CBN 30mg; Blood Orange THC 32mg/CBD 32mg/CBG 32mg/CBC 10mg) and high-THC dried flower 21–29% THC across DE, PL and CA.
    • Format context: BLS produces up to 3m pastille units/month — ~two-thirds of the AU pastille market, which rose from <5% (2024) to >25% (Dec 2025), overtaking oils as the second-most prescribed format behind flower; AU imports 77,000 kg in 2024, ~80% from Canada.
  • Parallel BC→AU lane: Herbal Dispatch completed its first international gummy export to AU on 30 April (A$350k revenue; top-three global cannabis customer, unnamed); follow-on shipments slated for 2026; firm now active across AU, PT, DE, BR, CZ, UK, CH and CR.
• The Penington-led demand correction was triangulated by Statistics Canada’s collapse in landed flower prices and a flat 905-prescriber SAS-B base, with Compass’s reopened compassionate access scheme providing only partial offset.
  • Penington Institute documented the H2 2025 medicinal-cannabis unit-sales fall (3.70m → 2.65m); Cannabiz framed it as “regulator tightens grip” — a structural correction tied to TGA-Ahpra enforcement against high-volume prescribers, not a cyclical dip.
  • TGA SAS-B March 2026: 20,166 approvals (third-highest on record); 905 prescribers (flat MoM); pastilles ~30% of approved scripts; Q1 2026 totals 56,122 (+9.5% YoY).
  • Statistics Canada Feb 2026 CIMT data: Canadian flower exports CA$51.6m (+8.7% YoY); AU cumulative CA$230m (Jan 2024–Feb 2026); AU landed flower price CA$1.06/g (−59.6% over two years); 6,928 kg AU volume (vs 2,237 kg prior period).
  • Partial counterweight: the Compass compassionate access scheme reopened to new patients in March 2026 after a six-month hiatus to fix governance.
• Operator earnings showed durability beneath the demand correction — Bioxyne’s record A$21.3m Q3 print and ECS Botanics’ third consecutive cash-positive quarter framed the upside, with Cann Group’s first UK export and Epsilon’s record receipts adding peer-level relief valves.
  • Bioxyne Q3 FY26: record A$21.3m revenue (+24% QoQ); A$1.2m positive operating cash flow; A$8.49m cash; first commercial psilocybin capsule orders (250 doses, ~60 patients over 12 months) via Authorised Prescriber pathway; FY26 guidance reiterated A$65–75m revenue / A$16.5–19m adj. EBITDA.
  • ECS Botanics Q3 FY26: A$4.81m revenue and A$118k positive operating cash flow (third consecutive); B2C A$3.4m (+55% YoY, ~71% of revenue); A$1.746m cash plus A$3.2m undrawn = ~A$4.9m total funding; AVANI AVA THC:CBD pessary launching early May; next step: first commercial OzSun flower batches to Germany (Nimbus Health) and first oil shipment to New Zealand (NUBU Pharmaceuticals) imminent.
  • Cann Group Q3 FY26: A$2.32m revenue (+42% QoQ; YTD A$6.84m); cash outflows −82% YoY to A$1.3m; first ~120 kg UK dried-flower export from Mildura; German AMRadV irradiation licences secured via partner; FY26 guidance A$9.2–10m revenue / A$3.5–4m EBITDA loss; A$0.330m cash at quarter-end.
    • Capital-runway precondition: A$750k convertible note from Obsidian Global (16 March, carry-over) — 18-month, 0% interest; conversion at A$0.015 or VWAP-discounted.
  • Epsilon Healthcare Q3 FY26: record receipts A$3.14m (+154% YoY); group revenue A$3.29m (+158% YoY); CDMO +149% YoY; pharmacy A$2.3m annualised; A$503k cash on hand (vs A$242k prior quarter).
    • Boardroom overhang lifted: Epsilon and former chairman Josh Cui (Watercrest Capital) settled the 2.5-year litigation via deed of settlement on 14 April.
• Capital-stress tails surfaced at the fragile end of the operator pool — Cannim’s liquidator chasing ≥A$13m and Nexalis funding its IRX-211 Phase 2 trial through 10:1 leverage.
  • Cannim Group liquidator (Olvera Advisors) is seeking external funding to pursue ≥A$13m recovery claims against directors and related parties; next step: funding round in progress, no recoveries yet.
  • Nexalis Therapeutics (ASX:NX1) operates an A$52.3m secured debt facility against ~A$5m equity (10:1 leverage; 15% interest capitalised monthly; ~20% warrant dilution) to fund the IRX-211 Phase 2 cancer-pain trial (156 enrolment / ~78 crossover).
• AIHA pitched hemp biofuel as a domestic answer to Australia’s fuel-price spike with crude above US$110/bbl.
  • Australian Industrial Hemp Alliance advanced a hemp biofuel pitch framed against crude oil >US$110/bbl (≈A$156), capital-city unleaded ~A$2.50/L and diesel >A$3/L.

🔬 Science — TGA rapid review finds no clinical evidence above 22% THC against AU pharmacy products at 88% THC; Nexalis IRX-211 Phase 2 first patient screened; Neurotech ‘Beyond Harmony’ Phase 3 first site at Monash Children’s Hospital; NWDMP Report 25 places Australia 7th globally at 152 doses/1,000/day

The TGA-commissioned rapid review of 16–22% THC products screened 15 studies (6 RCTs + 9 observational) from 9,669 records and found no clinical evidence above 22% THC, even as Australian pharmacy products reach 88% THC and >20% THC flower is projected to ~87% of pharmacy volume by 2027; Nexalis Therapeutics screened the first Phase 2 IRX-211 patient on 20 Apr (multicentre cancer-pain crossover, 156 enrolment / ~78 crossover) and Neurotech International activated the first Phase 3 ‘Beyond Harmony’ clinical site at Monash Children’s Hospital for NTI164 in paediatric ASD; the ACIC‘s NWDMP Report 25 placed Australia 7th globally at 152 doses/1,000 people/day with persistent regional skew.

TGA rapid review of high-THC medicinal cannabis: 15 studies (6 RCTs + 9 observational) screened from 9,669 records; no clinical evidence above 22% THC; mixed efficacy and mild–moderate adverse events. Published 1 April and feeding directly into the ACMS scheduling-committee evidence base for the June 2026 interim decision (final ~August), the review documents the structural evidence vacuum at the heart of the Schedule 9 rescheduling debate.

• A 143-patient registry on 22% THC granulated flower reported 23.1% nervous-system disorders and 9.7% GI adverse events; single-dose inhalation 1 mg THC achieved ≥30% pain reduction (0.5 mg gave 25%); a fibromyalgia trial reported drug ‘high’ in 20/20; UC RCT 7/17 cough; Parkinson’s MTD landed ≈17 mg/day THC.
• Cross-reference: see the Regulation section’s ODC plant-growth-regulator regulatory review — the same cultivation-chemistry strand surfaces in a published-science paper below.

Domestic biotech advanced two cannabinoid trials at the Phase 2 / Phase 3 frontier; an ANZ-region 1:1 THC/CBD cancer RCT provided the cautious-evidence counterweight.

• Nexalis Therapeutics screened the first Phase 2 IRX-211 patient on 20 April: multicentre, randomised, double-blind, placebo-controlled cross-over study targeting 156 opioid-tolerant patients (~78 progressing to Part B) in breakthrough cancer pain; global cancer-pain market projected ~US$11 bn by 2028 (CAGR 6.4%, US$8.87 bn 2026 → US$12.91 bn 2032).
• Neurotech International activated the first Phase 3 ‘Beyond Harmony’ clinical site at Monash Children’s Hospital for NTI164 in paediatric ASD: 150 patients planned under adaptive design (HREC approval 2 Feb 2026); recruitment ongoing, additional sites expected.
• A double-blind ANZ-region RCT (n=144) of 1:1 THC/CBD oil in advanced cancer (Supportive Care in Cancer, 24 Jul 2025; ingested April 2026) missed its primary symptom-burden endpoint at day 14 (TSDS change −6.30 vs −6.98, p=0.76); pain-score improvement was modest (−1.42 vs −0.46, p=0.04); psychomimetic AEs (confusion 37.7% vs 16.7%, p=0.005; “feeling high” 29.0% vs 13.9%, p=0.02) and attrition (54.2% vs 30.5% by day 28, p=0.007) ran higher in the active arm.

Population-level science reaffirmed cannabis as Australia’s highest-consumed illicit drug, while cultivation chemistry surfaced in published research at the same plant-growth-regulator frontier the ODC opened a review on.

• The ACIC‘s National Wastewater Drug Monitoring Programme Report 25 (30 Apr) placed Australia 7th globally at 152 doses/1,000 people/day (April 2024) — vs USA 683 / Canada 659 — with August 2025 national consumption dipping; nicotine consumption rose +4% YoY (Aug 2024 → Aug 2025); cannabis dose calibrated to 8 mg THC-COOH (210–450 mg dried at 15% THC).
  • Persistent regional skew: regional consumption ~2–3× capital-city levels, especially Northern Territory, South Australia and Western Australia; Hobart leads capital cities and Tasmania regional sites; Adelaide registered a historically high reading Feb 2025.
• An MDPI Plants paper (22 Apr) documented chemical sex reversion in Cannabis sativa: silver thiosulfate (STS) achieved ~100% female-to-male reversion; ethephon (ETH) achieved male-to-female shift; GA₃ effects were limited to axial nodes; the STS+GA₃ combination delivered the most complete reversal with fertile flowers — across 9 PGRs / 4 combinatory treatments / 2 accessions / 4 genotypes / 6 clones per treatment. The same PGR class is now under .

Process status snapshot for in-progress science items at end of April 2026:

• TGA rapid review: published 1 Apr; feeds the ACMS scheduling-committee evidence base for the June 2026 interim decision (final ~Aug 2026).
• Nexalis Phase 2 IRX-211: first patient screened 20 Apr; targets 156 enrolment (~78 crossover); see Market section for the company’s 10:1 leverage capital structure.
• Nexalis Phase 1 IRX-616a (CBD panic disorder) + pre-clinical oral ketamine: next pipeline gates; no first-patient yet.
• Neurotech Phase 3 ‘Beyond Harmony’: first site activated at Monash Children’s Hospital; additional sites expected; HREC approval 2 Feb 2026; recruitment ongoing.
• ANZ 1:1 THC/CBD cancer RCT: published Supportive Care in Cancer (24 Jul 2025); ingested April 2026 as cautious-evidence anchor; no further trial activity expected from this protocol.
• NWDMP Report 25: published 30 Apr; next quarterly bulletin expected ~Q3 2026.
• MDPI Plants sex-reversion paper: published 22 Apr; regulatory follow-through depends on ODC PGR review (examination stage).

🇬🇧 UK — MCCS Good Practice Guide V4 formalises safer prescribing as Releaf passes 25,000 patients and Tilray absorbs Lyphe

🔭 On the radar: UK–EU SPS agreement target mid-2027 with FSA ministerial decisions on three publicly consulted CBD dossiers expected later in 2026 (>700 of ~12,000 products already exited the novel-foods process); ACMD review of the 2018 CBPM framework and Oliver’s Law eight asks pending consideration. Bioxyne–Aurora vape lines (AU/UK/DE) onboarding and Cann Group FY26 guidance A$9.2–10.0 m with M&A discussions under way; UKMCR migraine RCTs and Addiction NMA follow-up trials flagged as still required. 🇮🇲 Isle of Man citizens’-jury motion to be debated at Tynwald’s May sitting; if approved, jury established by December 2026.

🏛️ Regulation — MCCS Good Practice Guide V4 formalises safer prescribing as Oliver’s Law presses eight asks and UK–EU CBD alignment risks >700/12,000 products

The Medical Cannabis Clinicians Society publishes the Good Practice Guide V4 on 9 April — a structured framework for private CBMP prescribing across ~95,000 patients, 160 prescribers and 40 clinics — as ‘Oliver’s Law’ demands eight statutory changes after the first UK coroner finding linking a cannabis prescription to a death; separately, UK–EU ‘reset’ talks put >700 of ~12,000 CBD novel-food applications at alignment risk against EFSA’s 2 mg/day vs the UK’s 10 mg safe level.

• MCCS Good Practice Guide V4 (9 April) standardises private CBMP prescribing. The Guide sets a structured framework — assessment, consent, documentation, product choice, monitoring and risk management — and positions prescribers as fully accountable within GMC, CQC, MHRA and NICE expectations; CBMPs remain unlicensed ‘specials’.
• ‘Oliver’s Law’ (launched 31 March) demands eight regulatory changes after the first UK coroner finding linking a cannabis prescription to a death. Oliver Robinson (34, dual diagnosis of recurrent depressive disorder and cannabinoid dependency) died in November 2023; Area Coroner Catherine McKenna recorded death by misadventure on 30 January 2026, finding the prescription contributed to ‘dysregulation’ and a ‘worsening mental state’ as part of a ‘causal chain of events’.
  • The eight asks include statutory contraindications for serious mental illness (bipolar, schizophrenia, psychosis, active suicidal ideation), mandatory NHS-psychiatrist consultation for any patient with mental-health history, tougher CQC oversight of private clinics, centralised MHRA adverse-event reporting with mandatory serious-harm reporting, and clearer GMC fitness-to-practise guidance.
  • The BBC case narrative (6 Apr) escalates public pressure as the Robinson family presses for tighter private-clinic rules for patients with complex mental-health histories.
  • The ACMD is already reviewing the 2018 CBPM prescribing framework for unintended consequences; the CQC‘s July 2025 controlled-drugs annual report flagged limited-evidence prescribing and gaps with NHS services.
  • Counter-framing: Glass Pharms CEO James Duckenfield contests the ‘commercial scale’ framing — ~30,000 active patients and ~100,000 items/month sit far below 1.77 m UK adults self-medicating and 5.6 m chronic-pain opioid scripts; focus should shift to compliance and UK-based cultivation standards rather than headline prescribing rates.
• Welsh Liberal Democrats pass motion protecting prescribed-cannabis patients; Flintshire County Council becomes the first Welsh local authority to adopt it. Brought by Clwyd East and Flintshire Liberal Democrats at the party’s spring conference (Cardiff, March), the motion commits councils to safe indoor spaces, officer training on the legal status of CBPMs, and letters to the North Wales Police and Crime Commissioner and housing associations.
  • PatientsCann UK (Sal Aziz, Mohammed Wassway) is targeting rollout across all 22 Welsh local authorities ahead of the next Senedd election; follows Salford City Council‘s 2024 precedent — the first UK motion of its kind.
• UK seeks novel-foods carve-outs in UK–EU ‘reset’ talks to keep higher-dose CBD foods and drinks (up to 10 mg) against EFSA’s 2 mg/day safe level (Feb 2026). Per the FT (18 Mar), the UK Cabinet Office is seeking carve-outs while accepting alignment in some areas; under dynamic alignment, EU market authorisation would be required to sell regulated products in Great Britain unless exceptions are agreed.
  • An FSA + Food Standards Scotland letter (12 March) tells CBD applicants to operate on the assumption that the UK will eventually align with the EU; SPS-agreement target mid-2027; the FSA continues assessing applications and will recommend ministerial decisions on three publicly consulted dossiers later in 2026.
    • Of ~12,000 CBD products entered into the UK novel-foods process since 2022, more than 700 have fallen out; EIHA projects GmbH alone has >4,000 products still under FSA assessment.
    • The Cannabis Trades Association (Marika Graham-Woods) argues the UK novel-food process must be exempt from any veterinary/SPS deal to avoid being ‘subservient’ to EU rulemaking without UK representation.
• Recreational enforcement and pilot-campaigning ran in parallel: Liverpool cafe raid sentencing 28 April; TRACD pilot campaign launched at 4/20 Hyde Park.
  • Gary Youds (56) faces sentencing on 28 April at Liverpool Crown Court on possession-with-intent-to-supply after the February Merseyside Police raid on Chillin’ Rooms near Anfield (cannabis brownies, cookies, sweets and branded merchandise seized); the premises-use charge was dropped. Sixth jail stint in nearly 20 years of cafe activism.
  • TRACD (Charlotte Caldwell) seeks pilots across the UK, Jersey, Guernsey and Isle of Man for adults 21+ with mental-health screening; 36–40 g/month supply cap; certificate of analysis and seed-to-shelf traceability; aggregated anonymised use/health data fed to legislators.
    • Partners: Cannavigia (Switzerland recreational pilot) and Caritas BioScience (Leigh Fell, ex-GW Pharmaceuticals); backers: Gavin St Pier (former Guernsey Chief Minister) and Dr Alex Allinson MHK (Isle of Man Treasury minister).
    • Caldwell cites a University of Bath study (Jan 2026): only 10.7% of medical-cannabis prescription holders source all cannabis legally; 50% of users surveyed still buy from a dealer.
    • Forbes (21 Apr) notes ~3 m annual UK recreational users under Class B prohibition (≤5 years for possession; ≤14 years for production/distribution; £90 fixed-penalty in practice for low-level possession).

💼 Market — Releaf hits £38m run-rate (25k patients) as Tilray absorbs Lyphe and Cann Group completes first ~120 kg UK dried-flower export

Releaf passes 25,000 patients and reports a £38 m annual run-rate from March 2026 (Q1 2026 revenue £9 m; ~10% MoM growth since June 2025); Tilray Brands absorbs UK clinic operator Lyphe; and Cann Group completes its first ~120 kg UK dried-flower export from Mildura — UK clinic demand and international EU-GMP supply hardening simultaneously against ~80,000 UK specialist-prescription patients.

• Releaf passes 25,000 patients; Q1 2026 revenue £9 m; £38 m annual run-rate from March 2026. Releaf is CQC-regulated and founded by Mason Soiza in 2022; 181,000 prescriptions issued to date with ~75% of patients reporting QoL improvements.
  • Stickiness signals: 12,500 Releaf+ subscribers (>59% retained beyond six months); >90% of medication sales to existing patients; 170 staff and 50 specialist prescribers.
• Tilray Brands acquires UK clinic operator Lyphe Group. Lyphe joins Tilray on a ‘patient-first’ remit citing better access to medication and supply, and continued investment in cannabinoid science; team and care arrangements unchanged. Deal value undisclosed.
• Rubicon Organics launches 1964 Supply Co. in the UK via 4C Labs (12 April). Rubicon opens its first international route-to-market for the brand (Canada Brand of the Year, 2024–25) with flower, vapes and extracts; 4C Labs holds UK and Channel Islands import/distribution licences.
  • Backed by Rubicon’s 47,500 sq ft Cascadia indoor facility (Hope, BC), expected to add ~40% to annual production capacity from H1 2026.
• Mamedica’s 4/20 campaign confronts the access-vs-awareness gap: ~80,000 UK specialist-prescription patients vs ~50% of the public unaware medical cannabis is legal; >80% of patients report stigma. Mamedica (12,000+ patients) launches a Lock-Stock-themed campaign (YouTube, OOH, cinema) fronted by Vas Blackwood, framed around stigma rather than direct product promotion to comply with prescription-only rules.
  • Big Narstie Medical raises advertising-rule concerns by promoting 15+ branded strains to 500,000 Instagram and 250,000 TikTok followers; Integro Clinics (medical director Dr Sunny Nayee) denies partnership but says it has prescribed the range ‘based on clinical need’.
    • The Human Medicines Regulations 2012 prohibit direct-to-consumer advertising of prescription-only medicines; campaigners (Oliver’s Law founder Xander Robinson) call on the MHRA to clarify whether influencer/branded promotion crosses the line.
• International EU-GMP capacity is being pre-positioned for UK supply: Cann Group’s first ~120 kg UK dried-flower export, Bioxyne–Aurora vape manufacturing for AU/UK/DE, and Cantourage’s UK growth-market designation.
  • Cann Group completes its first ~120 kg UK dried-flower export from Mildura; secures German AMRadV irradiation licences; Q3 FY26 revenue A$2.32 m (+42% QoQ); FY26 guidance A$9.2–10.0 m.
  • Bioxyne / Breathe Life Sciences signs a 12-month rolling manufacturing agreement with Aurora (six months’ notice) to produce GMP-certified vapes for Australia, the UK and Germany; initial GMP oil deliveries to Australia already completed.
    • Initial purchase orders cover >5,000 sublingual oils and >20,000 vape units; BLS holds a Scottish Borders manufacturing site backed by £848,250 grant from South of Scotland Enterprise Fund (target up to 100 jobs).
  • Cantourage (CEO Philip Schetter, SdK strategy meeting 7 Apr) names the UK and Poland as key growth markets alongside Germany; ~€100 m FY25 revenue target; >100,000 patients/month served; >80% of supply from Canada via 30+ exclusive partners.
  • See for Aurora‘s $26.5 m Safari Flower acquisition (Ontario EU-GMP, 59,000 sq ft) — the UK is one of four named destination markets but the deal is Canadian primary news.
• Illicit retail signal: BBC undercover finds organised-crime mini-marts selling 3.5 g cannabis for £30 and 1 g cocaine for £95 across four West Midlands towns; >70 shops linked nationally. BBC (23 Apr) cites the NCA and CTSI; the Home Office says it is working with police, NCA and Trading Standards on stronger powers and longer closure orders.
• 🇯🇪 Jersey — sector turns profitable for the first time in 2025; Northern Leaf supplies 3,590 kg to Germany (more than Colombia), with capacity utilisation rising 25% → 75% at its 100,000 sq ft St Lawrence facility and revenue up fivefold.
  • Jersey Economy Department: >£12 m sector revenue; ~£50 m invested; ~70 people employed; energy ~30% of operating costs.
  • Observer profile (12 Apr): Northern Leaf accounts for 90% of island production (10 t/yr capacity); EU medical-cannabis market projected at €1.5 bn by decade-end; >20 private clinics on the island; 6% of Jersey’s 104,500 population prescribed cannabis (vs ~0.3% in Germany).
  • Economic Development Minister Kirsten Morel backs the ‘recommitment’ call (Jersey Evening Post, 4 Apr): eight-year path to profit; six to seven medicinal-tech firms now operating, taxed at 20%; political enthusiasm had waned around Northern Leaf’s neighbour disputes.

🔬 Science — UK Medical Cannabis Registry: 203 migraine patients show sustained 24-month QoL gains; Addiction NMA pools 57 RCTs (5,906 participants) for cannabis use disorder

The UK Medical Cannabis Registry migraine case series (Curaleaf Clinic, Brain & Behavior, 6 Apr; n=203) reports sustained 24-month improvements on HIT-6, GAD-7, SQS and EQ-5D-5L (p < 0.01) and 12-month gains on MIDAS (p < 0.05); higher THC dosing predicts greater migraine-specific improvement and 15.27% of patients reported 249 adverse events (1.20% life-threatening).

• UKMCR migraine case series (n=203) confirms sustained quality-of-life gains while flagging a dose-response signal: higher THC dose is a positive predictor of MIDAS improvement. Curaleaf’s registry held 34,563 patients on 6 January 2025 (91.16% with baseline PROMs; 71.61% enrolled ≥2 years); 203 (0.59%) carry a primary migraine diagnosis.
  • Female sex (OR 0.48, 95% CI 0.23–0.98, p=0.046) and a bottom-quartile THC dose (OR 0.25, 0.06–0.93, p=0.047) emerge as negative predictors of MIDAS improvement; wide confidence intervals warrant caution.
  • Adverse-event severity profile: 44.18% mild, 31.73% moderate, 26.91% severe, 1.20% life-threatening; authors flag RCTs as still required to establish causation.
  • Cannabiswirtschaft (citing NORML, 9 Apr) amplifies the finding internationally with a dosing-guidance frame for future randomised trials, highlighting greatest gains for higher-THC products.
• The Addiction network meta-analysis (57 RCTs, 5,906 participants) finds dialectical-behavioural / acceptance-and-commitment therapies and contingency management most effective for cannabis use disorder; pharmacotherapy evidence is highly uncertain. The 2 April analysis pools 57 RCTs across 5,906 participants (21 psychosocial, 36 pharmacological) in adolescents and adults aged ≥16.
  • DBT/ACT (mean difference -0.18, 95% CrI -0.26 to -0.09) and MET-CBT with contingency management (-0.15, -0.23 to -0.07) reduce cannabis-use frequency vs non-specific comparators; both also improve treatment completion.
  • Cannabidiol (OR 2.91, 0.45–27.98), N-acetylcysteine (1.30, 0.55–3.74) and varenicline (4.85, 0.65–48.26) emerge as the strongest pharmacological abstinence candidates but with very wide credible intervals.
  • Mixed-action antidepressants, benzodiazepines, bupropion and buspirone show more adverse events than placebo without effectiveness signals; certainty of evidence is low to very low across all comparisons.
• Vaporised THC + CBD raises plasma THC, OH-THC and COOH-THC exposure above THC alone in a 48-participant cross-over; Phytome moves a proprietary cultivar into licensed UK cultivation to generate production data.
  • A randomised double-blind placebo-controlled cross-over (48 participants aged 16–17 and 26–29; 35 with complete PK datasets) finds 8 mg THC + 24 mg CBD/75 kg raises plasma THC AUC and Cmax above THC-alone (8 mg/75 kg), except for OH-THC Cmax; no age-related moderation observed (PubMed, 20 Apr).
  • Phytome Life Sciences (Cornwall) moves a cultivar into licensed UK production (28 Apr) to capture yield, chemical-expression and batch-consistency data feeding into a botanical-medicine development platform aimed at IND-track standardisation.

Process status snapshot for in-progress science items at end of April 2026:

• UKMCR migraine case series: published 6 April 2026 in Brain & Behavior; observational case series — randomised controlled trials still required to establish causation; CBMPs remain unlicensed ‘specials’ under MHRA.
• Addiction NMA on cannabis use disorder: published 2 April 2026; certainty of evidence low to very low across all comparisons; no pharmacotherapy currently recommended for CUD in UK clinical practice.
• Vaporised THC ± CBD pharmacokinetics: published 20 April 2026; further research flagged to resolve CBD–THC PK discrepancies across studies.
• Phytome Life Sciences UK cultivation transfer: announced 28 April 2026; cycle-on-cycle production data being captured; future biomanufacturing partnerships referenced but not contracted.

<page url=”https://app.notion.com/p/e01537b3ea09486ea689e2272b552d28″>Jersey — Apr 2026 — Northern Leaf books £12M revenue and 3,590 kg German exports as 6% of population reach Rx access</page>

<page url=”https://app.notion.com/p/f1110e9208484888977cbc3a5d0af384″>Isle of Man — Apr 2026 — Tynwald to debate citizens’-jury motion on drug policy at May sitting</page>

🇨🇦 Canada — Record sales and exports collide with operator distress and Indigenous-rights flashpoints

🔭 On the radar: Ontario 7am–11pm retail hours commence 1 May 2026 (O. Reg. 468/18, AGCO). Three CCAA SISP outcomes pending (THC BioMed C$21.65m, Noble Growth C$9.5m, CanadaBis C$7.6m) — Aurora–Safari Flower closing and Emblem–Ayurcann completing with Auxly back-up. Avicanna 6th Clinical Symposium 11–12 June (MaRS Toronto, recorded) — Mi’kmaw four-applicant sentencing, Health Canada on-premise beverage decision, and Cannabis Act five-year review (overdue from October 2023) all pending.

🏛️ Regulation — Indigenous-rights pressure escalates from courts to highways while provinces liberalise retail rules

Ontario extended retail hours to 7am–11pm effective 1 May 2026; the Ontario Superior Court rejected a Mi’kmaw constitutional challenge to s. 10(2) of the Cannabis Act and First Nations blocked three Nova Scotia highways after an RCMP cannabis-shop raid; provinces’ 2026/27 budgets projected over C$800m in federal excise transfers (cumulative legal-era CRA receipts: C$5.4bn, to 31 Aug 2025); StatsCan March 2026 cannabis CPI fell 3.2% YoY.

Ontario extended permitted retail hours to 7am–11pm under O. Reg. 468/18, effective 1 May 2026 — the first material AGCO retail-framework change since 2019. The Ministry of the Attorney General consultation (9–24 April 2026) cited illicit-market competition and “operational efficiencies for inspectors”; delivery window unchanged at 9am–11pm. AGCO confirmed the extended hours on the same instrument.

• BC: Village Farms piloted THC potency range labelling (e.g. 18–24%) in lieu of single-figure declarations, addressing post-harvest variability that drives mislabelling complaints.
• Alberta: an independent retailer paired customers with a registered cannabis nurse for health queries — a grey zone in retailer health-advice activity.

Two Indigenous-rights challenges to s. 10(2) of the Cannabis Act surfaced in April. Ontario Superior Court rejected the Mi’kmaw constitutional challenge brought by four applicants, citing absence of historic cannabis use predating 1923 criminalisation; next step: sentencing to follow. Days later, First Nations blocked three Nova Scotia highways (Hwy 102, Route 4, Cape Breton) after an RCMP raid on a Millbrook/Sipekne’katik cannabis shop.

Provinces’ 2026/27 budgets projected over C$800m in federal cannabis excise transfers; cumulative legal-era CRA receipts reached C$5.4bn (to 31 Aug 2025). Province breakdown: ON C$405m, AB C$229m, QC C$146m, BC C$130m.

• StatsCan March 2026 cannabis CPI: −3.2% YoY, led by Atlantic provinces (PEI −17.2%, NS −9.7%); Quebec steady at 96.3.
• BC LDB Q4 FY2025 wholesale: C$142.9m total (−0.8% YoY) at C$3.76/g; direct-delivery channel +643% YoY to C$17.8m.

Industry coalition asked Health Canada to permit on-premise cannabis beverage service in licensed venues, currently barred under the Cannabis Regulations. Status: Health Canada considering, no commencement date.

💼 Market — Industry growth meets operator shake-out: three CCAAs feed Aurora and Emblem capacity while exports tilt to Germany

Canada’s legal cannabis sales hit C$5.5bn in 2025 (+12%); Health Canada Q3 2025 reported medical units +12% YoY and non-medical +19% YoY; SNDL Q1 2026 posted C$195.9m revenue and C$213.4m cash; Aurora acquired Safari Flower for C$26.5m; THC BioMed, Noble Growth and CanadaBis entered CCAA; Canada exported 275 tonnes in 2025 (+143% YoY), with Germany taking 62.3% of February flower.

Canada’s legal cannabis sales hit C$5.5bn in 2025 (+12%); Health Canada’s Q3 2025 release reported medical units +12% YoY (3.19m) and non-medical units +19% YoY (75.4m). Alcohol sales fell ~7% in ON/BC over the same period as substitution effects deepened.

• Health Canada Q3 2025 dataset: extracts share 28% (+4pp), edibles 24%, dried flower 48% (−3pp); licensed indoor area +8% YoY; destroyed unpackaged flower 7.9% (vs 12.1% YoY).
• Edibles multipacks jumped from 2% to 28% of category sales in under a year.

SNDL posted Q1 2026 results of C$195.9m revenue (−4.4% YoY) and C$213.4m cash with no debt.

• Avant Brands Q1 2026 results: recreational revenue +37%.
• Avicanna‘s FY2025 audited results: increased profits, declining losses; expanded Cannabinoid Therapeutics Symposium (see Science).
• High Tide opened a probe into potential share-price manipulation after repeated post-earnings selloffs.
• Glow Lifetech expanded to ~140 Ontario retail sites and added CBD and live-resin THC SKUs.
• Rua Bioscience completed the first live cannabis genetics export from New Zealand into Canada.
• Vlad Marcenco’s Week 21 review showed equity cushions compressing across listed Canadian producers.

Canada exported 275 tonnes of cannabis in 2025 (+143% YoY); Germany took 62.3% of February 2026 flower exports. February flower exports totalled C$51.6m: Germany C$30.4m, Portugal C$1.67m (−86.6%).

• Germany volumes rose +298% YoY in the broader 2025 view; global price compression is tightening margins.

THC BioMed, Noble Growth and CanadaBis entered CCAA in April; Aurora acquired EU‑GMP cultivator Safari Flower for C$26.5m; Emblem won the Ayurcann CCAA asset sale.

• THC BioMed entered CCAA with C$21.65m in liabilities vs C$10.67m assets, including C$3.4m CRA arrears.
• Noble Growth entered CCAA on 14 April with C$9.5m liabilities, a looming licence expiry, and EY appointed monitor.
• CanadaBis entered CCAA citing significant excise debt: C$7.6m excise debt, C$4.2m secured debt, ~C$4m debentures.
• Aurora acquired EU‑GMP cultivator Safari Flower for C$26.5m (C$15m cash + 2,417,180 ACB shares + C$2m contingent); the 59,000 sq ft purpose-built Ontario indoor cultivation/manufacturing facility supplies Germany, Australia, Poland and UK, with positive Adj. EBITDA contribution expected FY2027.
• Emblem won the Ayurcann CCAA asset sale (2,500 retail sites cited) after Auxly’s stalking-horse bid was rejected; Auxly named back-up bidder with up to C$2m DIP financing.
• Wayland/Maricann (Newstrike-era) class settlement: ~C$8m available to Canadian claimants.

🔬 Science — From Quebec’s policy-driven consumption contrast to Sclerotinia genomics and Avicanna’s clinical scale-up

The Canadian Cannabis Survey 2023–24 (n=7,238) found Quebec lowest on five frequent-use outcomes including ≥weekly use and inhalable extracts; a Cannabis sativa–Sclerotinia sclerotiorum dual-RNA dataset (GSE284432) provided the first detailed histopathology of the pathosystem; and Avicanna‘s 6th Cannabinoid Therapeutics Symposium at MaRS Toronto (11–12 June, expanded to two days) anchors the Canadian clinical-evidence calendar.

Canadian Cannabis Survey 2023–24 (n=7,238 past-12-month consumers) found Quebec lowest on five frequent-use outcomes — including ≥weekly non-medical use and inhalable extracts — but highest on illicit sourcing and >10 mg/unit edible/beverage exposure (Quebec’s product cap is 5 mg/unit). Goodman, Dann & Abramovici published the analysis on 24 April in Canadian Journal of Public Health (open-access).

• Newfoundland and Labrador and the territories posted the highest prevalence of frequent (≥weekly) use; Alberta led on inhalable extract use (≈8% of past-year consumers).
• Quebec’s lower frequent-use odds correlate with restrictive retail rules: >30% THC cap on extracts, delayed vape-oil availability, and the 5 mg/unit edible limit.

Dual RNA sequencing of Cannabis sativa infected by Sclerotinia sclerotiorum mapped host defence and pathogen redox / sugar-catabolism reprogramming at the inflorescence; raw data are public under accession GSE284432. Belmonte and Wilkins (NSERC-funded) published the dataset on 16 April in Scientific Reports.

• Anatomical work showed initial epidermis and cortical-parenchyma degradation, followed by widespread vascular-phloem infection — the first detailed histopathology of the Cannabis–Sclerotinia pathosystem.
• S. sclerotiorum infects >600 plant species globally; recent North-American crop-loss reports (Alberta 2000, Oregon 2021, South Carolina 2023) make the dataset directly relevant to Canadian outdoor and greenhouse cultivars.

Avicanna’s 6th Annual Clinical Symposium on Cannabinoid Therapeutics expands to two days at MaRS Toronto (11–12 June 2026), live and virtual, with 12 speakers across primary care, pain, neurology, psychiatry, oncology and women’s health. Avicanna published the 12-speaker agenda on 20 April.

• Women’s health track: menopause pathophysiology and cannabinoid therapeutics (Erin Mignault, NP — June Health/KixCare); cannabinoids in gynaecologic care (Dr Luiza Marouelli, OB-GYN — Santé Cannabis).
• Pain and oncology: RWE-led pain prescribing (Dr Hance Clarke, Toronto General Hospital); n-of-1 medical-cannabis-extract trial in cancer-related symptoms (Dr Dilshaan Panjwani, BC Cancer); the Maverick Medical Cannabis Project’s overdose-crisis intervention (Michael Koehn, Cannsolve).
• Sessions recorded for the Avicenna Academy clinical-resources library; next: event delivery on 11–12 June, recordings posted thereafter.

🇳🇱 Netherlands — Wietexperiment Year 1 audit closes with 42 violations and no criminal infiltration as Village Farms opens Groningen and Raad van State tightens mayoral coffeeshop caps

🔭 On the radar: Amsterdam coalition decision on the I-criterium tourist-coffeeshop ban once the post-18 March 2026 PvdA-GroenLinks majority is formed (>700 shops, ~25% foreign-visitor exposure); CanAdelaar / Cronos Group ~€60M acquisition and ~€3M odour-filter upgrade due to close spring 2026 under maatwerkvoorschrift 1.2.4; Hersenstichting–Amsterdam UMC CBD-psychosis trial opens recruitment summer 2026, results 2029; Wietexperiment statutory evaluation runs to end-2029, +1.5-year extension under discussion.

🏛️ Regulation — Wietexperiment Year-1 audit closes with 42 violations and no criminal infiltration as Raad van State tightens mayoral coffeeshop caps

April closed the first full year of the Netherlands’ closed coffeeshop chain pilot with Inspectie Justitie en Veiligheid recording 42 violations and 32 sanctions across 46 inspections of the 10 licensed growers, with no contact with the illicit circuit detected. In parallel, Raad van State case-law from Apeldoorn (2023) and Heerlen (2025) entered operational practice — mayors must now justify any coffeeshop cap with objective, evidence-based proportionality under the Awb — and Amsterdam‘s post-18 March 2026 PvdA-GroenLinks majority reopened the residents-only tourist-ban file in the country’s largest market.

Inspectie JenV recorded 42 violations, 32 sanctions and four coercive penalties up to €20,000 across 46 inspections of the 10 licensed growers in the wietexperiment’s first full year, with no contact with the illicit market detected. All ten growers are now operational; the pre-2025 phase was treated as a run-up before real sanctions began.

• Inspectorate’s first-year audit ties most breaches to digital-registration entries and security-rule compliance — not product or chain-integrity failures — with coercive penalties ranging €1,000–€20,000 in the four cases where growers failed to remedy in time.
  • DutchNews independently confirms one year, no signs of crime across 80 coffeeshops in 10 municipalities.
  • Trouw‘s one-year evaluation calls the pilot hard to reverse — €11/g legal vs ~€7/g illicit price gap and odour complaints persist; Hollandse Hoogtes (Bemmel, Gelderland) is expanding capacity.
  • Breda — first in the December 2023 run-in with Tilburg — reports zero coffeeshop violations since 2023; municipalities retain final say on coffeeshop sanctions while the inspectorate reports.

NVWA codified the operational rulebook for the 10 growers: 5 g consumer-pack cap, 30%-area mandatory labelling with QR leaflet, three-sample-per-batch retention, mandatory destruction on microbiological failure and a strict advertising ban that explicitly captures consumer tasting sessions. NVWA splits supervision with Inspectie JenV (closed-chain integrity) and municipalities (advertising ban, age limit, nuisance).

• NVWA may impose fines under the Closed Coffeeshop Chain intervention policy (Specifiek Interventiebeleid Gesloten Coffeeshopketen); Wageningen Food Safety Research runs the lab analysis on retained samples.
  • Voorne aan Zee mayor Arno Scheepers demanded rule changes at VWS hearing over CanAdelaar (Hellevoetsluis) odour — ~2,500 DCMR complaints over 4.5 years; revised maatwerkvoorschrift 1.2.4 sets a ≥20-reports / 4-week threshold plus dual-inspector 15-minute verification before enforcement; Cronos Group‘s ~€60M takeover and ~€3M filter upgrade are in flight.
  • Almere resident groups VvE Equator and Indische Buurt flagged a dual-operation risk for The Boxx — operator runs a wietexperiment shop in Almere and a tolerated, unregulated coffeeshop in Zwolle, raising product-flow-mixing and credibility concerns for the closed chain.

Two Raad van State rulings (Apeldoorn 2023, Heerlen 2025) tightened the legal test mayors must meet to cap coffeeshop numbers, and Amsterdam’s post-election PvdA-GroenLinks majority reopened the residents-only tourist-ban file in the country’s largest market.

• Bond van Cannabis Detaillisten reads the case-law as a constraint, not an obligation: the historic vuistregel of one shop per 15,000–20,000 inhabitants becomes a benchmark, not a discretionary ceiling, and any de facto scarcity must clear an objective necessity-and-proportionality test under the Awb (articles 3:2, 3:4, 3:46), with omgevingsplan zoning a less-intrusive alternative.
• Amsterdam‘s post-18 March 2026 PvdA-GroenLinks merger could deliver majority for the I-criterium ban on tourist coffeeshop access — >700 shops at peak — with Mayor Femke Halsema signalling willingness to implement unilaterally; one cited study finds ~25% of foreign visitors would shift to the black market under a ban.
  • Adviesburo Drugs (August de Loor) argues extending the I-criterium would amplify nuisance, not reduce it — displacement to street dealers and online platforms, more public-space consumption, and a weakened soft/hard-drug-market separation; the I-criterium remains in force in only 7 municipalities across 4 provinces 15 years after its 2012 introduction.

Politie’s Nationaal Overzicht Drugslocaties 2025 (published 20 April) records 759 dismantled cannabis grow sites — down from 895 in 2024 — alongside ~65,000 kg of cannabis seized by Customs in 2025, mainly from North America and Thailand.

• Oost-Nederland (127) and Limburg (104) led dismantlings; clone sites rose to 41 (+10 YoY) while drying sites fell to 11 (from 25); Politie attributes lower detections to rising imports and enforcement deprioritisation, with total synthetic-drug, heroin and cocaine production locations down 15% to 142.

💼 Market — Village Farms opens Phase II Groningen (~10 t/yr planned, 5× Leli Holland output) as Rijkswaterstaat A58 hemp-sign trial and IsoHemp HL Mix grant-listing open state-backed hemp-build channels

April closed the supply-side year of the wietexperiment with Village Farms International opening its Phase II Groningen indoor facility on 24 April 2026 through subsidiary Leli Holland — once fully ramped, annual capacity reaches ~10 tonnes, quintupling the group’s contribution to the closed coffeeshop chain on top of a Phase I Drachten plant that already supplies 91% of participating coffeeshops. Alongside it, the industrial-hemp track advanced on two state-backed fronts: Rijkswaterstaat‘s 12-month A58 trial of 24 biobased hemp-fibre traffic signs (from 15 April) and IsoHemp‘s HL Mix loose-hemp insulating aggregate joining the Dutch ISDE renovation-grant eligible-materials list (effective 1 March, announced 9 April).

Village Farms International opened its purpose-built Groningen indoor facility on 24 April 2026 through majority-owned subsidiary Leli Holland; once fully ramped, annual capacity reaches ~10 tonnes, quintupling the group’s wietexperiment output and positioning the company for wider European market access. Leli Holland holds 1 of 10 federal wietexperiment grower licences; Mike DeGiglio (CEO) and Orville Bovenschen (President, Canadian Cannabis & Leli Holland) framed the build as Canada-derived know-how returning to its Dutch source.

• The Canada-inspired indoor build opens with calibrated odour-control engineering designed so neighbouring sites read like a tomato grower; Village Farms International (NASDAQ: VFF) bought out the remaining 15% of Leli Holland in September 2024 for ~US$0.8M, taking it to 100% ownership.
  • Process status: facility opened 24 April 2026; ~10 t/yr is planned at full ramp, not realised output; Phase I Drachten began cultivation in 2025. Inspectie JenV‘s Year-1 audit covered all 10 growers (42 violations / 32 sanctions / 46 inspections) without publishing Leli Holland-specific compliance data.

Hemp construction advanced on two state-backed fronts: Rijkswaterstaat began a 12-month A58 trial of 24 biobased hemp-fibre traffic signs from 15 April, and IsoHemp’s HL Mix loose-hemp insulating aggregate joined the ISDE renovation-grant eligible-materials list effective 1 March 2026 (announced 9 April). Both channels route Dutch (and Belgian-EU) hemp fibre into public-infrastructure and building-envelope demand under direct state funding rather than tax deductions.

• Rijkswaterstaat‘s Living Lab InnovA58 partnership installs 24 biobased traffic signs near Oirschot, made from Groningen hemp and a bio-resin derived from sugar-industry and vegetable-oil residues; partner Plantics won the 2024 Hemp Product of the Year award with the prototype. Signs are technically equivalent to aluminium, fully circular, and biodegrade in soil after damage rather than leaving microplastics or metal residues.
• IsoHemp‘s HL Mix loose-hemp aggregate — used for cavity filling and complementary insulation — is now eligible alongside hempcrete blocks for ISDE grants, administered by RVO via the ISDE regeling; grants apply directly to total project cost rather than as tax deductions. The Belgian manufacturer (Fernelmont, founded 2012) is one of Europe’s largest hempcrete-block producers.

🔬 Science — Hersenstichting funds €371,904 Amsterdam UMC CBD-vs-placebo trial in 90 psychosis-vulnerable cannabis users (recruitment summer 2026)

The Hersenstichting awarded €371,904 to Amsterdam UMC for a six-week double-blind trial of daily CBD vs placebo in 90 cannabis-using patients with psychosis vulnerability — measuring cannabis use, psychosis-symptom severity and withdrawal alongside usual care, with recruitment scheduled from summer 2026 and results expected in 2029. The trial joins the international STEP-study consortium and is the first Dutch-funded clinical evaluation pairing CBD’s psychosis-symptom and cannabis-cessation effects in a single intervention.

The trial pairs psychosis-symptom relief with cannabis-cessation support in a single intervention, led by Dr. Lindy Boyette (Amsterdam UMC) with Dr. Marieke van der Pluijm and Dr. Jentien Vermeulen. Hersenstichting frames the rationale as the gap between rising CBD-for-psychosis evidence and limited prior data on combined cessation / symptom outcomes — psychosis-vulnerable cannabis users frequently struggle to stop because of sleep and mood withdrawal symptoms.

• Recruitment opens from summer 2026 at the Vroege Psychose department (Early Psychosis) of Amsterdam UMC, with 90 participants randomised to daily CBD or placebo for six weeks alongside usual care; cannabis use, psychosis-symptom severity and withdrawal severity are the primary endpoints. Process status: trial not yet started — recruitment scheduled summer 2026; results due 2029.

🇵🇹 Portugal — Infarmed temporarily delists 10 medicinal-cannabis operators in early April as NDSWEB cut-over and SOMAÍ–Bedrocan EU-GMP partnership reshape the sector

🔭 On the radar: NDSWEB platform exclusive-use cut-over 8 May 2026 (Licensing+ portal closes; 22 Apr info session completed); remaining Infarmed list-removal cases pending renewal/assessment outcomes; OPCM autism scientific opinion at four-year wait with no Ministry of Health or Infarmed commitment as of April. Operation “Portugal Sempre Seguro 2026” (SSI/PJ/ASAE/AT, Infarmed support) continues year-long; Anicann constitutional review of the 2021/2022 hemp Portarias and Decreto-Regulamentar 2/2020 in preparation; CAP 2028–2032 enters force January 2028 with hemp flower acquiring fibre/seed parity. SOMAÍ–Bedrocan EU-GMP product commercialisation pending — agreement signed only, no shipping yet.

🏛️ Regulation — Infarmed temporarily delists 10 medicinal-cannabis operators in early April as NDSWEB platform exclusive-use begins 8 May

Portugal’s medicinal-cannabis sector entered April under regulatory turbulence as Infarmed temporarily removed eight licensed operators from official lists in the first week — across cultivation, import, export, wholesale and manufacturing — preceded by the 2 April removal of Sunlight Greens and Sinnabis and partly reframed by the regulator as administrative renewal timing after a clerical reversal for CANNA.BIZ within 24 hours. In parallel, the new NDSWEB electronic platform replaces Licensing+ for controlled-substance import/export certificates with exclusive use from 8 May 2026.

Apr 6 cornerstone — eight Infarmed-licensed operators temporarily removed from official lists across all categories (cultivation, import, export, wholesale, manufacturing) in what CannaReporter described as an unprecedented one-week drop.

• Sabores Púrpura (5 categories), Canascer (Castelo Branco, 4), Symtomax (3), Green Donation/Kannabeira (3), Emeraldestiny (Leiria, 3), Labialfarma (Viseu, manufacturing/export) and Quantung (Aveiro, export/wholesale) were removed from the licence register — annual renewal cycles, restructuring, ongoing inspections or post-2025 financial pressure cited as possible drivers, not necessarily compliance failure.
  • On 2 April, Sunlight Greens, SA (Lisbon) and Sinnabis – Plantas Orgânicas, Lda. (Santarém) had already been removed from the licensed-operator lists; Sunlight Greens’ Jonathan Goldman confirmed the licence was “temporarily suspended” and being remediated; Sinnabis (share capital €142,500, 2019 incorporation) flagged for project-implementation deadlines.
  • On 7 April, Infarmed reinstated CANNA.BIZ (Torres Vedras cultivator/manufacturer) after admitting a “lapse in entering a date on the licence document”; CANNA.BIZ confirmed all licences were fully valid throughout the episode.
  • On 10 April, Infarmed clarified that delistings often reflect renewal timing rather than non-compliance, recommending a 2-month lead time before authorisation expiry; late submissions can trigger expiry and require fresh applications. Next step: remaining cases pending renewal/assessment outcomes.

NDSWEB platform launch — Infarmed UNODC/INCB-developed e-certificate system replaces the Licensing+ portal for controlled-substance imports/exports with exclusive use from 8 May.

• Infarmed circulated information circular 035/CD and held a 22 April information session on the NDSWEB rollout (PDF e-certificates with QR-code authentication; 10-day transition); from 8 May, Licensing+ submissions will no longer be accepted. Non-compliant post-shipment reporting (10-day window) triggers immediate certificate-issuance suspension and, on recurrence, administrative proceedings to revoke activity authorisations.

OPCM advocacy — reimbursement, route-of-administration diversification and therapeutic-indication review still pending after a four-year wait on Infarmed scientific opinion.

• OPCM (Observatório Português de Canábis Medicinal) called for state reimbursement and broader indication review on the back of 15 Infarmed-approved cannabis-based preparations (vs zero in 2019), arguing high out-of-pocket pharmacy prices block second-/third-line access; OPCM flagged a 4-year wait on its autism scientific opinion submitted to Infarmed, with no Ministry of Health or Infarmed commitment as of April.

Hemp / illicit-market enforcement — year-long SSI operation continues; ICAD confirms unregulated cannabis-gummies vending channel.

• Operation “Portugal Sempre Seguro 2026” — coordinated by the Internal Security System (SSI) across PJ, ASAE and AT with Infarmed support and launched 2 March — continues throughout 2026, framing all April hemp-shop and vending-machine enforcement events.
  • On 30 April, ICAD (Institute for Addictive Behaviours and Dependencies) confirmed 12 illegal cannabis-gummies vending machines operating 24/7 across three Portuguese cities — confirming awareness only after Público’s enquiry.
  • CannaReporter issued an editorial statement on 28 April (ERC-registered no. 127889) reaffirming editorial independence and rejecting industry pressure linked to its Infarmed list-removal coverage.

💼 Market — PT flower-export share to Germany collapses to CA$1.67M (−86.6%) as SOMAÍ–Bedrocan EU-GMP partnership signs and hemp area scales to ~480 ha (+~800% over two years)

Portugal’s external positioning compresses on two cross-border axes: Canadian flower-export data shows the Portuguese share collapsing 86.6% to CA$1.67M in February 2026 as Germany consolidates 62.3% at CA$30.4M, while a CannaReporter pricing analysis surfaces a structural €544/g Sativex / €46/g Hexacan / €9–10/g flower pharmacy bubble vs €1–2/g EU-GMP wholesale; SOMAÍ–Bedrocan EU-GMP manufacturing partnership signals an export-to-domestic pivot, and the hemp track scales from 68 ha (2024) to ~480 ha (2025).

Cross-border supply route reconfigures — direct Canada→Germany flower flows replace Portuguese transhipment; PTMC pushes back on the reputational-damage narrative.

• The Canadian-flower-export amplification (Business of Cannabis, Ben Stevens, 13 Apr) shows Portugal received CA$1.67M flower in Feb 2026, down 86.6% from the April 2025 peak of CA$12.4M; Portugal’s emergence (Q1–Q2 2025) and retreat (Aug 2025+) form a complete cycle, with no migration into extracts (cumulative CA$4,018 only). See for the Statistics Canada CIMT primary export-flow numbers.
  • PTMC‘s João Duarte rebutted the reputational-damage narrative attached to the licence-revocation episode, arguing the 8-tonne revoked-licence flow is <5% of Germany’s 200-tonne 2025 imports; structural pricing pressure comes from Colombia, Costa Rica and Brazil supply expansion; criticised “EU-GMP washing” via European-facility conversion of imported flower; flagged Portugal’s proximity-to-fresher-flower advantage and an 8-year operational GMP track record.

Pharmacy-pricing bubble — vast delta between EU-GMP wholesale and Portuguese pharmacy retail; reimbursement-design risk surfaced.

• João Duarte’s 3 April CannaReporter analysis anchors the price-to-margin gap on concrete benchmarks — GACP <€1/g, EU-GMP ~€2/g wholesale; CBD isolate Switzerland ~€300/kg; THC isolate Germany broker ~€5,000/kg — vs Portuguese pharmacy 22% THC flower €9–10/g, Hexacan (Portocanna) €46.12/g and Sativex €544.21/g (€342.85 reimbursed).
  • European wholesale deflation track: CBD has fallen ~90% since 2017 (€3.50/g → <€0.50/g); INCB 2026 forecasts unprecedented THC production growth, with Costa Rica (78 t) and Denmark (57 t) signalling saturation rather than scarcity.
  • Reimbursement-design risk: Duarte warns that any state co-payment built on inflated pharmacy base prices would lock in private-company margins on public money; flags HAS France’s 65/30/10/0% stratified-reimbursement model with prices fixed for 3 years in homogeneous categories (e.g. “flower with 20% THC”) as a cautionary reference.

SOMAÍ–Bedrocan EU-GMP manufacturing partnership — export-to-domestic pivot via API-to-finished-dosage conversion.

• SOMAÍ Pharmaceuticals (Lisbon) signed a 21 April manufacturing partnership with Bedrocan International — Bedrocan supplies cannabis flower as API; SOMAÍ converts it into EU-GMP-compliant oral solutions (and potentially other extract-based formulations) for international medical markets under the Bedrocan brand. Quoted: George Bellow (SOMAÍ Co-Founder), Jaap Erkelens (Bedrocan CEO). Next step: product commercialisation pending — agreement signed only, no shipping yet.

Hemp track scales 8× in two years; sector launches two trade associations to defend producers and CBD retailers ahead of CAP 2028–2032.

• DGAV data shows Portugal’s hemp area expanding from 68 ha (2024) to ~480 ha (2025) — a ~800% increase over two years — even as approvals tightened from 41 (2024) to 33 (2025); Alentejo dominated with Beja 49% (~235 ha) and Portalegre 21% (~100 ha); multi-purpose fibre+seed led (385.27 ha vs 87.81 ha fibre-only and 8.1 ha seed-only).
  • The Portuguese hemp sector launched two new trade associations on 23 April — Anicann (full value chain; Humberto João Nogueira; formalised end-March 2026) and Associação Cannabis CEE (CBD retailers; José Santos; formalised September 2025) — to defend producers and retailers against PJ/ASAE/Infarmed enforcement and push legislative change.
    • Joint priorities: raise THC threshold from 0.3% to 1% (citing Switzerland and Czech Republic at 1%, Italy at 0.6%, South Africa at 2% proposal); push CAP 2028–2032 rollout (hemp flower acquiring fibre/seed parity from January 2028); file Provedor de Justiça complaints; pursue Tribunal Constitucional review of the 2021/2022 hemp Portarias and Decreto-Regulamentar 2/2020.
    • Next steps: workshops €10 (Porto 26 Apr / Lisbon 10 May / Algarve 24 May); first Feira Nacional da Indústria do Cânhamo planned October 2027; both ministries (Economy + Agriculture) committed to forming a working group with Infarmed re-engaged.

🇫🇷 France — Permanent medical-cannabis regime begins April as Cour des comptes calls AFD enforcement structurally broken and DGAL launches national CBD crackdown

🔭 On the radar: HAS draft decree on evaluation/reimbursement targeted to Conseil d’État by end-June 2026; HAS Transparency Commission final opinion expected Oct/Nov 2026; first routine prescriptions plausibly 2027, with slippage risk to 2028 — ~700 pilot patients on continuity extensions until then. DGAL national CBD/cannabinoid enforcement campaign starts mid-May 2026 with no transition period; ComplAlim repurposed as detection tool (Cannabis sativa repositioned “non-authorised”); SPC legal challenge testing French doctrine vs EU free-movement principle in preparation. Cour des comptes AFD recommendations submitted; full statutory rework pending; government still planning to extend AFD to illegal street races and rave participation. OCRTIS appeal lodged by Thierry’s counsel Angélique Peretti; informant Sofiane Hambli detained in Morocco with 20-year sentence in absentia and ≥15 t hashish unaccounted for.

🏛️ Regulation — Permanent medical regime begins as Cour des comptes calls AFD enforcement broken (€1.1bn unpaid) and DGAL preps mid-May CBD crackdown

France’s regulatory signal moved on four fronts in April: the experimental medical-cannabis programme (~3,200 enrolees 2021–2024) transitioned to a permanent nationwide regime with indoor-only cultivation, certified-physician prescription as last-resort therapy and reimbursement still under negotiation; ~700 patients on continuity extensions to Q1 2027 (HAS final opinion targeted Oct/Nov 2026); Cour des comptes delivered a damning verdict on the amende forfaitaire délictuelle (AFD) scheme (€1.1bn unpaid since 2018; 24% pay rate); and DGAL announced an unprecedented national CBD/cannabinoid enforcement campaign starting mid-May 2026 with no transition period.

Permanent medical-cannabis regime starts April; HAS-led generalisation timeline depends on Conseil d’État decree (end-June) and Transparency Commission opinion (Oct/Nov 2026), with ~700 pilot patients on derogations until then.

• Newsweed (Aurélien Bernard, 8 Apr) reports Health Minister Stéphanie Rist signed a lettre de couverture extending experimental access to potentially Q1 2027 for the ~700 patients still treated under derogations (vs ~3,200 enrolled in the 2021–2024 pilot); DSS and DGS are reported to be aligning a draft decree for submission to the Conseil d’État by end-June 2026, with the HAS Transparency Commission final opinion expected October/November 2026 and conditioning reimbursement.
• Long-run patient-pool potential cited at ~400,000 patients within current indications (cancer, epilepsy, treatment-resistant chronic pain) if generalisation completes; first routine prescriptions targeted 2027, with slippage risk to 2028 if any of the three implementing texts (decree on cannabis-based medicines; product-specifications order; Conseil d’État evaluation/reimbursement decree) are delayed beyond summer 2026 — UIVEC president Ludovic Rachou quoted in Le Quotidien du Pharmacien.

Cour des comptes hands AFD scheme a damning institutional verdict — €1.1bn unpaid, 24% pay rate, 49× rise in disputes, calls for complete revision.

• The Cour des comptes report (15 Apr) concludes AFD has only “limited” effectiveness, with deep structural weaknesses in enforcement and equity: AFDs delivered rose from 57,300 (2019) to ~500,000 (2024) — ~10% of all infractions — yet €1.1bn remained unpaid since 2018, with only €137.5M collected on non-traffic AFDs across 2020–2025 and a payment rate of just 24%; drug-consumption AFD disputes rose 49× between 2020 and 2024 and detected irregularities climbed from 0.6% to 8.6%.
  • CBD-defence legal grey zone: many contestants argued they were consuming legal CBD products, not illegal cannabis; police authorities reportedly instructed agents to demand purchase receipts, but the Cour flagged that no law requires individuals to carry a CBD receipt, echoing the May 2023 Défenseur des droits recommendation to abolish AFDs for minor delicts on arbitrariness/equality grounds. Next step: government plans to extend AFDs to illegal street races and rave participation despite the Cour’s call for “complete revision”.

DGAL announces unprecedented national CBD/cannabinoid enforcement campaign — starts mid-May 2026, no transition period, ComplAlim repurposed as detection tool.

• At a 15 April DGAL meeting, SPC, Synadiet, UIVEC and Simple were briefed on the operational procedures for a 2026 national control plan targeting all food products and food supplements containing CBD, THC or any other cannabinoid — anchored in EU Regulation 2015/2283 (Novel Food); only hemp seeds and their derivatives (oils, flours) and aqueous infusions of hemp leaves keep an acceptable status, all other CBD-labelled extracts/isolates treated as unauthorised Novel Food.
  • Enforcement tiers: products mentioning CBD/THC/cannabinoid on the label trigger suspension of placing on the market followed by withdrawal; Δ₈-THC + Δ₉-THC > 1 µg/kg body weight (EFSA contested ARfD) triggers continued recall; total THC > 0.3% triggers a specific judicial procedure under the Arrêté of 22 February 1990; failing operator self-recalls, prefectoral orders can impose them after an adversarial procedure that has historically rarely sided with CBD operators.
  • The plant Cannabis sativa will be repositioned as “non-authorised” in the ComplAlim declaration database (originally a supplement-declaration platform), automatically routing any declaration mentioning the species to a reinforced procedure with no automatic attestation; SPC announces rapid mobilisation, a census of affected products and a legal analysis testing French doctrine vs EU free-movement principle (CJEU Kanavape, 2020).

Former OCRTIS chief François Thierry convicted over botched 7.1 t Paris controlled-delivery; informant Sofiane Hambli sentenced 20 years in absentia.

• The Bordeaux criminal court (1 Apr) handed Thierry a one-year suspended prison sentence for complicity in drug trafficking and destruction of evidence over the October 2015 Paris seizure of 7.1 tonnes of cannabis resin; the prosecution had requested acquittal but presiding judge Catherine Bonnici told Thierry: “Vous saviez que vous facilitiez une opération de trafic de drogue.” Informant Sofiane Hambli (detained in Morocco) was sentenced 20 years in absentia; the broader case involved at least 15 tonnes of hashish imported from Morocco via Spain, most of which remains unaccounted for. Next step: Thierry’s counsel Angélique Peretti announced an appeal.

💼 Market — France supplies 74.29% of China’s 2025 bast-fibre imports at 44,370 t (−52.16% YoY; figures sit within a broader flax-led bast-fibre aggregate per HempToday clarification, not pure hemp); Tarmac CBD elite-cut clone reshapes the French CBD top-tier with limited-drop fresh-sale model

France’s market signals concentrate in the hemp/CBD vertical: Chinese customs data (republished 24 Apr by HempToday with a bast-fibre clarification) shows France supplying 74.29% of China’s 2025 “hemp”-classified fibre imports at 44,370 t (−52.16% YoY from 92,744 t; Belgium share collapsed to 3.26% from 19.73%), while a Newsweed profile of the Tarmac CBD elite-cut clone signals a top-tier shift towards small-batch, fresh-sale premium CBD with limited grower distribution.

France strengthens position as main European gateway into China’s natural-fibre market — the 44,370 t aggregate sits within a flax-dominant bast-fibre category, not pure hemp.

• HempToday (24 Apr) republished SunSirs customs analysis with an explicit Update and clarification: figures reported as “hemp” in Chinese commodity data sit within a broader bast-fibre system including flax, jute and other plant fibres often substituted or blended in textile production — figures “primarily represent flax imports, but include hemp, jute and other minor fibres”; the YoY decline likely reflects substitution towards flax (strong 2024 European flax harvest) and a 2024 increase in industrial-hemp planting in Northeast China rather than a pure hemp contraction.
  • France share rose to 74.29% (2025) from 63.66% (2024); total category exports out of China fell $2.018bn (−15.23% YoY) across fibres/yarns/fabrics/finished goods; exports to the US grew +1.75% YoY, with fabrics 33.19% and finished products 66.81% of US-bound shipments. See for the Chinese customs primary numbers.

Tarmac CBD elite-cut clone reshapes premium French CBD — limited grower distribution, distinctive volatile-sulphur aroma, fresh-sale model now standard at the high end.

• Newsweed (Aurélien Bernard, 24 Apr) profiles Tarmac CBD — a Legendary OG Diesel-derived clone bred by Izno and limited to four growers (Weneed, Les Frères Canna, Etik CBD, Pinnacle) — framed as the first true “élite cut” of French CBD; Izno’s selection process screened several hundred phenotypes vs the 4-plant tent norm, with the resulting profile dominated by volatile sulphur compounds (VSCs) generating a rare gas/rubber/burnt-tyre aroma absent from standard terpene panels.
  • Sales-model implication: because rubber/gas VSCs are highly volatile, long curing degrades the signature — pushing growers towards small batches, rapid sale and maximum freshness in a California-style limited-drop model, repositioning the French CBD top-tier away from industrial standardised flower towards connoisseur fresh-product positioning.

🇧🇷 Brazil — STJ validates ANVISA’s 2026 resolution stack; market hits R$970m as cannabis enters top-10 most-judicialised medicines

🔭 On the radar: RDC 1015/2026 takes effect 4 May with new pharmacy and retail rules. PL 399 and PL 5511 (cultivation and regulatory frameworks) remain pending plenary deliberation. ANVISA regulatory-sandbox pilots and further STJ-linked implementation steps expected through H2 2026.

🏛️ Regulation — STJ validates ANVISA compliance but Conitec non-incorporation keeps access litigation-led

April delivered two data-led developments. STJ ruled that the Union and ANVISA had complied with the court-ordered plan to regulate medical cannabis production, citing five 2026 board resolutions covering cultivation-for-research, sanitary authorisation for manufacture and import, and a regulatory-sandbox framework. Cannabis-derived products entered Brazil’s top-10 most-judicialised medicines list, with public provision costing R$378m+ since 2015 and pharmacy-supply share falling from 70% (2023) to 61% (2024) as patient-association supply rose almost six-fold.

STJ’s compliance finding cements the new ANVISA resolution stack but leaves access mechanics unchanged. The court explicitly noted expectations of reduced judicialisation remain limited because home cultivation and flower sales are still not authorised.

• The ruling cites five 2026 board resolutions covering cultivation-for-research, sanitary authorisation, and the regulatory-sandbox framework.
• A follow-on April analysis frames the decision as a regulatory floor, arguing the next debate is whether the model is proportionate and access-expanding given strict sanitary controls and continued reliance on imports, associations, and court orders.

Conitec non-incorporation keeps procurement litigation-led, with channels shifting between pharmacy and patient associations. Cannabis-derived products now sit among the most-judicialised medicines in Brazil, per Kaya Mind’s 2025 yearbook cited in a Poder360 analysis.

• Public provision has cost at least R$378m since 2015; pharmacy-available products’ share of public-supply routes fell from 70% (2023) to 61% (2024).
  • Patient-association products’ share rose almost six-fold over the same period.
• Litigation concentration is visible in three law firms filing 300+ actions in Bahia; the ANVISA regulatory sandbox is positioned as the experimentation lane for alternative supply models.

💼 Market — Kaya Mind projects R$970m → R$1.2bn by 2027 as Abicann reaches ~300 members and operators scale telemedicine-to-pharmacy chains

April delivered two data-led developments. Kaya Mind estimates Brazil’s medical cannabis market reached R$970m in 2025 (+14% YoY) and could reach R$1.2bn by 2027, serving ~870,000 patients today with long-term potential of 6.9m. Operator scaling is now visible in association-led cultivation buildout and a “second-career” executive influx, with Abicann counting ~300 participants and Valor projecting ~15% annual growth on a R$970.9m 2025 base.

Association-led cultivation and processing are scaling alongside the formal market. Patient associations are expanding capacity to serve a litigation-driven access pipeline.

• A profile cites a R$1m investment in a 17-ha plot in Paraíba to expand cultivation capacity.
  • Kaya Mind estimates the market serves ~870,000 patients today and could reach 6.9m in the long term.

Executive hiring is rising as operators build regulated telemedicine-to-pharmacy operations. Valor frames 2025 volume at R$970.9m with ~15% projected annual growth and describes a “second-career” executive influx.

• Cannect scaled from 4 to 70 employees since 2021; Blis made 10 hires in 2025 with 9 more by March 2026 and opens a compounding facility in São Paulo in May; Ease Labs distributes through 4,000 points of sale.
• Abicann now counts ~300 participants as the trade body scales alongside the operator base.

🔬 Science — INTA and EMBRAPA align cross-border applied R&D from genetics to extraction at General Roca binational conference

April surfaced one Brazil-tagged science signal: a 16 April binational (Argentina–Brazil) hemp and medical-cannabis R&D conference anchored by INTA and EMBRAPA in General Roca (Río Negro), pointing to cross-border applied R&D (genetics → agronomy → traceability → extraction) rather than a Brazil-only clinical milestone.

INTA and EMBRAPA are aligning applied R&D across genetics, agronomy, traceability and extraction. The 16 April conference brought together INTA, EMBRAPA, UNCo and private-sector actors.

• The source flags an extraction-lab buildout and financing needs, while describing regulatory updates as a dependency for moving from research into scaled value-chain activity.

🇲🇦 Morocco — ANRAC reports 2025 record harvest of 1,957.6 t dry (+4% YoY) with 5,765 active permits; Cannaflex Maroc × Sothema ship first GMP-certified Beldia extract export

🔭 On the radar: ANRAC × AMMPS implementation continues — additional GMP-certified product registrations pending after the inaugural Cannaflex × Sothema export; broader European, Australian and South African export pipeline scaling from 2025 pilot shipments. Goldbar420‘s Swiss-managed medical cannabis distribution entity (origin-classified productions) flagged for launch in 2026; Swiss authorisations, partner-country volumes and timing not disclosed.

💼 Market — 4,147 new 2025 authorisations lift active permits to 5,765 across 4,776 growers and 3,141 ha; Cannaflex Maroc × Sothema deliver first commercial GMP Beldia API; Goldbar420 imports 700 kg Moroccan CBD resin for 350+ Swiss shops at CHF 700/30 kg

ANRAC published 2025 official data showing 1,957.6 tonnes dry output (+4% YoY) across 3,141 ha and 4,776 licensed growers, with first legal exports reaching Europe; one week later Cannaflex Maroc and Sothema delivered Morocco’s first GMP-certified pharmaceutical cannabis extract from the Beldia variety, operationalising the ANRAC × AMMPS product-registration protocol signed 14 March 2026.

ANRAC’s 23 April release lifts active permits to 5,765 (4,147 new authorisations in 2025) across 3,141 ha and 4,776 growers; first legal exports now reaching Europe confirm the pivot from raw-material supplier to regulated-product exporter under Law 13-21.

• Cultivation footprint: 5,492 cultivation licences benefiting 5,318 farmers; 1,957.6 t dry output (+4% YoY vs 1,881 t in 2024); 4,147 new permits issued in 2025 against a base of 5,765 active.
• First legal European exports framed as a milestone rather than a sustained corridor — partner-country detail and volumes not disclosed; next step: scale and diversification of destination markets under the new product-registration framework.

Cannaflex Maroc and Sothema shipped Morocco’s first GMP-certified pharmaceutical cannabis extract (Beldia variety) on 30 April, intended as an active pharmaceutical ingredient. The export operationalises the ANRAC × AMMPS protocol signed 14 March 2026 and is positioned as the first commercial GMP test of the regulated value chain.

• Extract produced at Sothema‘s facilities; complementarity framed as Cannaflex (supply chain) + Sothema (GMP processing); regulatory supervision split between ANRAC and AMMPS (Moroccan Agency for Medicines and Health Products).
• Builds on 2025 pilot shipments to Europe, Australia and South Africa — first commercial GMP shipment under the new pharmaceutical-product registration protocol; next step: additional product registrations pending under the ANRAC × AMMPS framework, broader export pipeline scaling.

Goldbar420 imported 700 kg Moroccan CBD resin from the 2025 harvest across 11 new genetics (series 0012–0022) for Swiss distribution. Terpene analyses (Morocco and CBD Test, Switzerland) report 3× higher terpene levels vs prior productions; crops grown ~10 km from Ketama on southern Jbel slopes without greenhouses or artificial light.

• Pricing: distributor CHF 700 / 30 kg; shop CHF 109/lingot (ex-VAT) and CHF 990/kg (ex-VAT); distribution in 350+ Swiss CBD shops.
• New Lifter American-genetics line priced at CHF 450 / 10 kg distributor, CHF 649 shop (ex-VAT), CHF 69 per lingot (ex-VAT) — positions the brand at the accessibility end alongside its premium Moroccan line.
• Swiss-managed medical cannabis distribution entity (origin-classified productions) flagged for launch — early-stage announcement; Swiss regulatory pathway, authorisations and timing not disclosed.

🔬 Science — ⭐ Peer-reviewed MDPI life-cycle assessment finds Law 13-21 cooperative model cuts climate impact to 3.020 kg CO₂e/kg oil (vs 4.524 kg artisanal) and reaches 80% ISO-26000 social conformity (vs 20% artisanal)

A peer-reviewed life-cycle assessment in MDPI‘s Pollutants (10 April) quantifies environmental and social gains of Law 13-21‘s cooperative seed-oil model across artisanal, cooperative and regulated industrial chains: climate impact 3.020 kg CO₂e/kg oil (vs 4.524 kg artisanal, 3.251 kg industrial); fossil-resource scarcity 0.596 kg oil-eq (vs 0.897 kg artisanal); 80% ISO-26000 social conformity (vs 20% artisanal, 88% industrial).

• Cooperative inputs: 3.0 kg seed/kg oil (vs 4.4 kg artisanal); 0.54 kWh/kg energy (vs 0.9 kWh artisanal/industrial); process losses 0.15 kg (vs 0.6 kg artisanal); freshwater eutrophication 0.000970 kg P eq (vs 0.001464 artisanal); terrestrial acidification 0.015294 kg SO₂ eq (vs 0.023051 artisanal).
• ISO-26000 dimensions: cooperative scores highest on community involvement; industrial highest on governance, fair operating practices and consumer issues — together validating the regulated cooperative/industrial models over informal artisanal production.
• Recommendations: drip/micro-irrigation (water use −30–50%), Beldia-cultivar improvement for Rif climate, co-product valorisation (animal feed, fertiliser, bioenergy), renewable processing energy and eco-designed packaging; authors call for national sustainability standards aligned with ISO 14040 / 14044 / 26000.

🇨🇭 Switzerland — Pilots scaling: Züri Can extended to October 2028 as Bern Script study and Cann-L Lausanne report continue the evidence base

🔭 On the radar: CanPG / LPCan parliamentary debate expected from autumn 2026; possible referendum December 2028; expected entry into force ~2030 per industry associations. Bern Script study results due autumn 2026. GrowMotion €8m digital investment round targeted for September 2026; Swissmedic GMP target 2027. Ticino reimbursement: CanMedTicino call for uniform federal rules remains in advocacy phase.

🏛️ Regulation — CFANT validates LPCan avant-projet on 30 March; Zurich extends Züri Can to Oct 2028 (~902 kg, 106,000+ sales, CHF 7.5m diverted); Bern Script readout due autumn 2026; Ticino patients lose reimbursement mid-treatment

Switzerland’s adult-use reform reached a structural inflection point in April. The Federal Commission for Addictions and Non-Communicable Disease Prevention (CFANT) validated the avant-projet of the Cannabis Products Act (LPCan / CanPG) on 30 March 2026, Zurich extended its Züri Can pilot to October 2028, Bern‘s Script pharmacy study advanced toward an autumn 2026 readout, and Ticino patients lost mid-treatment medical-cannabis reimbursement — together building both the evidence base and the political case ahead of the autumn CanPG parliamentary debate.

CFANT’s favourable expert report frames a state-managed, non-profit retail model with cantonal monopolies and a dual quantity/THC tax — positioning the regulated market as the public-health response to a Swiss illicit market estimated at over 50 tonnes per year. The Commission validated the LPCan avant-projet on 30 March.

• Architecture: cantonal monopolies on physical retail (Geneva, Vaud, Neuchâtel cited); dual taxation on quantity and THC content to fund prevention; up to 3 home plants per adult.
• Process: parliamentary debate expected from autumn 2026; possible referendum December 2028; expected entry into force ~2030.

Zurich City Council extended Züri Can to October 2028 in a 101–13 vote, approving a CHF 800k supplementary budget (total city investment CHF 2.76m) and CHF 156k from the University Psychiatric Clinic for operational costs. The vote on 25 March 2026 reflects sustained political support; programme tallies cite ~902 kg dispensed and 106,000+ legal sales as of March 2026.

• The Zurich extension (Cannareporter) was echoed by industry voices flagging 20+ authorised sales outlets and a ~CHF 7.5m shift from the illicit market.
• The parallel GREA evaluation reports ~88,000 legal sales since August 2023, stable use over two years, rising pre-sale counselling uptake, and some users opting for lower-potency products.

Bern’s Script study runs to October 2028 with ~1,100 participants at CHF 9–15/g pharmacy pricing and a 10 g monthly cap, targeting 20% of participants switching to less harmful consumption methods. Der Bund detailed the pilot architecture: Pure Production AG supplies bio-certified flower from secured outdoor farms under the federal Experimentierartikel (2021), with 4 flower varieties, 2 hashish types and e-liquids dispensed via the Apotheke Unitobler and other Bern pharmacies.

• Pricing deliberately simulates a future taxation regime, exceeding black-market rates — study leader Reto Auer (Institut für Hausarztmedizin, University of Bern) frames the price differential as a research variable rather than a defect.
• First results due autumn 2026.

Ticino patients on doctor-prescribed medical cannabis lost insurance reimbursement mid-treatment, prompting CanMedTicino to call for uniform federal criteria. Corriere del Ticino collected four patient testimonies — a 44-year-old with chronic pain, ADHD and neuropathy; a psychiatric patient near-hospitalised; a multiple sclerosis patient; a 33-year-old who had returned to work — describing rapid clinical deterioration once reimbursement stopped.

• Of an estimated 1,160 Swiss medical-cannabis patients in the Federal Office of Public Health (FOPH) reporting system, only ~11% receive partial or full reimbursement (parliamentary question 25.7818, response by Federal Councillor Elisabeth Baume-Schneider).
• No cannabis-based medicine is currently on the Specialities List (the prerequisite for mandatory basic-insurance reimbursement); CanMedTicino president Gennaro Ausiello is collecting testimonies to anchor a federal advocacy push.

💼 Market — medcan.ch reports broader access but persistent reimbursement and prescriber gaps four years after the August 2022 reform; GrowMotion targets €8m round and 2027 GMP; Goldbar420 imports 700 kg Moroccan CBD resin and signals Swiss medical entry

April produced a four-year retrospective on the medical-cannabis reform, an upstream capacity-scaling signal, and the largest Moroccan CBD-resin import disclosed to date. Medical Cannabis Verein Schweiz (medcan.ch) reviewed four years since the August 2022 reform: easier prescribing and a wider product range (five formats — flower, oral extracts, capsules, suppositories, inhalable extracts), but persistent reimbursement and prescriber gaps especially in French-speaking Switzerland. GrowMotion detailed a Swissmedic-licensed scaling path, and Goldbar420 disclosed a 700 kg Moroccan CBD-resin import alongside a Swiss medical entity in formation.

The four-year medcan.ch review frames the reform as structurally positive but operationally incomplete: prescriptions rising, supply diversifying, prices slowly falling — yet specialist prescribers remain scarce and insurance reimbursement is rare. A March 2026 exchange with the Bundesamt für Gesundheit (BAG) and Swissmedic confirmed regulators still treat medical cannabis as a niche, placing the burden on patients and industry to drive change.

• Telemedicine fills the prescriber gap in Romandie, where specialist coverage is most acute.
• Driving rules remain a grey zone given very low THC blood thresholds; the association calls for improved insurance coverage as the precondition for sustainable access.

GrowMotion AG operates a Swissmedic-licensed Zuchwil facility at ~15% capacity (1.5–1.8 t/yr GACP), with permits in hand to scale to 6–8 t/yr; a September 2026 digital investment round targets ~€8m and Swissmedic GMP certification is targeted for 2027. The openPR release frames Germany’s import surge (~30 t → ~200 t in 18 months) as the demand backdrop for European producers already in operation.

• Plant footprint: 6,000 m² production hall; modular three-level vertical farm with up to 3,000 plants per 157 m²; ~900 m² currently active.
• Strategy: complete a vertically integrated seed-to-sell chain; proprietary genetics with reproducible cannabinoid and terpene profiles.

Goldbar420 imported 700 kg of 2025 Moroccan CBD resin across 11 new genetics (series 0012–0022); terpene analyses in Morocco and at CBD Test (Switzerland) report 3× higher terpene levels vs prior productions. The LinkedIn disclosure prices the line at CHF 700/30 kg distributor, CHF 990/kg shop (ex-VAT) and CHF 109/lingot (ex-VAT), distributed in 350+ Swiss CBD shops.

• Cultivation: southern Jbel slopes ~10 km from Ketama, without greenhouses, artificial light or forced cycles.
• A parallel Lifter American-genetics line is priced at CHF 450/10 kg distributor, CHF 649/shop, CHF 69/lingot (ex-VAT); a Swiss-managed medical cannabis distribution entity (origin-classified productions) is flagged for launch — Swiss regulatory pathway, authorisations and timing not disclosed.

🔬 Science — Cann-L Lausanne 2025 report shows 1,700+ registrants (~20% of estimated local users) and CHF 2m+ diverted from the illicit market; Geneva-led peer-reviewed steroid-profiling study links cannabis use to altered androgen and progesterone metabolism in young men

Cann-L Lausanne released its 2025 evaluation (Research Report No. 192) showing 1,700+ registrations (~20% of estimated Lausanne cannabis users), CHF 2m+ turnover diverted from the illicit market, and harm-reduction measures (counselling, vapourisers, oils) implemented by end-2025.

• A parallel BAG / Sucht Schweiz interim update on 28 April reported 1,750+ adults enrolled, ~20% of local consumption covered, a ~20% reduction in average use across a 670-participant cohort followed for ≥18 months, CHF 60k VAT and CHF 300k earmarked for local prevention and research.
• Product potency: Cann-L flower averages 12.5% THC and resin 17.5% in 2025 — below illicit-market reference values of 14.5% (flower) and >32% (resin) cited by a Vaud illicit-market study.
• An extension to mid-2029 has been requested from the BAG to investigate further regulation-related questions; enrolments remain open to Lausanne adults already consuming cannabis.

A Geneva-led peer-reviewed study in Nature’s Communications Medicine identifies altered steroid metabolism in young men consuming cannabis: testosterone, androstenedione and DHT significantly elevated; progesterone metabolites 5β-DHP4 and 11β-OHP4 markedly higher. The LC-MS/MS profiling of 70 endogenous steroids in 47 cannabis users vs 47 controls supports a possible link between phytocannabinoid exposure and disruption of the hypothalamic–pituitary–gonadal (HPG) axis.

• Key effect sizes: testosterone +7% (p=0.002); androstenedione p=0.008; DHT p=0.029; 17α-OHP4 p=0.03; 5β-DHP4 p=1.9×10⁻⁵; 11β-OHP4 p=5.7×10⁻⁵.
• C11-oxy androgens showed no significant change, pointing to selective effects on gonadal (rather than adrenal) androgen synthesis; chronic users showed stronger signals than occasional users.

🇵🇱 Poland — Centrum decriminalisation bill (15 g / 1 plant) enters public consultation 2–29 April 2026

🔭 On the radar: Centrum decriminalisation bill (15 g / 1 plant) closed public consultation 29 April; drafting-committee finalisation and Sejm first reading both unscheduled — bill text not yet in force.

🏛️ Regulation — Centrum decriminalisation bill (15 g possession / 1 home-grown plant) opens 2–29 April public consultation; Sejm first reading not yet scheduled

Centrum-backed bill decriminalising possession of up to 15 g of cannabis and one home-grown plant opened public consultation from 2 to 29 April 2026 — Poland’s first formal legislative step toward decriminalisation. The consultation phase is procedural; drafting-committee finalisation and Sejm first reading both remain unscheduled at end of April, and bill text is not yet in force.

💼 Market — Curaleaf Centrum Medyczne integration (16 cities, 40,000+ consultations); four high-THC pharmacy launches (27.3% / 23% / 22% / 20%); Kombinat Konopny NewConnect debut (+800% theoretical opening, PLN 0.90)

Poland’s medical cannabis market consolidated structurally in April 2026: Curaleaf International completed Fitokan’s integration as Curaleaf Centrum Medyczne (16 cities, 40,000+ consultations, 10,000+ patients) — the largest clinic-platform consolidation of the cycle — while four high-THC pharmacy launches (Pavé S1 27.3%, Humble Warrior 23%, Mimosa 22%, Bakerstreet 15 g) reached pharmacies. In parallel, Kombinat Konopny drew an 800% theoretical opening spike (PLN 0.90) on its Warsaw NewConnect debut — the first cannabis-adjacent IPO in Poland.

Curaleaf Centrum Medyczne completes the largest medical-cannabis platform consolidation of the cycle, integrating Fitokan into the wider European network spanning the UK, Germany, Portugal, Spain, Sweden and Canada. Curaleaf International announced the rebrand on 1 April 2026; operations, services and clinical leadership remain unchanged under founder Dr Paweł Dryżałowski.

• The clinic has run 40,000+ consultations for 10,000+ patients across 16 Polish cities; Curaleaf International posted FY2025 revenue of $172.5 m (+63% YoY; >$200 m run-rate) following a $500 m bond offering.
  • Nine Polish doctors visited Curaleaf’s Portugal facilities; an educational platform for Polish physicians is being adapted from the UK market.
• A Polish-language confirmation via BudCare (9 Apr) reinforces the patient/distributor messaging while signalling full integration into Curaleaf International’s European network.

Four high-THC pharmacy launches reach Polish shelves in two weeks (17–23 April), led by Cantourage’s Pavé S1 (27.3% THC) and supported by SUPROBION, S-Lab and a 15 g Bakerstreet pack format.

• Cantourage launched Pavé S1 (27.3% THC) into Polish pharmacies on 17 April — the highest-potency entry in the April pharmacy roster.
• SUPROBION delivered Humble Warrior (23% THC) on 21 April.
• Two further pharmacy launches reached shelves on 23 April:
  • S-Lab shipped Mimosa (22% THC) into pharmacies.
  • Canopy Growth‘s Bakerstreet (20% THC) launched in 15 g packs — the larger pack format aimed at extended-treatment patients.

Canopy Growth Polska signals a premium MTL pipeline for Polish patients, pending full URPL registration — products not yet on Polish pharmacy shelves.

• Canopy Growth Polska signalled Poland-bound MTL strains — Dante’s Inferno (28–34% THC), Frost’d Flakes (27–33% THC) and Pablo’s Revenge (28–33% THC) — pending full URPL registration (comprehensive dossier; T0/T3/T6 stability testing with ±10% THC conformity; Ph. Eur. analytical certificates covering microbiology, pesticides and heavy metals).

Kombinat Konopny’s Warsaw NewConnect debut draws an 800% theoretical opening spike on PLN 0.90, marking the first cannabis-adjacent IPO on the Warsaw Stock Exchange. Buy orders far exceeded available shares, triggering an exchange-rule trading delay; CEO Maciej Kowalski expects trading to begin within two weeks.

• The hemp-textile and CBD producer (founded 2020; vertically integrated; based near Elbląg) raised 23 m zlotys (~$6.2 m) across crowdfunding rounds since 2020 from ~2,500 retail investors — including 4.2 m zlotys in 38 minutes in its initial 2020 offering.

🔬 Science — Polish in vivo rat carrageenan study finds Tygra/Dora hemp extracts and CBD fail to inhibit inflammation; ASA remains superior

Polish researchers (J. Bartkowiak-Wieczorek et al.) reported in MDPI Nutrients (April 2026) that hemp extracts from the Tygra and Dora cultivars and pure CBD failed to inhibit inflammation in a carrageenan-induced rat paw-edema model, while acetylsalicylic acid (ASA) validated the model and remained superior — challenging anti-inflammatory positioning of hemp-derived cannabinoid extracts in vivo.

Cultivar- and dose-dependent signals undermined a clean anti-inflammatory readout: mRNA expression for pro-inflammatory cytokines and cannabinoid receptors moved inconsistently, and Tygra and Dora extracts behaved differently from one another.

• mRNA levels of pro-inflammatory cytokines (TNF-α, IL-1β, COX-2) and cannabinoid receptors (CB1, CB2) were inconsistent across tissues and doses, with some conditions showing up-regulation rather than suppression.
• Cultivar-specific differences between Tygra and Dora extracts suggest extract composition materially shapes biological activity — a caution for pharmaceutical pipelines positioning standardised CBD-based formulations as anti-inflammatory therapeutics.
• The result contrasts with in vitro literature reporting anti-inflammatory effects for CBD, underscoring model- and dose-dependency: the carrageenan paw-edema model may not be the appropriate assay, or formulation and dose selection may be the limiting variable in vivo.

🇳🇿 New Zealand — Puro scales to 2,121 kg exports (+138% YoY) as Ora Pharm opens extraction and Rua delivers first live-genetics export to Canada

🔭 On the radar: Government considering enduring multi-consignment export licences and licence-free low-THC cultivation. Ora Pharm‘s north-Waikato extraction facility pursuing EU-GMP certification. Puro planning ~90,000 plants next season and developing a contract-growing model (first partner: Te Rūnanga o Kaikōura); domestic supply still bottlenecked by packaging rules that require export-and-reimport for patient access.

🏛️ Regulation — Medsafe cuts export-licence processing to 6.4 working days as government weighs enduring multi-consignment licences and licence-free low-THC cultivation

New Zealand signalled a deliberate export-growth posture in April. Medsafe processing time for medicinal cannabis export licences fell to 6.4 working days year-to-date (from 22.5 in 2022/23 → 17.8 in 2023/24 → 10.0 in 2024/25), per Associate Health Minister David Seymour, while application volume rose from 26 (2022/23) to 65 (2024/25).

• Exported cannabis flower volumes referenced in the same release: 49 kg (2021) vs 2,310 kg (2025).
• Government is considering enduring multi-consignment export licences to reduce per-shipment friction; Medsafe is also moving to allow medicinal cannabis cultivators to grow low-THC plants without a licence, freeing more plant material for medicinal products.

💼 Market — Puro scales to 2,121 kg exports (+138%, 92% national share) and signs US$16m UK supply deal; Ora Pharm launches NZ Grow Co with 400 kg/day extraction capacity targeting EU-GMP; ECS Botanics reports A$118k operating cash flow with first NZ oil shipment imminent; Rua Bioscience completes NZ’s first live-genetics export to Canada

April’s New Zealand market story was export-led scaling at the cultivation, processing and genetics layers, with one operator delivering the country’s first live-cannabis-genetics export.

Puro scaled outdoor cultivation to 65,000 plants at its Kekerengu coastal farm (vs 16,000 last year) and grew 2025 exports to 2,121 kg (+138% YoY) — 92% of all New Zealand medicinal cannabis exports — after signing a US$16m UK supply agreement with IPS Pharma in November. The first shipment cleared just before Easter.

• Process innovation: live-drying (freeze flower at harvest, process to order) and solventless extraction (ice-water hash, mechanical rosin) preserve terpene and cannabinoid profiles end-to-end.
• Plans for next season: ~90,000 plants and a contract-growing model — Te Rūnanga o Kaikōura is the first partner, growing on iwi land under Puro production systems with Puro processing and on-selling the harvest.
• Friction: a regulatory rule requiring offshore packaging before re-import means New Zealand patients still access mostly imported products despite domestic production scaling.

Ora Pharm launched NZ Grow Co alongside the opening of its north-Waikato extraction facility, which is in the process of securing EU-GMP certification and can process up to 400 kg of flower per day. The Rural News tour with Deputy PM David Seymour framed the launch as a step from a fragmented sector to a coordinated export model.

• Ora Pharm reported 30 cultivators already associated and is expanding a satellite-grower programme where it obtains licences on growers’ behalf to streamline participation.
• Executive chair Stuart Wilcox positioned the model as a premium, science-led export sector anchored on consistency, traceability and compliance, with Seymour drawing the kiwifruit / mānuka honey / wine sector comparison.

ECS Botanics reported Q3 FY26 revenue of A$4.81m and a third consecutive quarter of positive operating cash flow (A$118k), with first commercial oil shipment to New Zealand partner NUBU Pharmaceuticals imminent. The ASX 28 April release frames branded B2C revenue at A$3.4m (~71% of total, +55% YoY) against an Australian industry sales decline of ~28.5% in H2 2025 (Penington Institute).

• Quarter-end liquidity: A$1.746m cash plus A$3.2m undrawn facilities = ~A$4.9m available funding.
• Parallel international flow: initial OzSun flower batches cleared German regulatory testing under the Nimbus Health partnership; commercial shipments to follow this quarter.

Rua Bioscience exported four cannabis varieties to Canadian nursery Apollo Green — the first known legal live-cannabis-genetics export from New Zealand, and Rua’s first entry into a legal adult-use cannabis market. The MMJDaily report cites industry estimates valuing the Canadian legal market at roughly CAD$4–5bn annually.

• CEO Paul Naske: the export reflects the company’s ability to navigate complex international regulations, with strategy centred on differentiated genetics connected to high-value global markets.
• Apollo Green MD Matthew Turner described the import as a notable development for the Canadian market.

🇿🇦 South Africa — DTIC misses April Cabinet deadline on omnibus cannabis law as ∼R28bn Grey Zone runs and Prince Western Cape High Court matter is set for 8 June

🔭 On the radar: Western Cape High Court Prince matter set down for 8 June 2026 (20-day answering affidavits, 15-day heads of argument), with interim relief sought against arrests, plant destruction and exclusion of traditional growers. DTIC interim retail-licensing system under exploration before an omnibus cannabis act; new commercial-trade law unlikely before mid-2028. SACCA Project Indlela pilot (83 applications since 12 March 2026 launch) feeding a pending DTIC submission on non-commercial cannabis legislation.

🏛️ Regulation — DTIC omnibus slips to mid-2028 as Prince Western Cape High Court hearing is set for 8 June and SAPS seizes >R8.5 m across nine provinces

April closed without the omnibus cannabis law South Africa’s industry has been waiting for: the Department of Trade, Industry and Competition (DTIC) missed its April Cabinet deadline for the draft commercialisation policy, with no commercial-trade cannabis law expected before mid-2028 — even as ~8,000 illegal outlets, ~2,000 private clubs and >500 tonnes of flower already operate in a Grey Zone valued at up to R28 bn (£1.28 bn). Judicial and enforcement tracks ran ahead of the legislative one: the Western Cape High Court set a 8 June 2026 hearing in Gareth Prince‘s constitutional challenge, and the South African Police Service (SAPS) stepped up illicit-market enforcement across nine provinces.

DTIC’s interim retail-licensing pathway stalls as the Small Business Development Department flags capacity gaps and the Justice Department resists recognising non-commercial cannabis clubs in Cannabis Act regulations.

• DTIC’s original Cannabis Master Plan targeted a regulated adult-use market by mid-2027; a 6 March 2026 parliamentary meeting estimated the Grey Zone at >500 t of flower across ~8,000 outlets and ~2,000 clubs, with retailers turning over R100,000/month to R100,000/day.
  • Small Business Development Department, drafting a new Small Business Act, told MPs it lacks the skills and capacity to handle cannabis licensing — narrowing the operational pathway for the interim retail framework DTIC favours.
  • Department of Justice spokesperson Makubela Mokulubete said the Department does not favour recognising not-for-profit cannabis clubs in Cannabis Act regulations, despite an incomplete review of public submissions.
• H3 legal strategist Charl Botha (6 March 2026 parliamentary presentation): “When the numbers keep shifting depending on who is speaking, Parliament loses a shared point of reference.” Next step: omnibus bill unlikely to reach the legislative process before mid-2028.

Cannabis Development Council of SA chair Gareth Prince’s urgent Western Cape High Court application proceeds to a 8 June 2026 hearing after the court refused the state’s request to remove the matter from the urgent roll.

• Court issued a procedural timetable of 20 days for answering affidavits and 15 days for heads of argument; matter set down for 8 June 2026.
  • Co-applicants: the RasTafari Nation Council and a group of small-scale farmers; interim relief sought against ongoing cannabis arrests, plant destruction and exclusion of traditional growers from the legal economy, pending a broader constitutional challenge to the Cannabis Act.
• Filed 14 April 2026 by Prince; even an unsuccessful application can keep the Cannabis Act under court process for months — cannabis remains classified as a narcotic under the Drugs and Drug Trafficking Act, blocking its formal recognition as an agricultural crop under the Plant Improvement Act.

South African Cannabis Clubs Alliance (SACCA) Project Indlela pilot has drawn 83 applications since the 12 March 2026 national webinar, building the evidence base for a DTIC submission on non-commercial cannabis legislation.

• Hosted on the Afrimeter platform, the survey collects aggregated and anonymised data from cannabis clubs, cultivators, legacy growers and township-based participants — targeting governance standards and practical regulatory parameters for the non-commercial sector.
• Project convener Albertus van Jaarsveldt: “Participation directly translates into influence… If the non-commercial sector wants to be properly recognised and regulated, it needs to be counted.” Next step: consolidated SACCA submission to DTIC pending.

SAPS intensified illicit-market enforcement in March 2026: >40 arrests and >R8.5 m in seizures across nine provinces, with a R5 m Johannesburg consignment as the largest single haul.

• Gauteng anchored the month: ten arrested over a R5 m cannabis consignment seized in northern Johannesburg (27 March), executed by the West Rand Hawks and K9 unit at a Ferndale address.
• KwaZulu-Natal ran the most retail-facing operation: the Provincial Organised Crime Narcotics Unit raided four Sativa Premium shops and a Clairwood warehouse, seizing R1.3 m in cannabis, edibles and vapes; owner Nivashan Moodley granted R10,000 bail at Durban Magistrate’s Court (30 March).
  • eThekwini District (19 March): five suspects (22–41) arrested across four shops in Umbilo, Amanzimtoti, Brighton Beach and Montclair; Westmead interception (6 March, Marshall Security): R30,000 street value.
• Cross-border and rural seizures: Limpopo Hoedspruit roadblock recovered 60 bales of eSwatini cannabis (R2 m street value, 20+ arrests); Free State R59 stop near Vredefort yielded ~110 kg of ‘Swazi dagga’ (R100,000); Mpumalanga Sulphursprings seized 64.1 kg (R390,000); Western Cape, North West and Northern Cape added further dagga and cross-substance operations.

💼 Market — ICBC Berlin pre-conference map sorts five operator tiers under PIC/S as Bassani Health discloses R330 m platform and KZN hands R5 m Okhahlamba project to CSIR

April produced the month’s most decision-relevant operator snapshot of South Africa‘s sector: an ICBC Berlin pre-conference industry map catalogued export leaders, infrastructure builders, genetics/cultivation specialists and domestic-market builders against a PIC/S regulatory backstop and an estimated 2,000+ consumption clubs and dispensaries operating since 2018 decriminalisation. At operator level, Bassani Health disclosed an end-to-end licensed seed-to-patient platform with R330 m invested in infrastructure and regulatory development, and KwaZulu-Natal Treasury transferred R5 m plus financial control of the Okhahlamba Insangu Project to the Council for Scientific and Industrial Research (CSIR) after corruption and a R34.6 m cash deficit derailed the Okhahlamba Local Municipality.

The ICBC Berlin pre-conference map identifies five operator tiers across export, infrastructure, genetics and domestic-market segments under a PIC/S regulatory umbrella.

• Export leaders cluster around regulated EU and CH demand: SafriCanna (GACP + EU-GMP, largest medicinal cannabis producer in Africa); MedCan (first SA high-THC flower export to the UK, indoor GMP facility in a former Johannesburg beer warehouse); Felbridge Medical (Limberlost) completed SA’s first commercial flower export (320 kg to Switzerland, June 2021), with Puregene genetics and Perfect Plants (Netherlands) tissue-culture co-operation.
  • Newer flows: Blommed executed 2025 shipments into Germany; ChroniCo logged multiple cross-border exports.
• Infrastructure builders scale processing, not cultivation: ImpiloVest/Afriplex (first SA cannabis processing licence, pharmaceutical-grade API extraction); CiloCybin (JSE-listed, 250 kg/day extraction capacity scalable to 1,000 kg, primary supply to Australia); Delta Nine Pharma (Cape Winelands EU-GMP toll manufacturer); GES Labs (advanced product development with German pharmaceutical partnerships).
• Genetics and cultivation specialists anchor the upstream: Rascal Medcan (SAHPRA GMP 2021, aeroponic system adapted from potato expertise, 130 employees, Mother Labs (Saskatchewan) partner); BioCann (3,500 m² indoor facility, 50,000+ plants/year, GMP/GACP/CUMCS-certified, Segra International genetics); Beyond Buds (Keisie Valley, 80% renewable energy); ILCO Farming (terpene expression at 3–4%, craft cultivation).

Bassani Health discloses a fully licensed seed-to-patient platform built around SAHPRA Section 21, with R330 m invested in infrastructure and regulatory development.

• Holds four distinct licences: SAHPRA Section 22C cultivation approval, Section 22C(1)(b) Manufacture and Packer licence, Department of Health manufacturing-pharmacy licence, and South African Pharmacy Council (SAPC) pharmacy-ownership certification.
  • The Packer designation authorises packaging and labelling of finished pharmaceutical products — a step the company frames as a structural bottleneck for most SA operators.
• Midrand facility built to GACP and GMP principles, with extraction, formulation and dose-ready product capabilities dispensed through licensed pharmacies under SAHPRA Section 21 unregistered-medicines access. Positioning is operator-level (no disclosed financials beyond the R330 m capex tag); strategy frames compliance as a competitive advantage as the regulatory framework formalises.

KwaZulu-Natal Treasury shifted R5 m and financial control of the Okhahlamba Insangu Project to the CSIR after a R34.6 m cash deficit and R11 m in missing pension contributions surfaced at the Okhahlamba Local Municipality.

• The R10 m provincial cannabis hub — launched in May 2025 by Economic Development MEC Musa Zondi in partnership with the Industrial Development Corporation (IDC) — targets oil and fibre production and small-grower incubation in the Bergville area of the Drakensberg.
  • KwaZulu-Natal CoGTA financial assessment cited “substantial cash flow deficits” at Okhahlamba and flagged that the municipality may be unable to pay salaries; the provincial Treasury reallocated the funding line from ‘Provinces and Municipalities’ to ‘Public Corporations and Private Enterprises’ with the CSIR as disburser.
• The CSIR is already procuring processing equipment: a tender for a portable NIR cannabinoid screening device (THC, CBD and related compounds, on-site quantification, spectroscopic measurement) closed 12 March 2026; next step: equipment delivery and project re-start under CSIR control.

🔬 Science — SAMRC longitudinal study logs adolescent cannabis treatment demand rising 43.4% → 56.2% of admissions (2020–2023) as baseline for 2024 Cannabis Use Act monitoring

The only April-dated cannabis-science item from South Africa is a South African Medical Research Council (SAMRC) longitudinal study by Prof Nadine Harker — also the Health Department‘s point person on cannabis-edibles regulation — finding cannabis treatment demand among adolescents and young adults rose from 43.4% (2020) to 56.2% (2023) of admissions; the paper (From courtroom to clinic) frames this as a ~23% increase and attributes it to the 2018 Constitutional Court Prince ruling that legalised private consumption plus COVID-19 social-isolation, academic-disruption and economic-insecurity stressors.

Risk-factor and lag-effect findings position the data as a baseline rather than a final readout on policy impact.

• Initiation at age 14 or younger and daily or weekly use are associated with elevated treatment demand and faster progression to cannabis use disorder; the paper notes that frequency alone does not capture the full picture — novel consumption methods and unknown potency are flagged as additional drivers.
• Lag effect: increases only became visible a few years after the 2018 ruling, consistent with stigma, regulatory uncertainty and market-stabilisation dynamics rather than an immediate policy-induced spike.
  • International comparator: post-legalisation Canada surveys reported 5.5% of 16–19-year-olds and 49.8% of 20–24-year-olds with increased cannabis consumption; the SAMRC frames the SA pattern as a partial mirror, with the COVID-19 channel layered on top.
• Next step: continued monitoring framed as essential for assessing the 2024 Cannabis Use Act — the study positions itself as a baseline against which post-Act surveillance data will be evaluated, with implications for the edibles regulations Prof Harker is helping draft.

🇮🇹 Italy — Cassazione 11058/2026 reaffirms Law 242/2016 offensività test; Imperia releases 530 kg seized hemp inflorescences

🔭 On the radar: Decreto Sicurezza on a final sprint in the Camera with a vote-of-confidence path on the broader instrument. Constitutional Court referral on art. 18 DL 48/2025 (hemp inflorescences) pending from late 2025/early 2026. National update to the Decreto 9 novembre 2015 medical cannabis framework flagged at institutional level; Sicily’s technical-committee confirmation marks the regional anchor. TAR and Tribunale del Riesame remain open avenues for industry seizure challenges.

🏛️ Regulation — Cassazione 11058/2026 reaffirms Law 242/2016 offensività test as +Europa contests DL 48/2025 art. 18

April 2026 ran the Italian cannabis-light dossier on two parallel tracks. The Corte Suprema di Cassazione (Terza Sezione Penale, ruling 11058/2026, decided 12/02/2026) declared inadmissible the Sassari prosecutor’s appeal and reaffirmed Sezioni Unite Castignani (n. 30475/2019, Rv. 275956): hemp cultivation under Law 242/2016 is lawful within parameters, and seizure cannot be maintained absent proven psychoactive efficacy. +Europa and the Italian Radicals mirrored the political track on 20 April with Parliament protests against DL 48/2025 art. 18 — the same provision the Cassation reading just narrowed.

Cassazione 11058/2026 closes a Cassation-level loop on the offensività test: even after DL 48/2025 art. 18 tightened the inflorescences regime, courts will not maintain seizures where the activity stays inside Law 242/2016 and the seized material is not a finished or semi-finished inflorescence product. On 8 April 2026, the Imperia public prosecutor’s office released 530 kg seized hemp inflorescences, citing the ruling.

• Procedural posture: appeal against the Tribunale di Sassari ordinance of 23/10/2025 — which annulled a probative seizure decree for lacking any indication of probative purpose, and found the cultivation by two agricultural/horticultural holdings pienamente lecita under Law 242/2016 parameters.
  • Panel: Presidente Luca Ramacci; Relatore Antonella Di Stasi; with Emanuela Gai, Ubalda Macrì, Alessandro Maria Andronio. R.G.N. 36325/2025; Procuratore Generale Maria Luisa Miranda also concluded for inadmissibility.
• Doctrinal anchor: Law 242/2016 covers cultivation of EU Common Catalogue hemp varieties (Directive 2002/53/EC, art. 17) for the purposes exhaustively listed at art. 2, sitting in the alveus of cultivations permitted by art. 26 DPR 309/1990. The 0.2%–0.6% THC band at art. 4 commi 5 and 7 protects compliant farmers but does not legitimise commercialisation of derivatives.
  • DL 48/2025 art. 18 introduced new artt. 1 comma 3-bis and 2 comma 3-bis Law 242/2016, excluding the law’s protection from inflorescence-based products (semi-finished, dried, triturated, extracts, resins, oils) — but the Tribunal found only plant residues not subject to processing in the holdings, so the new prohibitions did not apply on the facts.

+Europa and the Italian Radicals, led by Secretary Riccardo Magi, brought DL 48/2025 into political confrontation inside Parliament on the symbolic 20 April date, framing it as a prohibitionist crackdown on minor drug offences and on the cannabis-light supply chain. Demonstrations landed in and around Montecitorio while the relevant parliamentary committees were examining the measure, which the opposition argued had been excessively rushed.

• Substantive grievances: revision of rules on minor drug-related crimes (framed as a step backwards from alternatives to detention); further pressure on a prison system already in overcrowding; cannabis-light production now limited to professional horticultural purposes, effectively excluding sales and processing of inflorescences for other uses.
  • Industry concern (farmers, traders): fear of seizures and legal consequences. Available legal avenues: TAR (Regional Administrative Court) and Tribunale del Riesame.
• Statutory baseline reaffirmed: recreational cannabis remains illegal under DPR 309/1990 (personal use → administrative penalties; trafficking → criminal sanctions). Medical cannabis remains available on physician prescription; supply and distribution gaps persist. Next step: Camera vote-of-confidence path on the broader Decreto Sicurezza signalled in companion reporting.

Sicily acknowledged persistent patient access barriers and confirmed that a national update to the 2015 medical cannabis framework decree is forthcoming, after an official request from PazientiCannabis APS ETS. PazientiCannabis flagged regional implementation as uneven across Italy’s 20 regions, with slow bureaucracy and prescribing friction persisting in practice.

• Institutional confirmation: a Technical Committee on Medical Cannabis already exists at the Sicilian Regional Health Authority level; a national update to the Decreto 9 novembre 2015 (framework decree) is anticipated. Critical issues are acknowledged at the institutional level, but day-to-day access remains constrained.
• Statutory frame: Decreto 9 novembre 2015; Legge 4 dicembre 2017, n. 172 (art. 18 quater); Legge 94/1998 (off-label prescribing); DPR 309/1990; DM 25 giugno 2018 (update of medicines list in Allegato III-bis of DPR 309/1990). Next step: national decree update flagged but not yet enacted.

🔬 Science — Italian cohort finds cannabis use disorder lowers adult ADHD pharmacotherapy response

A retrospective cohort study from multiple Italian ADHD outpatient centres, published in the MDPI Journal of Clinical Medicine on 2 April 2026, identifies cannabis use disorder as modifiable barrier to ADHD pharmacotherapy response in adults, with co-occurring alcohol use disorder (AUD) and autism spectrum disorder (ASD) further diminishing efficacy. The paper supports systematic screening for comorbid substance-use disorders — including CUD — in adults initiating ADHD pharmacological treatment.

• Method and scope: routine clinical data from Italian ADHD outpatient services; multi-centre, retrospective, real-world evidence — ecological validity emphasised by the authors.
• Findings: CUD independently associated with significantly reduced likelihood of clinical response; AUD and ASD co-occurred as additional moderators, with combined presence compounding poor outcomes.
  • DOI: 10.3390/jcm15072688. Stakeholder impact: medical practitioners (screening protocols at intake) and patients (treatment planning for adult ADHD with comorbid CUD).

🇨🇿 Czechia — Konopex’s 9th edition (130+ exhibitors, Ostrava 24–26 April) frames first post-decriminalisation cannabis fair

🔭 On the radar: Cannabis social clubs and regulated retail still politically alive but no draft federal legislation tabled in April; first commercial cohort of CBD-flower brands (Trippy, Svatý Sedláček) trialling pricing under decriminalisation. Personal cultivation regime (three plants, 100 g dry per adult ≥21) in force since 1 January 2026.

🏛️ Regulation — Shared apartment-block cultivation and §16(4) composting-only disposal clarified under 3-plant / 100 g regime

Implementation Q&As from lawyer Adam Biňovec clarify two recurring compliance gaps under the 1 January 2026 personal-cultivation regime (three plants, 100 g dry per adult ≥21): how adult cohabitants share home-grow setups in apartment blocks, and how to dispose of surplus without breaching air-protection rules. No new draft federal legislation on cannabis social clubs or regulated retail was tabled this month.

Adult cohabitants may legally combine personal-cultivation allowances in shared apartment-block spaces, subject to a provable legal relationship to the property. Each adult home-grower (≥21) keeps the statutory three-plant / 100 g entitlement; shared balconies, hallways or gardens are permitted provided each grower can prove the conditions are met for their own plants.

• Adam Biňovec (Magazín Konopí, 3 April) details compliance safeguards for shared cultivation in apartment blocks: written agreement among growers describing the setup, clear physical separation of each person’s plants (e.g. fencing), and written consent from the property owner for non-owners — the latter not legally required but recommended.

The Czech Ministry of the Environment’s air-protection guidance excludes open burning of home-grow surplus, leaving effective composting as the recommended disposal route. The state has issued no cannabis-specific methodological guidance; the gap is bridged by the existing biological-waste regime.

• Adam Biňovec (Magazín Konopí, 16 April) maps the disposal compliance route: §16(4) of Act No. 201/2012 Sb. on air protection in principle excludes open burning, per the Ministry of the Environment’s methodological statement of 4 April 2025.
  • Disposal should aim at the fastest possible degradation of the regulated substances; effective composting carried out so as to preclude further use of the plant material is the recommended approach.

💼 Market — Konopex stress-tests post-decriminalisation demand as Trippy and Svatý Sedláček debut CBD SKUs

Konopex 2026 (Ostrava, 24–26 April) functioned as the first national market-side stress test after 1 January 2026 decriminalisation: 130+ exhibitors, hundreds of visitors across generations, and a product mix spanning CBD flower, hemp consumables, cosmetics, pet supplements and textiles — with notable retiree turnout signalling demand normalisation beyond the under-30 base.

Konopex’s 9th edition showcased broad consumerisation across CBD, hemp food & drink and ancillary categories, with mixed-age demand challenging the youth-led market assumption. Regional press framed the fair as the first edition reflecting the new era of legal personal cultivation in Czechia.

• Deník.cz (24 April) reports the 9th-edition exhibitor count and product mix: free CBD-infused cotton candy, hemp ice-cream, hemp lemonade and beer at 60 CZK, alongside hemp clothing and dog granules / CBD drops for animals.
  • Moravskoslezský deník (24 April) confirms mixed-age demand — younger visitors driving CBD cotton-candy uptake, retirees buying cosmetics, ointments and seedlings; hemp textiles and food & drink straddle both segments.
• Fakty Konopne (18 April) previewed Konopex 2026 as the first Czech cannabis fair after decriminalisation, covering medical, recreational, hemp and pharmaceutical verticals.

Czech brand formation accelerates around CBD flower and hemp-tea SKUs, with operators positioning ahead of any future cannabis-club legislation. Both debut brands present at fair-format channels with explicit price points and SKU-level cultivar/blend differentiation.

• Trippy (Radim Horák and Vít Zubr, Třebechovice pod Orebem) debuted three CBD cultivars at Konopex — Harlequin, Sweet Cherry and Critical XL — at 149 CZK/g, falling to 89 CZK/g at 20 g bulk.
  • Hydroponic NFT cultivation; ~70-day grow plus ~one-month dry cycle. The brand operates informally as a cannabis club pending Czech legislation enabling formal cannabis social clubs along the German / Spanish model.
• Svatý Sedláček launched a four-blend cannabis-led tea line (Spink for sleep, Ommm for daytime balance, Ejchuchu for alertness, Ksichtík for skin) at 145 CZK per 20-bag pack via the brand’s e-shop; hand-grown and processed in the Jeseníky foothills.

🇮🇪 Ireland — MCAP review launches under Prof Shane Allwright; 74 patients in 5 years; Ava’s Protocol and Schedule 1/2 access in scope

🔭 On the radar: Review formally commences Q2 2026 with full report due within 12 months; review group membership and terms of reference to be agreed with the Chair across April 2026; eligibility expansion (neuropathic pain), Ava’s Protocol national hospital policy and border-confiscation issues all sit within scope.

🏛️ Regulation — MCAP review launched under Allwright; Schedule 1, Schedule 2 and Ava’s Protocol in scope

Ireland’s medical-cannabis access framework moves into formal review. Health Minister Jennifer Carroll MacNeill announced on 1 April the appointment of retired Trinity College Dublin epidemiologist Professor Shane Allwright as chair of the Review of Access to Cannabis for Medical Use, which will examine both the five-year-old Medical Cannabis Access Programme (MCAP) — which has approved just 74 patients via 22 consultants since 2021 — and the parallel ministerial-licence pathway, over a 12-month period from a Q2 2026 commencement.

MCAP scope and HRB evidence base anchor the review’s clinical remit. The review will examine the operation of MCAP and the availability of Schedule 2 cannabis products alongside the ministerial-licence route for Schedule 1 products, with an explicit mandate to assess whether the programme’s narrow eligibility should expand.

• The Department of Health press release of 1 April sets terms covering MCAP operation, Schedule 2 product availability, Schedule 1 / ministerial-licence operation, and development of a national policy on Schedule 1 administration.
  • MCAP eligibility is limited to MS spasticity, chemotherapy-induced nausea/vomiting, and treatment-resistant epilepsy; prescribing rights are restricted to medical consultants and patients must have exhausted standard treatments.
  • The Health Research Board January 2024 evidence assessment of 47 systematic reviews supported use for MS spasticity and chemo-induced nausea/vomiting and flagged promising evidence for neuropathic pain — the most likely candidate for eligibility expansion.
• Allwright’s tobacco/public-health background (2004 environmental tobacco-smoke report chair; Trinity College Dublin Fellow emerita) rather than cannabis-medicine experience has drawn comment; review group membership and detailed terms of reference remain to be agreed in April 2026.

Ava’s Protocol and border-access gaps confirmed within scope. Deputy Pádraig Rice‘s written question on 14 April produced ministerial confirmation that the 2024 Cork City Coroner recommendations — known as Ava’s Protocol — will be examined as part of the review.

• The Minister’s written answer of 14 April confirmed the chair appointment and stated that Schedule 1 product access, ministerial-licence operation and the Coroner’s recommendations all fall within scope; review duration set at one year from commencement.
  • Ava’s Protocol responds to the absence of any national hospital policy for administering Schedule 1 cannabis products, surfaced by an inquest jury recommendation after the 2023 death of Ava Barry in Cork.
  • Family barrister Doireann O’Mahony has framed the further review step as a delay to implementation already signalled in 2024.
• Border-confiscation cases — notably UK patient Jason Pickering‘s December 2024 Dublin Airport seizure of a validly prescribed UK cannabis flower product — sit alongside Ava’s Protocol as documented access gaps the review will address.

🔬 Science — New Phytologist maps Monoecy1 locus on the X chromosome; three tightly linked genes within 60 kb

A Dublin-led New Phytologist paper published on 21 April identifies three tightly linked X-chromosomal regulators (CsREM16, lncREM16, CsKAN4) within a 60 kb Monoecy1 locus that explains roughly 15% of phenotypic variance for the monoecy–dioecy trait in Cannabis sativa — the first QTL-anchored sex-determination locus mapped to a placed chromosomal region and a concrete molecular target for stabilising monoecious hemp cultivars.

Monoecy1 reframes the 2025 candidate-gene debate; ethylene-pathway genes positioned downstream. The work — funded by Taighde Éireann – Research Ireland and the Irish Research Council, with the F2 mapping population grown in Dublin — combines QTL mapping in 252 F2 individuals, comparative transcriptomics, and X–Y chromosome divergence analysis.

• Toscani et al. in New Phytologist place Monoecy1 in the oldest, most-diverged X-chromosomal region (80–82 Mb), with up to 40% Y-gene loss in the terminal block and trans-specific polymorphisms shared with Humulus indicating the locus predates the ~28 Myr Cannabis–Humulus split.
  • F2 segregation (43% female, 29% monoecious, 20.1% male; χ² = 18.3, P<0.001) and a 2.3× higher monoecy rate from monoecious vs female F2 mothers confirm X-linked, recessive monoecy with maternal influence.
  • Proposed combinatorial model: females express CsREM16 + CsKAN4 (lncREM16 off); males express lncREM16 + CsKAN4 (CsREM16 silenced); monoecious plants express CsREM16 only — positioning CsETR1 and CsACS3 (Akagi 2025, Carey 2025) as downstream floral-expression effectors rather than master switches.
• HlREM16 / HlKAN4 conservation in hop (189.9–190.0 Mb of the Humulus X; 83.3% and 59.3% protein identity to Cannabis orthologs) extends relevance to a Cannabaceae-wide sex-determination system; lncREM16 is not detectable in hop, indicating regulatory-layer divergence over evolutionary time.

🇬🇭 Ghana — NACOC opens medicinal/industrial cannabis licensing (≤0.3% THC, citizens-only) as US$45k/ha fees face Supreme Court challenge

🔭 On the radar: Smallholder farmer Mariam Alhassan’s constitutional challenge to the US$45k/ha fee regime pending before the Supreme Court; ZCCA technical-support offer to NACOC remains informal pending bilateral formalisation; diaspora investment pitch (US$7.8bn 2025 remittances framed as the primary FX channel) to translate into licence applications across the rest of 2026.

🏛️ Regulation — NACOC opens value-chain licensing under Act 1100 + LI 2475 as Zambia offers farmer-inclusive template

Ghana operationalises one of Africa’s newest medicinal and industrial cannabis frameworks. The Narcotics Control Commission (NACOC) opened licence applications in April 2026 under the Narcotics Control Commission Amendment Act 2023 (Act 1100) and LI 2475, covering cultivation, processing, R&D, testing, transport, import/export, sales and advertising — restricted to varieties ≤0.3% THC and to Ghanaian citizens or permanent residents aged 18+. Operational since the Interior Minister Mubarak Mohammed-Muntaka February 2026 Accra launch; recreational use remains prohibited.

Licensing rollout and diaspora-restricted access frame the regulatory architecture. NACOC’s licence categories span the full value chain under a citizenship-restricted regime that structurally privileges diaspora capital over foreign direct investment.

• NACOC opened applications across the full value chain on 12 April, with categories covering cultivation, processing, breeding/genetics, R&D, testing, storage, transport, import/export, sales/distribution and advertising/promotion under the ≤0.3% THC ceiling.
  • THC cap aligns Ghana’s framework with North American and European low-THC regimes; cultivation of psychoactive cannabis remains a criminal offence under existing narcotics law.
• Ghana Investment Promotion Centre CEO Simon Madjie pitched the regime to diaspora investors at the Remit2Invest roundtable in Virginia (19 April), positioning licences restricted to citizens/permanent residents as a competitive advantage over foreign corporates.
  • Bank of Ghana Governor Dr Johnson Asiama framed the US$7.8bn 2025 remittances flow — now exceeding FDI — as the primary capital channel for the regulated sector.
  • Government framing: economic diversification (pharmaceuticals, wellness oils, textiles, cosmetics, industrial materials), not recreational liberalisation.

Smallholder constitutionality challenge and Zambia’s farmer-inclusive offer test the cost regime. The cost architecture — US$45,000/ha for a cultivation licence plus a multi-tiered transport regime — drew formal pushback from the local hemp sector and a regional offer of regulatory assistance.

• Hempire Association of Ghana CEO Nana Kwaku Agyemang publicly criticised NACOC’s regime at a Cheeba Africa webinar (31 March), with the Zambian Cannabis Control Authority (ZCCA) offering technical support on a farmer-inclusive model.
  • Fee architecture (cited as among the highest globally): US$45,000/ha for a cultivation licence; US$2/km to transport industrial cannabis; two armed NACOC guards required per transport shipment.
  • ZCCA chair Dr Prosper Sievu offered to engage NACOC on adapting Zambia’s model — Zambian Defence Force and traditional leaders making land available for smallholder hemp cultivation; ZCCA pivoting from export-only to domestic medical cannabis and cannabinoid research.
• Smallholder farmer Mariam Alhassan is challenging the constitutionality of the fee regime in the Supreme Court, arguing the cost architecture breaches the constitutional principle that Ghanaians must be beneficiaries of government economic-development policy.
  • SACHIDA director Cian McLelland (Druids Garden) and Hemp Innovations Botswana‘s Lameck Nthlekela pledged regional support, framing Africa’s regulatory patchwork — a CSIR/Gauteng-funded hemp ‘superfood’ still blocked from school-feeding schemes — as the structural backdrop to Ghana’s affordability debate.

🇯🇲 Jamaica — CLA gazettes fee-free community permits and 2-year transitional pathway as legal market hits US$63.5m (+63% YoY)

🔭 On the radar: Cultivators’ transitional special-permit window (two-year ramp to Tier One cultivator status) to begin producing first cohort outcomes from 2027; GGPAJ industry-association advocacy for accelerated reform to capture US Schedule III tailwind without a corresponding government commitment yet documented; international-partner outreach (Minister of State Delano Seiveright) to translate the framework into export positioning.

🏛️ Regulation — CLA Special Permit Programmes widen access for traditional and small-scale growers

Jamaica’s Cannabis Licensing Authority (CLA) operationalised the most substantive overhaul of the island’s medical-cannabis framework since the original 2015 licensing regime. Cabinet promulgated the Dangerous Drugs (Cannabis Licensing) (Interim) (Amendment) Regulations, 2025, gazetted in April 2026, introducing fee-free community permits, a two-year cultivators’ transitional special permit, standardised three-year licence tenure and uniform six-foot fencing across cultivation tiers — with the CLA explicitly citing the legal market’s US$63.5m 2025 valuation (+63% YoY) as the trigger for accelerated reform.

Permit-framework reform widens access for traditional and small-scale growers. Two new fee-free permit categories anchor the package, paired with operational changes to tenure, fencing, ID cards and retail delivery.

• The CLA launched Medical Cannabis Special Permit Programmes on 16 April under the gazetted 2025 amendments, with CEO Farrah Blake and Minister of State Delano Seiveright framing the package as a removal of barriers for traditional ganja growers.
  • Special community permit: fee-free collective participation; access to CLA Cannabis Specialisation Unit technical support; sales permitted within the licensed space; participants not required to share a single physical location.
  • Cultivators’ transitional special permit: fee-free two-year pathway to Tier One cultivator status for small-scale farmers.
• Operational standardisation accompanies the new permits in the interim regulations gazetted to expand access, tightening continuity of operations and reducing administrative friction.
  • Licence tenure standardised at three years across all categories (previously one year for cultivation); full operation — including sales — permitted during licence-extension/renewal periods.
  • Employee ID cards introduced for mobility between licensed operators without per-move CLA authorisation; uniform six-foot fence height across all three cultivator tiers; authorised retailers permitted to deliver to clients.

Market growth cited as reform trigger; industry association warns of US Schedule III exclusion. The CLA pegged the reform pace directly to the legal market’s expansion, while the Ganja Growers and Producers Association of Jamaica (GGPAJ) flagged a downside scenario.

• Jamaica’s legal cannabis industry was valued at US$63.5m in 2025, up 63% year-on-year from US$38.9m in 2024 — a US$24.6m absolute increase the CLA cited as the rationale for the accelerated reform pace.
  • Reform-market linkage made explicit by the regulator: growth trajectory framed as a participation problem (traditional/small-scale growers under-represented) rather than a capacity problem.
• GGPAJ welcomed the US Schedule III reclassification on 28 April but warned Jamaican cultivators risk exclusion from the resulting tailwind without faster regulatory reform.
  • Industry-association framing: positions US Schedule III as a risk, not an opportunity, in the absence of accelerated CLA implementation — no corresponding government commitment to further reform documented in April.

🇯🇵 Japan — MHLW opens anti-illicit cannabis campaign (1 May) as CBN ban takes effect 1 June, closing the ¥10bn consumer market

🔭 On the radar: First MHLW eradication campaign since the 2024 Cannabis Control Act amendment came into full force opens 1 May; CBN (cannabinol) scheduling designation takes effect 1 June, closing the ¥10bn (≈US$62.6m) domestic consumer market; 17 April patient-exemption deadline frames the policy window for legitimate therapeutic supply continuity.

🏛️ Regulation — MHLW Narcotics Control Division opens nationwide eradication campaign as CBN designation closes ¥10bn consumer market

Japan’s enforcement track sharpens as the Ministry of Health, Labour and Welfare (MHLW) — via its Pharmaceutical Affairs Bureau Narcotics Control Division — announced the launch of the anti-illicit cannabis and poppy eradication campaign on 24 April, effective 1 May 2026 — the first nationwide eradication campaign since the 2024 Cannabis Control Act amendment came into full force, with a ¥120m enforcement budget against 4,500 reported cases. It runs concurrent with the 1 June CBN (cannabinol) scheduling designation that closes a ¥10bn (≈US$62.6m) domestic consumer market.

• Campaign architecture: coordinated inspections, education initiatives and data analysis spanning patients, policymakers and regulators; first eradication operation under the fully-in-force amended Cannabis Control Act.
• CBN cliff-edge: 17 April patient-exemption registration deadline frames the legitimate-therapeutic-supply window; 1 June effective date ends consumer-channel sales of CBN-based products.
• Enforcement context: 2025 cannabis arrests reached a record 6,832 (70% under 30; 50% first used cannabis under 20), framing the demographic targeting of the May campaign.

🇮🇱 Israel — Supreme Court seals Greencom exit and Green Fields enters confidential proceedings as Canareva and RCK collapse

🔭 On the radar: Green Fields gag order expiry on 3 May 2026 — possible sale and confidential licence-revocation announcement, with a permitted sale marking a sharp departure from the Greencom and Colibri precedents (where the Supreme Court authorised no plant sale); Greencom Group final licence cutoff on 1 June 2026 with Cloud9 patient supply transition pending; Health Ministry committee recommendations on a phased 3-year ban on smoked medical cannabis (HMO-led oversight, addiction protocols) surfaced just outside the April window — to be tracked in the May 2026 brief; THC driving-threshold draft regulations still unpublished four years after the HCJ pledge, with defence counsel Michael Carmel weighing a fresh High Court petition; RCK rescue-investor decision delayed ∼7 weeks beyond the original three-week window with no closure as of 27 April.

🏛️ Regulation — Licensing crackdown forces Greencom and Green Fields exits as inter-ministerial deal opens foreign-worker access for export-led cultivators

Israel’s medical cannabis licensing regime is forcing the simultaneous exit of two of the country’s largest licensed operators — Greencom Group and Green Fields — on confidential-intelligence grounds, while a parallel inter-ministerial agreement approves first-ever foreign workers on medical cannabis farms. The result is a sharp paradox: exit pressure on existing licensees through closed-door evidentiary proceedings sits alongside policy support designed to keep the surviving export industry supplied with stable labour.

The Supreme Court’s Greencom ruling seals the exit of Israel’s largest medical cannabis group on confidential-intelligence grounds. President Yitzhak Amit and Justices Ofer Grosskopf and Alex Stein dismissed both Greencom Group appeals on 20 April, finding a “solid administrative evidentiary infrastructure” sufficient even under the stricter standard required to revoke an existing licence.

• Cannabis Magazine reported that the Supreme Court rejected Greencom Group’s two appeals against licence revocation, confirming the Ministry of Health and Israel Police revocation of licences for Greencom Agro (Kfar Achim greenhouse) and the Technological Company for Growing Medicinal Plants (Shafir indoor facility).
  • ∼170 families lose employment across the two facilities; the Greencom 4U pharmacy permit also closes; tens of millions of shekels invested in the Shafir indoor build (≈NIS 18.2m) written off; thousands of Cloud9-brand patients need alternative supply.
  • Licences revoked on 30 April 2026 with a single partial extension granted to Greencom Agro to 1 June 2026 as a final deadline — the court clarified no further extensions will be granted.
  • Doctrine signal: the court rejected the Tikkun Olam structural-change remedy, ruling that a transfer of controlling shares and replacement of management was not sufficient to eliminate cannabis-leakage risk where ties to criminal elements were documented; aligns with Justice David Mintz‘s 6 March 2026 ruling in the Colibri case.

Green Fields faces a parallel confidential licence-revocation proceeding with a gag order expiring 3 May. Israel’s largest medical cannabis cultivator — ∼42 dunams in Moshav Magdim, ∼170 staff, ∼100 SKUs at any time, white-label producer to many marketers including MBA, Wiz Khalifa and Compound Genetics — has gone silent as confidential proceedings run behind closed doors.

• Cannabis Magazine reported that Green Fields is the subject of pending confidential licence-revocation proceedings, with a gag order expiring 3 May 2026, with industry sources suggesting a permitted sale to new owners — an outcome denied to Greencom and Colibri.
  • Process anomaly: the gag order — issued by the District Court and upheld by the Supreme Court — is unprecedented vs comparable cases (Greencom, Colibri, Telecan, Canomed), all run in open court.
  • Background threads: a December 2024 police recommendation to the Ministry of Health; the August 2025 Straw Companies affair (David “Dudu” Vaknin / Emerald Leaves, NIS 20m secret financing) where police stated Vaknin “bought cannabis… mainly from Green Fields Farm” — owners Ido Saada Piso and Lior Piso were questioned with warning, not arrested, and the company was not classified as part of the criminal organisation.
  • Family-history context: the Wooden Doll affair (November 2011) against the Piso family‘s Formica Source group produced NIS 169m in fictitious invoices, NIS 41m in money laundering and ≈NIS 70m in total payments to the state, with Yohai Piso sentenced to 40 months and Meir Piso to 20 months. Lior Piso herself was never charged; the same counsel, Attorney Jacques Chen, bridges both matters.

First-ever foreign-worker approval offers narrow relief to a sector growing exports >100% YoY. An inter-ministerial agreement among the Ministries of Agriculture, Health, National Security and the Israel Police — framed by Yuval Lipkin (head of the Food Safety Administration, Ministry of Agriculture) as “oxygen” for the industry — allows legal foreign workers already employed in Israeli agriculture to work on medical cannabis farms for 24–48 months, subject to background checks and the same no-criminal-record standard applied to Israeli workers.

• Cannabis Magazine reported the inter-ministerial agreement opening medical cannabis farms to foreign workers for the first time, ending a regulatory standoff first raised by growers in 2017 and blocked in the Knesset Committee on the Medical Cannabis Law in 2022 over police concerns about intelligence-gathering on foreign nationals.
  • Sector backdrop: exports surged more than 100% over the past year per the Ministry of Agriculture; many cultivators have closed or scaled back; recurring labour shortages, high turnover and training costs flagged as the operative bottleneck.
  • Operational details — quotas, allocation across farms and the oversight mechanism for resolving the previously cited intelligence-gathering gap on foreign workers — are not yet specified.

THC driving-impairment law remains on standby four years after the HCJ pledge. Drivers continue to be prosecuted as “drunk” under the Traffic Ordinance based solely on THC-COOH — the inactive metabolite — even when active THC is not detected.

• Cannabis Magazine documented drivers prosecuted on inactive THC metabolites four years after the Ministry of Health’s HCJ commitment (made on 2 May 2022 before President Esther Hayut, Justice Dafna Barak-Erez and Justice David Mintz) to publish draft regulations within 60 days.
  • The draft proposes a 3 ng/mL THC blood threshold (or 6 ng/mL plasma/serum), in line with Germany 3.5 ng/mL and UK 2 ng/mL — never enacted; cases cited include a 22-year-old from Zichron Yaakov (THC not detected, THC-COOH 46 ng/mL) and a ∼30-year-old from Haifa (THC not detected, THC-COOH 86 ng/mL).
  • Current penalty: up to two years imprisonment, mandatory 24-month licence revocation, insurance denial and potential manslaughter exposure under the “drunk is at fault” doctrine; defence counsel Attorney Michael Carmel is weighing a fresh HCJ petition.

💼 Market — Canareva and RCK collapses widen insolvency list as InterCure pivots The Flowery Israel toward DE/UK export expansion

Commercial-side fragility runs in parallel to the licensing crackdown. Canareva — Israel’s largest indoor medical cannabis facility — has ceased operations after a multi-year financial deterioration, and RCK — the Kibbutz Ruhama genetics breeder behind Freud Super-Ego and Galileo — has frozen operations and laid off ∼77% of its staff. At the premium end, InterCure‘s The Flowery Israel brand pivots toward DE/UK export positioning on a craft + Israeli-precision narrative.

Canareva’s closure removes Israel’s flagship indoor producer. Launched in 2020 in Moshav Tzofar (Arava region) as Israel’s first large purpose-built indoor cultivation site, Canareva had progressively moved to predominantly white-label production for marketers — most notably Bazalt, which has separately entered insolvency proceedings with debts in the hundreds of millions of shekels.

• Cannabis Magazine reported that Canareva has ceased operations under cumulative debt and supplier disputes, with the Moked Matara security-services lawsuit (NIS 475,663 unpaid since August 2025) settled on 25 February 2026 for NIS 250,000.
  • NIS 181,000 was transferred from seized Globus Pharma accounts (subsidiary of Together) toward the settlement, with seizures on Discount Bank and Globus Pharma accounts lifted on 19 March 2026.
  • Triggering events: a 2024 commercial dispute with Hiliz settled in mediation in December 2024; a November 2025 theft of medical cannabis from the Tzofar facility (agents posing as couriers, goods worth millions); supplier non-payments from August 2025.

RCK’s freeze closes the country’s leading indoor-genetics breeder. The Kibbutz Ruhama genetics company behind Freud Super-Ego (chosen as best Israeli cannabis strain in a 2022 large patient survey) and Galileo (T10/C10 balanced indica, licensed exclusively to Cannassure) ran out of cash after its 2023 strategic pivot away from vegetative propagation toward F1 hybrid seeds failed to produce commercial scale.

• Cannabis Magazine reported that RCK froze operations and laid off ∼10 of 13 staff, with hearings in early February and layoffs effective early March 2026.
  • Three rescue investors under NDA — one “very large and significant entity” — promised a decision within ∼3 weeks; ∼7 weeks elapsed by 27 April with no closure. A parallel commercialisation track for RCK’s genetics is also under negotiation in case the investors do not materialise.
  • Pivot risk realised: the September 2025 F1-seed export to F1 Seed Tech in the Netherlands (under a 2021 multi-million-dollar collaboration) was described internally as a “first swallow” — pilot-scale volumes that did not cover fixed monthly R&D costs.
  • Sector context: RCK joins Bull Pharma, Tikun Olam, Intellicana, Better, Pharmacan, Canashur, Greencom, Colibri and Telecan on the list of Israeli cannabis companies that have closed or scaled back operations.

InterCure pivots The Flowery Israel brand toward DE/UK export positioning. The Flowery Israel — InterCure’s premium flower platform — frames its DE/UK expansion narrative around U.S. brand partnerships (Wizard Trees, Preferred Gardens, Doja), Israeli scientific precision and culture-led storytelling rather than commodity-volume positioning.

• Honeysuckle Magazine profiled InterCure’s The Flowery Israel as a premium flower platform targeting DE/UK medical-market expansion, built on collaborations with Wizard Trees, Preferred Gardens and Doja and structured on InterCure’s pharmaceutical-grade operations.
  • Positioning: quality-over-volume framing anchored on cultivation precision, controlled-environment know-how and artistic collaboration with Israeli street artist Pilpeled; DE/UK expansion is a stated brand target, not a confirmed shipment.

🇺🇾 Uruguay — Yuzu Pharmaceutical opens Hospital de Clínicas chronic-pain THC/CBD trial as illicit share holds at 6.7% and Bullrich criticises legalisation model

🔭 On the radar: Yuzu Pharmaceutical six-week interim readout pending; full chronic-pain trial conclusions expected in ≈18 months and contingent MSP second-phase approval for commercialisation; IRCCA proposal for temporary visitor permits to break the 13-year residents-first rule under Law 19.172/2013 still in design; Yuzu’s medium-term plan to shift soft-gel capsule manufacture from Canada to domestic production pending evidence base.

🏛️ Regulation — Illicit-share cut to 6.7% under Law 19.172/2013 reframes the model as Bullrich brings external criticism on micro-trafficking and homicide grounds

Uruguay’s 2013 regulated-cannabis framework re-enters regional debate. The Institute for the Regulation and Control of Cannabis (IRCCA) second-evaluation finding — illicit share cut to 6.7% of the legal market — carries over into April as the central macro datum, while Argentine Senator Patricia Bullrich (former National Security Minister under President Javier Milei) visited Montevideo on 23 April to publicly criticise the legalisation model on micro-trafficking and homicide grounds.

External political criticism reframes Uruguay’s legalisation as a regional security debate. Bullrich’s visit added diplomatic pressure on the framework without triggering any Uruguay-side regulatory step.

• Bullrich criticised Uruguay’s legalisation as failing to curb micro-trafficking at the Manantiales Foundation conference at the World Trade Center, arguing the regulated market’s low potency limits uptake versus the illicit channel.
  • Homicide figures cited (Uruguay Ministry of the Interior, 2025): 372 homicides, rate 10.3 per 100,000 (down 3.1% YoY), 57% linked to inter-gang/drug-trafficking conflicts; Argentina comparator 3.7 per 100,000 with robberies down 20% during Bullrich’s tenure.
  • Bullrich advocated territorial-targeting strategies (“90% of homicides occur in 10% of the territory”) and the Argentine anti-mafia law (Italian technical assistance) as a regional template; framed Tren de Aragua infiltration in Uruguay and Chile as the regional backdrop.

💼 Market — IRCCA second-evaluation finding cuts illicit share to 6.7% as visitor-permit proposal tests the 13-year residents-first rule

The regulated framework’s headline market datum carries over from the IRCCA-linked second evaluation: illicit share down to 6.7% of total cannabis sales — one of the lowest globally for a regulated recreational market. The figure resurfaced in April coverage and frames the policy debate around whether to open temporary visitor permits to non-residents.

• The legal framework cut the illicit cannabis market to 6.7% of total sales per the second evaluation cycle, positioning Uruguay among the most successful regulated recreational markets globally.
  • Open policy tension: IRCCA weighing temporary visitor permits for tourists — a structural break with the 13-year residents-first rule (40 g/month cap; pharmacy/club/home-grow channels for residents only) under Law 19.172/2013.
  • Carry-over context: the 6.7% figure originates in the March 2026 second evaluation findings; April coverage re-surfaces the datum without an enacted policy change in the month.

🔬 Science — Yuzu Pharmaceutical opens first opioid-sparing THC/CBD chronic-pain trial at Hospital de Clínicas (n≥150; ≈US$1M; results ≈18 months); 5th Congreso Uruguayo de Cannabis Medicinal consolidates the professional forum

Uruguay’s medical-cannabis evidence base takes its first formal step. US-backed Yuzu Pharmaceutical opened recruitment for the country’s first opioid-sparing chronic-pain trial at Hospital de Clínicas, Montevideo — announced 17 April and presented to the medical community on 9 April at the 5th Congreso Uruguayo de Cannabis Medicinal (organised by Opción Médica at Hotel Regency Way, hybrid format) — testing THC/CBD soft-gel capsules in 150 chronic osteoarticular pain patients with reduced opioid consumption as the endpoint.

The Yuzu trial establishes Uruguay’s first domestic opioid-sparing RCT in chronic pain. Trial mechanics combine an ≈18-month full-readout window with a 2-week efficacy gate, and pair an initial Canadian-imported capsule supply with a stated medium-term goal of full domestic manufacture.

• Yuzu Pharmaceutical opened the first opioid-sparing THC/CBD chronic-pain trial in Uruguay at Hospital de Clínicas, Montevideo, with legal adviser Viviana Cervieri (Cervieri Monsuárez) citing Law 19.172/2013‘s medical-cannabis development clause as the regulatory enabler for the US$1m initial investment.
  • Trial design: n=150 chronic osteoarticular pain patients (20 enrolled at launch); soft-gel capsules at varying THC/CBD dose combinations; ≈US$1m initial investment; soft-gel capsules imported from Canada with medium-term goal to manufacture in Uruguay.
  • Endpoint and timing: reduced opioid (morphine-derivative) consumption; first monitoring at 6 weeks; full conclusions in ≈18 months; MSP second-phase approval contemplated for subsequent commercialisation (domestic first, then export).
• Parallel EFE/Infobae coverage from the 9 April Congreso presentation, with Mauricio Cuello (Instituto Nacional del Cáncer director) detailing the trial’s chronic-pain protocol as Uruguay’s first domestic medical-cannabis RCT.
  • Protocol mechanics: one tablet every 4 hours; weekly clinical assessment with pain diary; 2-week efficacy gate (drop-out if no response); 6-week total protocol with optional continuation; IRCCA and MSP institutional support cited.
  • Industry context: Uruguay’s prior cannabis economy export-tilted (≈45 tonnes exported in 2025, ≈85% to Brazil); successful RCT positioned as feeding both domestic patient-access pathway and the export proposition.

The 5th Congreso Uruguayo de Cannabis Medicinal consolidates the country’s professional forum. The fifth edition operates as the ecosystem-maturation marker rather than a clinical event, bridging clinical practice, academia, the productive sector and regulators.

• Opción Médica held the fifth edition of the Congreso Uruguayo de Cannabis Medicinal on 9–10 April at Hotel Regency Way (hybrid format), bridging physicians, pharmacists, researchers, business operators and institutions.
  • Audience scope: physicians, healthcare professionals, pharmacists, researchers, business operators and institutions; submissions of original research, papers and working-group projects accepted; positions the congress as a national reference forum after five editions.

🇮🇳 India — Delta Botanicals wins first federal cannabis-breeding grant since 1985 NDPS Act as CSIR-IIIM Jammu PPP advances toward human trials

🔭 On the radar: Delta Botanicals multi-year phenotyping/genotyping programme on Himalayan and Odisha landraces in delivery phase; CSIR-IIIM Jammu 8,000 sqm facility under construction with human trials expected to follow; FSSAI hemp/CBD/nutraceutical guidelines still pending; Vizag Range Police PIT-NDPS preventive-detention proposal for 114 individuals awaiting court approval; commercial-scale industrial hemp horizon Mitra-estimated at 5–7 years pending THC-threshold and processing-infrastructure decisions.

🏛️ Regulation — NCB Q1 2026 secures 73 convictions (₹1.22 cr in fines; 4× 20-year sentences); Vizag Range Police lock in 129 convictions across 72 ganja cases and propose PIT-NDPS preventive detention for 114

The NDPS enforcement track sharpens in parallel to the research-side opening. The Narcotics Control Bureau (NCB) posted its Q1 2026 conviction tally on 21 April, and Vizag Range Police released a 22-month rolling enforcement summary covering June 2024 to April 2026, with a preventive-detention escalation under PIT-NDPS proposed against 114 individuals.

Federal NCB enforcement and Andhra Pradesh sub-national prosecution reinforce the hard-prohibition counterweight. Conviction densities and asset seizures signal continued centrality of NDPS in India’s cannabis policy mix.

• NCB secured 73 convictions in Q1 2026, with 4 maximum 20-year sentences, 54 sentences ≥10 years, and ₹1.22 cr in fines under the Narcotic Drugs and Psychotropic Substances Act, 1985.
  • Q1 conviction density reinforces NDPS as the policy lead on the recreational vertical, running parallel to (not displaced by) the federal research-track opening on industrial and pharmaceutical pathways.
• Vizag Range Police logged 129 convictions across 72 ganja cases (June 2024–April 2026), seized ₹11.6 cr in property and proposed PIT-NDPS preventive detention for 114 individuals.
  • Andhra Pradesh sub-national signal: PIT-NDPS proposal indicates preventive-detention escalation distinct from ordinary NDPS prosecution; pending court approval before activation.

💼 Market — Industry voices frame India as a ‘treasure trove’ of cannabis genetics constrained by FSSAI silence on hemp/CBD, 0.3% THC compliance and processing-infrastructure gaps

With no FSSAI guidelines yet for hemp foods, CBD or nutraceuticals, India’s cannabis economy stays caught between centuries-old Ayurvedic use (the Ministry of AYUSH‘s ‘Vijaya’ whole-plant pathway) and the NDPS Act 1985‘s restrictions on resin and flowers. April industry coverage — a HempToday interview with Vikramm Mitra (Delta Botanicals) and a NuFFooDS Spectrum feature — frames the bottleneck as upstream genetics, processing infrastructure and definitional clarity rather than demand.

Genetics is the binding upstream constraint on industrial hemp and pharmaceutical scale. Mitra estimates a 5–7-year horizon to commercial-scale compliant industrial hemp contingent on THC-threshold and processing decisions; Uttarakhand’s 2016 licensing baseline supplies the empirical read.

• Delta Botanicals managing director Vikramm Mitra told HempToday that India is a ‘treasure trove’ of cannabis genetics but policy will determine whether the endowment translates into a commercial industry under the 0.3% THC compliance threshold.
  • Uttarakhand baseline: 30+ industrial hemp cultivation licences sanctioned since 2016; only one operator has produced a stable fibre variety — a measurable read on genetics, not licensing, as the binding constraint.
  • Forward indicators: central, southern, north-eastern and western regions remain closed to cultivation despite the land-bank opportunity; commercial scale estimated 5–7 years out; CSIR and ICAR working on standardisation, seeds, cannabinoid extraction and fibre.

Regulatory ambiguity — FSSAI silence on hemp/CBD foods — stalls the hemp, CBD and medicinal pathways. Industry framing positions India as a missed cannabis economy until definitional clarity and FSSAI guidelines arrive.

• NuFFooDS Spectrum‘s World Cannabis Day feature framed India’s ‘missed cannabis economy’ on the fragmented NDPS/AYUSH framework, with Wholeleaf‘s Shivraj Sharma and Awshad‘s Richa Jaggi flagging the absence of FSSAI guidelines as the structural blocker.
  • Asymmetry of the NDPS Act: resin and flowers strictly regulated; leaves and seeds in a legal grey area enabling state-regulated bhang consumption and Ayurvedic leaf-based formulations under the Ministry of AYUSH.
  • Ayurvedic licensing tightening: central authorities now require preclinical safety data for cannabis-leaf Ayurvedic formulations — a gradual shift toward stricter medical positioning while FSSAI hemp/CBD nutraceutical guidelines remain pending.

🔬 Science — Delta Botanicals secures India’s first government-funded cannabis breeding grant since the 1985 NDPS Act; CSIR-IIIM Jammu Rs 55 cr PPP advances toward human trials

India’s federal research apparatus opens a pharmaceutical/genetics path on cannabis for the first time since the 1985 NDPS Act. Bhubaneswar-based Delta Botanicals & Research secured a Department of Agriculture and Farmers Welfare grant under the Rashtriya Krishi Vikas Yojana‘s National Farmers Development Scheme, incubated by Indira Gandhi Krishi Vishwavidyalaya (IGKV R-ABI) under Prof. Hulas Pathak, while CSIR-IIIM Jammu‘s Rs 55 cr medicinal cannabis PPP advances toward human trials with an 8,000 sqm facility under construction.

The Delta Botanicals grant is the first federal cannabis breeding-research award since the 1985 NDPS Act. The multi-year programme targets the genetics bottleneck upstream of both compliant industrial hemp and pharmaceutical standardisation.

• Delta Botanicals was awarded India’s first government-funded cannabis breeding research grant since 1985 under the Rashtriya Krishi Vikas Yojana’s National Farmers Development Scheme, with IGKV R-ABI as incubator.
  • Scope: multi-year phenotyping and genotyping of cannabis landraces from the Himalayas and Odisha; controlled indoor and outdoor cultivation trials targeting stable seed varieties compliant with the 0.3% THC threshold.
  • Strategic framing (Mitra): without stable genetics, neither compliant cultivation nor reproducible clinical data is achievable; the project positions India — ‘Pharmacy of the World’, ≈20% of global generics — as a future supplier of cannabis-based pharmaceuticals.

CSIR-IIIM Jammu’s medicinal cannabis PPP advances toward human trials. The state research network’s commitment marks the first cannabis-based medicinal project of this scale since the 1985 NDPS Act.

• CSIR-IIIM Jammu‘s medicinal cannabis public-private partnership advanced toward human trials under a Rs 55 cr PPP investment with an 8,000 sqm facility under construction.
  • Companion programme to the Delta Botanicals grant on the upstream genetics side; first cannabis-based medicinal project of this scale since 1985 NDPS Act under the Council of Scientific and Industrial Research.

🇹🇭 Thailand — Medical-only conversion locks in as BE 2569/2026 caps >0.2% THC extracts at four purposes with 31 Dec 2026 licence cliff

🔭 On the radar: Three-year shop-to-clinic transition rolls forward on a licence-renewal trigger across the surviving ≈3,000 outlets; 31 December 2026 licence cliff under BE 2569/2026 for permissions issued under the 2020–2021 regulations; broader Cannabis and Hemp Act still awaiting parliamentary passage; a separate ministerial regulation on cannabis as a controlled herb is being prepared by the Department of Thai Traditional and Alternative Medicine; new nationwide outlet-mapping system and shopfront licence stickers to come online during the transition window.

🏛️ Regulation — Shop-to-clinic upgrade locked in (≈3,000 of 18,000 outlets remain) as BE 2569/2026 caps >0.2% THC extracts at four purposes

Thailand’s medical-only pivot moves from policy direction to enforceable architecture. Public Health Minister Pattana Promphat confirmed on 1 April that the country’s surviving ≈3,000 cannabis outlets (≈15% of the post-2022 ≈18,000 peak) will have to upgrade into licensed medical clinics, pharmacies or traditional pharmacies on licence renewal under a three-year transition window, and a ministerial regulation BE 2569/2026 — effective 26 April 2026 — narrowed legal use of cannabis/hemp extracts containing >0.2% THC to four purposes (official enforcement; medical; analysis/education/research; industrial), with permissions issued under the 2020–2021 regulations valid only until 31 December 2026.

The shop-to-clinic conversion is locked in as the structural rule. Outlet collapse from ≈18,000 to ≈3,000 is treated as the baseline; the rolling three-year transition runs on licence renewal, not a hard cut-off, and is paired with expanded enforcement powers and a nationwide outlet-mapping system.

• Public Health Minister Pattana Promphat confirmed that cannabis shops will be forced into a medical-clinic model on licence renewal, with the Department of Thai Traditional and Alternative Medicine director-general Dr Phongsathorn Phokphoemdee setting out the three-element policy package.
  • Outlet base: ≈3,000 of the ≈18,000 post-2022 peak (≈15%) remain; renewing outlets must be staffed by qualified professionals — doctors or Thai traditional medicine practitioners — with hospitals nationwide also set to dispense medical cannabis.
  • Three policy elements: expanded administrative enforcement authority (Public Health Ministry + police, under the Protection and Promotion of Traditional Thai Medicine Wisdom Act); conversion of shops to medical facilities at licence renewal with a three-year transition; nationwide outlet-mapping system with shopfront licence stickers.
• Independent analysis flags consolidation risk as the framework tightens around prescription-only retail, with Thailand’s market shifting toward a ‘medical-only’ model.
  • Hybrid framework persists: possession and home cultivation remain legal while retail access increasingly requires prescriptions; the broader Cannabis and Hemp Act has still not passed parliament; smaller operators face squeeze as larger dispensaries internalise clinician overhead.

BE 2569/2026 hardens the licensing regime for >0.2% THC extracts. The new ministerial regulation replaces the 2021 medical-only-purpose framework with a four-purpose licensing architecture, locks in Thai juristic-person applicants, and sets a 31 December 2026 licence cliff for permissions issued under the 2020–2021 regulations.

• The Public Health Ministry confirmed new >0.2% THC extract rules limiting licensed use to four purposes under BE 2569/2026, gazetted 26 March and effective 26 April; FDA (Thailand) to administer audits and monthly reporting.
  • Four permitted purposes: official enforcement (narcotics suppression); medical; analysis/education/research; industrial — replacing the prior medical-only framing of the 2021 regulation.
  • Compliance regime: Thai juristic-person licences (non-foreign under foreign business law) for producers, importers, exporters and sellers; per-shipment import/export permissions; THC analysis every production run; signage, labelling, monthly operational reports within one month of period close; existing 2020–2021 licences valid only until 31 December 2026.

🔬 Science — Kasetsart HPLC chemotaxonomy of 36 chemovars supports compliance under BE 2569/2026

Thai academic output in April lined up with the regulatory pivot. Kasetsart University published a chemotaxonomic framework directly relevant to QA/compliance under the new extract regime; Naresuan University published an early-stage sex-identification assay for breeding programmes; a Phitsanulok group reported the first demonstration of an AMF + endophytic fungi combination raising hemp fibre and cannabinoid yield without synthetic NPK — all in the same month the medical-only architecture took effect.

The Kasetsart HPLC + multivariate chemometrics study is the decision-relevant science output. Chemotaxonomy as a regulatory compliance and seed-certification tool underpins the licensing framework operators will need to satisfy under BE 2569/2026.

• A Kasetsart University team proposed a hierarchical chemotaxonomy for 36 cannabis varieties using HPLC cannabinoid profiling and PCA/HCA/LDA chemometrics, with high LDA discriminatory accuracy across THC-dominant, CBD-dominant, intermediate and balanced chemovars.
  • Ten major cannabinoids quantified (including THC, THCA, CBD, CBDA, CBG, CBN); framework framed as directly applicable to compliance testing, seed certification and pharmaceutical standardisation under the new extract regime.

Cultivation and breeding tools nest beneath the chemotaxonomy as the secondary track. Two Nature Sci Reports outputs add a sex-identification assay and a biological-fertility option for hemp.

• Naresuan University (Phitsanulok) published a multiplex high-resolution melting assay using MADC2 and SCAR markers for early sex identification of Cannabis sativa, supporting breeding programmes that depend on early male/female screening.
  • Detection limit 1:10 male:female in bulk samples; MADC2 + Cs_197 combination flagged as most accurate and cost-effective; supported by NSRF Thailand grants R2567B002 and R2566C051.
• A separate Phitsanulok-based team showed arbuscular mycorrhizal fungi + endophytic fungi raise hemp fibre and cannabinoid yield, first reported demonstration in hemp.
  • Best combination: Rhizophagus aggregatus + Lasiodiplodia theobromae; increased cellulose, acid-detergent and neutral-detergent fibre fractions plus cannabinoid mass fraction (especially CBD) in leaves and shoots without synthetic NPK — 90-day factorial pot experiment under controlled conditions.

🇪🇺 EU (umbrella) — BGH refers § 9 HWG telemedicine advertising ban to the ECJ (I ZR 118/24) for EU Services Directive review; David Hyde (Hyde Advisory) maps 5 European buyer cohorts, asset-light data wins, US Schedule III as European M&A tailwind

🔭 On the radar: ECJ ruling on Case I ZR 118/24 (§ 9 HWG / EU Services Directive compatibility) pending, expected to set the EU-wide digital-health/cannabis advertising baseline; MedCanG amendment still in the German Health Committee with mandatory in-person initial consultations and possible mail-order flower restrictions; US Schedule III rescheduling flagged by practitioners as a European M&A accelerant via lower 280E burden and broader US-buyer capitalisation; EU-wide sub-tracks (Greece flower-ban consultation, Austria BFG hemp-flower ruling, Flanders hemp expansion, North Macedonia smuggling investigation, Malta CHRA roster) handled in their own country sections this month.

🏛️ Regulation — BGH refers Germany’s § 9 HWG telemedicine advertising ban to the ECJ (Case I ZR 118/24) for EU Services Directive compatibility review; outcome will set the digital-health/cannabis advertising baseline across member states

The sole EU-wide structural action in April originates from Germany but binds across the bloc. On 8 April 2026 the Bundesgerichtshof (BGH) referred questions on § 9 of the Medicines Advertising Act (HWG) to the European Court of Justice in Case I ZR 118/24, asking whether the German ban on advertising individual telemedicine treatments is compatible with the EU Services Directive — a referral triggered by Wettbewerbszentrale lawsuits against platforms advertising cannabis telemedicine offers.

• The BGH referred § 9 HWG to the ECJ for EU Services Directive review after Wettbewerbszentrale successfully challenged platforms advertising cannabis telemedicine; the ECJ ruling will reach beyond cannabis into the wider digital-health sector.
  • Procedural posture: Case I ZR 118/24; referral issued 8 April; the BGH had previously confirmed the ban in earlier proceedings before the EU-law question crystallised.
  • Cross-border stakes: any ECJ finding of incompatibility with the EU Services Directive would obligate German legislative correction and set a precedent on Member State advertising restrictions for telemedicine offers more broadly.

💼 Market — Practitioner read on 2026 European cannabis M&A: investors buying meaningful data sets, 5 buyer cohorts active, asset-light models command highest multiples, US Schedule III flagged as European tailwind

David Hyde (founder, Hyde Advisory & Investments) used an ICBC-partnership interview with Krautinvest to lay out the structure of European cannabis M&A in 2026. The read: Germany’s prescription base is locked in despite the pending MedCanG amendment, valuations have normalised after the 2024 “hope premium” compressed, and capital is flowing toward asset-light “connective tissue” between producer and patient rather than cultivation.

• David Hyde (Hyde Advisory & Investments) told Krautinvest that investors are buying meaningful data sets — prescribing trends, patient outcomes, strain efficacy — not greenhouses; direct relationships with pharmacists and prescribing physicians have become the leverage point under restricted-marketing regimes.
  • Demand anchor: medical cannabis prescriptions in Germany surged ≈3,300% between 2024 and late 2025; even a narrowed telemedicine pathway leaves the patient base locked in. Draft MedCanG amendment (mandatory in-person initial consultation; possible mail-order flower restrictions) flagged as a structural overhang, with SPD/Greens resistance pointing toward a “video consultations where medically justifiable” compromise.
  • Deal architecture: heavy reliance on performance-based earn-outs, equity swaps and milestone-driven closings as 2026 marks the valuation normalisation; asset-light models without cultivation overhead command the highest multiples.
• The same interview mapped five buyer cohorts active in European cannabis and identified US Schedule III rescheduling as a structural M&A accelerant for European targets.
  • Buyer cohorts: US MSOs hunting platform acquisitions with patient data + infrastructure as European HQ; European consolidators (Sanity Group, Cantourage, Demecan) doing bolt-ons and pharmacy partnerships; pharma-Mittelstand targeting EU-GMP-compliant distribution hubs; family offices and PE moving on EBITDA-positive asset-light roll-ups; Canadian LPs pursuing supply-chain synergy rather than land grabs.
  • US Schedule III mechanism: removal of the IRC 280E tax burden plus reduced federal-risk profile would broaden traditional bank financing and NYSE/NASDAQ access for US operators, translating into more aggressive, better-capitalised US buyers active on German targets.

🇪🇸 Spain — Organic Law tightens Art 255(3) on grid-theft for cannabis cultivation as Spannabis 2026 (Bilbao) anchors market activity

🔭 On the radar: RD 903/2025 medical cannabis decree backdrop persists — AEMPS monograph window since 10 Jan 2026, product registration possible from 10 Jul 2026, sales launch est. Q2–Q4 2026, with only two companies registered for hospital supply as of March; Aurora‘s Canada–Leuna hybrid model lists Spain among four EU-GMP target markets as the European supply architecture firms up; CSC litigation and Cannabis Hub recurso carry-over from March await fresh decisions; Penal Code Art 255(3) reform now in force, with first convictions and operational follow-through to track across Andalusian hubs.

🏛️ Regulation — Organic Law hardens Art 255(3) penalties for grid-theft tied to cannabis cultivation

Spain’s federal cannabis docket was otherwise quiet in April. The single structural lever was a narrow but operationally targeted Penal Code reform: the Spanish Congress-approved Organic Law amending Article 255(3) entered into force, criminalising electricity fraud whenever the stolen power feeds drug cultivation, processing or trafficking, regardless of amount defrauded.

• The Spanish Congress tightened penalties for illegal grid connections used in cannabis cultivation under the Organic Law against multiple repeat offences, with the reform driven by the government’s sub-delegations in Sevilla and Granada.
  • Penalty architecture: 6–18 months’ imprisonment or 12–24 months’ fines under Art 255(3); combined with narcotics-cultivation offences, final sentences can exceed two years — increasing the likelihood of effective prison terms that rarely materialised under the prior framework.
  • Operational targets: recurring grid-overload zones in Andalusia where indoor cultivation has triggered neighbourhood blackouts and fires; recent Blessed and Empire operations seized thousands of plants and frame the enforcement runway under the new framework.

💼 Market — Spannabis 2026 (Bilbao) anchors April as Silent Seeds × Julian Marley, VOTUM LABS and Aurora signal EU-processing positioning

Market activity orbited Spannabis 2026 in Bilbao (17–19 April). The most concrete brand event was a seed-bank collaboration anchored at the show; alongside, a Spanish biotech lab credentialed its processes and a Canadian LP framed Spain as one of four near-term European target flows in a Krautinvest interview — reinforcing Spain’s positioning as a European processing node rather than a domestic-demand engine.

Genetics and seed-bank activity led the recreational track. Silent Seeds used Spannabis as the launch venue for its highest-profile brand collaboration of the year.

• Silent Seeds launched four new strains with Julian Marley at Spannabis 2026 in collaboration with Juju Royal powered by BioBizz, distributed via the Silent Seeds online shop and selected European retailers.
  • Strains: Julian Marley Special (Kush Mints × Apple Fritter); King of Kings (OGKB × MAC Stomper); Jamaican Mountain (High School Sweet Heart × Lemon Meringue); Jamaican Sunset (Mendo Breath × Sunset Sherbet).
  • Track record: 13 international awards to date; Best Seed Bank 2025 at the Spannabis Champions Cup in Barcelona; the Marley collaboration extends a pattern of cultural brand partnerships (Booba 2022; Sherbinski, Lemon Tree, Cookies).

Process credentialing and import-supply architecture led the medical/pharma track. Two distinct developments — one Spanish-domestic, one cross-border — sit under the same infrastructure theme.

• VOTUM LABS announced ISO 9001 (quality management) and ISO 56001 (innovation management) certifications, framing its biotech-laboratory model around traceability, continuous improvement and structured innovation governance.
  • ISO 56001 (innovation management) is a recent international standard and remains uncommon among Spanish cannabis-adjacent labs; paired with ISO 9001 it formalises process discipline for clinical-grade activity.
• Alex Miller (EVP Operations & Supply Chain, Aurora Cannabis) told Krautinvest the company runs a hybrid Canada–Leuna supply model with Spain among four EU-GMP target markets alongside Germany, Poland and the UK.
  • Canada anchor: over 10 years of legalised medical cultivation, large export scale, EU-GMP and other manufacturing standards, lower energy costs; Aurora Leuna ports Canadian expertise into local German production, framed as complementary to imports rather than a replacement.
  • Spain framing: positioned as a near-term European watch-list flow within a deliberate, demand-aligned scaling model — “won’t be linear, but the direction is clear” as EU regulators tighten around quality and patient safety.

🇦🇷 Argentina — Misiones dissolves MisioPharma (Decree 539/2026) as REPROCANN moves from Health Ministry to SEDRONAR

🔭 On the radar: MisioPharma liquidation under Fiscal de Estado Eduardo Duarte with Francisco Malica named liquidator — watch the fate of public cannabis research and Biofábrica Misiones continuity; REPROCANN → SEDRONAR ministerial framing under review by civil society, with potential drift from a public-health frame to a drug-policy frame; ARICCAME still under federal intervention since September 2024 with no productive-licensing advance; INASE seed-registry deadline rolls to 1 October 2026; World Marijuana March scheduled for 2 May at Plaza de Mayo; provincial licensing pile-up (Mendoza, Salta, ReproCABA, ReproChubut) deepening fragmentation risk through Q2.

🏛️ Regulation — MisioPharma dissolved in Misiones as REPROCANN moves to SEDRONAR and World Marijuana March readies for 2 May

Argentina’s April regulation track is defined by institutional retreat at the sub-national level and institutional drift at the national level. Misiones dissolved its state medical-cannabis company MisioPharma under Decree 539/2026, with Governor Hugo Passalacqua citing efficiency and a ‘mature’ global market; in parallel, REPROCANN moved out of the Ministerio de Salud into SEDRONAR (Secretaría de Políticas Integrales sobre Drogas), unwinding a backlog of thousands via digitisation but tightening review for minors and mental-health applications.

MisioPharma dissolution is the structural sub-national event. Six years on from launch, the province pivoted from a consolidated public production model (cultivation → oil → hospital distribution) toward private supply or imports.

• Governor Hugo Passalacqua ordered the dissolution of state medical-cannabis company MisioPharma via Decree 539/2026, citing cost optimisation and a normalised global market.
  • Liquidation under Fiscal de Estado Eduardo Duarte, with Francisco Malica named liquidator; closure formal from 16 April 09:00; technical staff to be reassigned to Biofábrica Misiones, leaving the fate of cannabis-specific scientific work open.
  • Strategic framing reads as a pivot from productive sovereignty to an external-supply logic; ARICCAME has been under federal intervention since September 2024 and has not advanced productive licensing nationally, so the Misiones retreat compounds the national-scale standstill.

REPROCANN moved from Ministerio de Salud to SEDRONAR while digitising approvals. Operational gains for new applications sit alongside institutional drift that civil society reads as a possible shift from a public-health framing toward a drug-policy framing.

• The programme’s digitisation now resolves most registrations and renewals in under 24 hours, per Claudia Pérez (civil-society referente, Aire de Rivera).
  • Backlog of thousands cleared after automation of data entry, informed consent and declaración jurada; pre-digitisation applications must be cancelled and restarted with a health professional.
  • Tighter scrutiny flagged for minors and mental-health pathologies; organisations seeking meetings with authorities to clarify how the Ministerio de Salud → SEDRONAR transfer will affect access criteria.
• The same source frames the transfer as material, with Claudia Pérez describing REPROCANN as una herramienta de política pública en salud and flagging risk of regressions in acquired rights.

Decriminalisation activism is mobilising. The annual World Marijuana March renewed its nationwide demand to end incarceration for cannabis offences.

• El Planteo reported the World Marijuana March 2026 renewing the Despenalización ya demand, with the main rally scheduled for 2 May at Plaza de Mayo from 14:00.
  • Stated focus: decriminalisation and basta de personas presas por marihuana; turnout and any policy reaction tracked into the May brief.

💼 Market — REPROCANN access vs industrial scale-up paradox locks in as Revista Mate publishes first nationwide cannabis price map (median AR$10,500/g)

The market reading paired a structural diagnosis with the first nationwide quantitative map. The country’s framework remains patient-access first via REPROCANN, with industrial scale-up stalled and provinces drifting toward parallel licensing; alongside, Revista Mate released the first nationwide cannabis price map (n=2,000) mapping a national median of AR$10,500/g and a dealer surcharge of 21–27% over cultivators and registered NGOs.

The access-vs-scale-up paradox is the structural diagnosis. Patient access via REPROCANN is operating; industrial-scale high-THC medicinal production remains stalled and the gap is filling at the provincial level.

• El Planteo (crediting High Times) framed the REPROCANN access vs industrial scale-up paradox as the operational centre of Argentina’s framework in April.
  • Licensing skews toward <1% THC hemp (fibre, grain, biomass); few effective pathways for large-scale high-THC medicinal production; seed/genetics oversight bottlenecks persist.
  • Provinces — Mendoza, Salta, ReproCABA, ReproChubut among them — explore their own licensing regimes to fill the national gap, raising fragmentation risk through Q2.

The Revista Mate price map is the first nationwide quantitative read. Two-thousand respondents in March 2026, processed by UNLP economists, paint a granular picture of access channels, quality tiers, and regional spread.

• Revista Mate published the first nationwide cannabis price map 2026, with methodology reviewed by UNLP economists Jimena Oviedo and Manuel Domínguez and commentary from Roxana Aguirre (Ciencia Sativa / FACC).
  • Headline numbers: national median AR$10,500/g; high-quality average AR$12,500, medium AR$10,500, low AR$8,500 (47% high-vs-low gap); full range AR$4,500–AR$20,000.
  • Channel structure: dealers 47.8% market share with a 21–27% surcharge over cultivators and NGOs; cultivators 37.7%; NGOs/clubs ≈10% — NGOs report the highest share of high-quality access (72.3%) at intermediate prices.
  • Regional and inflation context: Patagonia >AR$18,000/g vs NOA ≈AR$6,000/g (almost double across the country); +80% nominal over two years vs 104% official inflation (real-terms decline); FACC’s 24 organisations across 10 provinces face rising compliance overhead under the cap of three cultivation sites and mandatory chromatography reporting every six months.

🔬 Science — INTA × UNCo × EMBRAPA hemp meeting in General Roca (Río Negro) consolidates Northern Patagonia as binational R&D hub

A counter-weight on the science axis came from General Roca (Río Negro), which hosted a binational meeting on medicinal cannabis and industrial hemp — the most concrete cross-border R&D anchor of the month and a shared item between Argentina and Brazil.

• INTA convened a binational meeting on medicinal cannabis and industrial hemp in General Roca on 16 April, with Brazil’s EMBRAPA, the Universidad Nacional del Comahue (UNCo) and private firms Ciencia Sativa and Pasedati SAS.
  • Agenda spans phytoimprovement, agronomic evaluation (yield, water-use, density trials), traceability and medicinal-product development; Gabriela Calzolari (INTA Patagonia Norte) frames the binational track as complementary R&D building on prior INTA–EMBRAPA cooperation.
  • Strategic outcomes flagged: new resin-extraction laboratory to add local value; UNCo masters programme in cannabis cultivation and health applications; technical roundtables with control bodies to update regulatory frameworks — positioning Northern Patagonia as a binational innovation territory.

🇨🇴 Colombia — Q1 Esmeralda Plus balance (99 t cannabis, 17,266 detentions) compounded by Antioquia and Meta multi-tonne seizures as Umaña elected to UN INCB

🔭 On the radar: Q2 enforcement trend — single-event Itagüí 3,393 kg seizure already exceeds the Q1 national prorated cannabis pace and the Meta 2,698 kg cargo confirms a Meta–Guaviare–Vichada export corridor toward Central/South American markets; Umaña‘s INCB seat opens leverage on UN drug-control statistics and on cannabis scheduling debates (1961 Single Convention Schedule I status; 2020 Schedule IV removal); Decree 1138/2025 implementation — pharmacy-sales rollout under Invima, ICA and Fondo Nacional de Estupefacientes oversight — will determine whether the ≈US$64M domestic market scales; PharmaCielo interest-share issuance pending TSX Venture Exchange approval; Avicanna 6th Annual Cannabinoid Therapeutics Symposium scheduled 11–12 June at MaRS Toronto; Bilateral context — US exclusion of Colombia, Brazil and Mexico from Trump’s Escudo de las Américas alliance frames Petro’s compliance-by-numbers counter-narrative.

🏛️ Regulation — Q1 Esmeralda Plus balance plus Itagüí and Meta multi-tonne seizures signal Q2 acceleration as Umaña takes UN INCB seat

Colombia’s April regulation track is enforcement-data led, with international-policy positioning at the diplomatic layer. The Policía Nacional released its Q1 anti-narcotics balance under the Esmeralda Plus strategy; two late-month multi-tonne seizures in Antioquia and Meta confirm cannabis as a financing line for GAOR/dissident structures and point to Q2 acceleration; and Camilo Umaña Hernández — former Vice-Minister of Justice — was elected to the UN International Narcotics Control Board on 9 April.

The Q1 anti-narcotics balance sets the enforcement baseline. Esmeralda Plus outputs combine cannabis-specific seizures with precursor interdiction and detentions, framed against US bilateral context.

• The Policía Nacional released its Q1 2026 anti-narcotics balance under Esmeralda Plus, led by Antinarcotics Director Brigadier William Castaño Ramos.
  • Cannabis-specific scoreboard: 99 t cannabis seized (the closest Colombia gets to a quarterly PKS-equivalent figure); alongside 124 t cocaine; 17,266 detentions; 2,035 ha of illicit crops eradicated; 981 illegal infrastructures destroyed; 40 captures with extradition purposes; 99 fentanyl units.
  • Precursor interdiction: 450,427 gallons of liquid and 396,000 kg of solid precursors; reference operations included 4 t cocaine intercepted at Puerto Antioquia (Urabá) bound for London Gateway and 500 kg hidden in Cali.
  • Bilateral framing: the release was timed against US exclusion of Colombia, Brazil and Mexico from Trump’s Escudo de las Américas alliance — Petro leveraged the figures as evidence of compliance with international obligations.

Two late-month multi-tonne seizures tie cannabis explicitly to dissident financing. Antioquia and Meta both delivered single-event volumes that point to Q2 acceleration and confirm distinct internal-distribution and export-corridor patterns.

• The Colombian Army’s CCONA, with DIJIN, Interpol and the Policía Nacional anti-terrorism unit, seized 3,393 kg of cannabis in Itagüí (Antioquia) traced to the Dagoberto Ramos Ortiz FARC-dissident structure (GAOR).
  • Cargo valued at COP 9,432m (≈US$2.3m); estimated 169,000 doses; cargo originated 10 days earlier in Miranda (Cauca); one suspect captured. Confirms a Cauca → Antioquia internal-distribution corridor.
  • Single-event 3.4 t volume puts the Q2 running total well above the 99 t national Q1 pace prorated by region, signalling possible acceleration rather than a one-off.
• El Tiempo reported the Colombian Army and Policía Nacional seized 2,698 kg of cannabis in Meta tied to the Segunda Marquetalia / Subestructura 53 Edison Romaña, bound for Vichada and CENAM/South American corridors.
  • Financial impact COP 1,681m (≈US$410k); ≈2,698,000 doses prevented; two suspects captured. Confirms a Meta–Guaviare–Vichada export corridor distinct from the Cauca–Antioquia internal pattern.
  • Structural shift: documented evidence that Segunda Marquetalia finances itself via cannabis exports, not only cocaine — a development that may reshape regulatory cost-benefit modelling for licit-market reform.

International-policy positioning anchors the diplomatic layer. Umaña’s INCB seat strengthens Colombia’s voice on UN drug-control architecture.

• Infobae Colombia reported Camilo Umaña Hernández elected to the UN INCB on 9 April, with President Gustavo Petro framing the appointment as a diplomatic triumph.
  • Policy leverage: INCB members influence multilateral interpretation of cannabis under the 1961 Single Convention (cannabis remained in Schedule I after 2020 Schedule IV removal); Petro flagged “máximo rigor científico en las estadísticas” as a priority and announced a ≈4,000 ha reduction in cannabis cultivation in 2025 (first reduction since 2020).
  • Symbolism: Umaña is the son of murdered jurist Eduardo Umaña Mendoza; the election is framed as continuity with Colombia’s human-rights and harm-reduction tradition.

💼 Market — Decree 1138/2025 reframes domestic market (US$64M, 35,000 users) as veterinary cannabis projects +35% and Avicanna/PharmaCielo reset capital

Market coverage in April clustered around three threads: a Forbes Colombia synthesis framing Decree 1138 of 2025 as the inflection point for the domestic market; a Colombian veterinary cannabis growth projection from Kunam Pets / Carmen’s Medicinals; and a Colombia-linked exporter corporate cycle from Avicanna and PharmaCielo.

Decree 1138/2025 is the domestic-market inflection. Pharmacy sales of dried medicinal flower under medical prescription, with Invima, ICA and Fondo Nacional de Estupefacientes oversight, reshape what has been an export-led industry.

• Forbes Colombia profiled the Colombian legal cannabis market at ≈US$64M / ≈35,000 active users in 2024, set against a US$61.9bn global market projected for 2026 (Business Research Insights) and >20% annual growth through 2035.
  • Colombian Sweet Leaves (CEO Javier Amaya Mercado) benchmarks against Germany (€420m sales in 2024, projected >US$1bn by 2030, 300,000 patients, 2,500 dispensing pharmacies, €9–12/g retail) and argues Colombian retail could land well below that level under Decree 1138.
  • Hepta (founder Marco Serrano) advocates magistral sublingual formulations distributed via Cruz Verde, calling for industry-wide GMP-grade post-harvest practice and chromatography; Sintrabacann‘s Conexión Natural / Casa Wêt-Wêt runs a dispensary model under Sentencia C-127 of the Constitutional Court, with mandatory patient registration and a harm-reduction frame.

Veterinary medical cannabis sits as the secondary domestic-growth signal. A regulatory framework already certifying products via ICA plus an existing endocannabinoid-system rationale anchors the projection.

• Caracol Radio reported Kunam Pets / Carmen’s Medicinals projecting Colombia’s veterinary cannabis market to grow 35% in 2026 vs 2025 company data — outpacing the >25% global rate cited by the company.
  • Indication mix (per Juan Romero, CEO Kunam Pets): geriatric pets (osteoarthritis, canine cognitive dysfunction); anxiety/stress (fireworks, separation); refractory epilepsy (CBD adjuvant); dermatological / inflammatory processes.
  • Competitive advantage: GMP plus traceability requirements under Colombian regulation framed as enabling contaminant-free formulations with exact dosing.

The Colombia-linked exporter corporate cycle reset capital and governance. Two TSX-V issuers — Avicanna and PharmaCielo — signalled distinct moves on board composition, capital and clinical convening.

• Avicanna Inc. (TSX: AVCN) appointed Ozgur Kilic to its Board effective 1 April, after John McVicar‘s resignation; Kilic brings 20+ years across US, UK, Italy and Switzerland pharma and is framed as supporting US expansion.
  • Avicanna’s four commercial pillars: RHO Phyto™ medical cannabis formulary; MyMedi.ca care platform (Northern Green Canada Inc.); pharmaceutical pipeline (dermatology, chronic pain, neurology); Aureus Santa Marta™ APIs supplied by majority-owned Colombian subsidiary Santa Marta Golden Hemp SAS (CBD, THC, CBG).
• PharmaCielo Ltd. (TSXV: PCLO) intends to issue 11,145,999 common shares at C$0.08 to satisfy C$891,681.85 in accrued interest on its 11% secured debentures, subject to TSX Venture Exchange approval.
  • Effective price set under TSXV Policy 4.3 §3.3; Interest Shares subject to the statutory hold period under Canadian securities laws; principal Colombian subsidiary PharmaCielo Colombia Holdings S.A.S. based in Rionegro.

🔬 Science — Avicanna’s 6th Clinical Symposium on Cannabinoid Therapeutics expands to two days at MaRS Toronto (11–12 June)

The science track in April produced a forward-calendar anchor rather than a discrete published finding. Avicanna Inc. — whose Colombian subsidiary Santa Marta Golden Hemp SAS supplies the Aureus Santa Marta™ APIs — announced the agenda for the 6th edition of its clinical symposium, expanded to two days following demand from the medical community.

• Avicanna released the agenda for its 6th Annual Clinical Symposium on Cannabinoid Therapeutics, 11–12 June at MaRS Toronto, with sessions recorded for the Avicenna Academy.
  • 2026 programme highlights: Dr James MacKillop (McMaster / St Joseph’s Hamilton) on the state of evidence for medical cannabis in Canada; Dr Hance Clarke (Toronto General/UHN) on RWE from pain-related prescription; Dr Dilshaan Panjwani (BC Cancer) on an n-of-1 trial of medical cannabis extracts for cancer-related symptoms; Erin Mignault on menopause and cannabinoid-based therapies; Dr Luiza Marouelli (Santé Cannabis) on cannabinoids in gynaecologic care.
  • Track focus: women’s health, evidence-informed care for veterans, neurology/psychiatry, pain management and clinical workshops on titration and patient management — framed by Karolina Urban (EVP Medical Affairs, Avicanna) as a deliberate focus on underrepresented areas.

🇨🇱 Chile — Constitutional Tribunal challenge filed against Ley 20.000 hardening as Corte Suprema reclassifies 100.3 g as personal use

🔭 On the radar: Constitutional Tribunal admissibility decision on the 37-deputy challenge — watch whether the TC suspends promulgation of the Ley 20.000 reform pending plenary deliberation; resolution of the Decreto N°867 (Ministerio del Interior) vs Decreto N°84 (Ministerio de Salud) classification conflict on cannabis toxicity; downstream effect of the Corte Suprema’s 100.3 g personal-use precedent (SCS Nº2.813-2012, SCS Nº2.270-2008 reaffirmed) on defence strategies in microtrafficking cases; sustained pressure on the Antofagasta northern-barrier corridor with cumulative ≈20 t cannabis YTD seized; whether the PDI’s annual Plan Cannabis cycle is renewed beyond its 25th-anniversary close.

🏛️ Regulation — Constitutional Tribunal challenge and Corte Suprema personal-use ruling diverge as Calama and PDI seizures hit record intensity

Chile’s two highest courts moved in opposite directions on cannabis in April. The constitutional-judicial divergence is the editorially distinctive structural development of the month, with the enforcement track — also at record intensity — sitting as parallel context.

The Constitutional Tribunal challenge is the structural axis of April’s regulation track. Thirty-seven opposition diputados filed a requerimiento de inconstitucionalidad against the Boletín 15.347-07 / 16.430-07 reform that would apply trafficking-tier penalties to small quantities of substances deemed capable of producing graves efectos tóxicos.

• Radio Bío Bío reported 37 opposition diputados filing a Constitutional Tribunal challenge to halt the Ley 20.000 penalty-hardening reform on 13 April at 20:23, led by deputy Ana María Gazmuri (Acción Humanista).
  • The challenged norm shifts the historical axis of Ley 20.000 from a quantity-based threshold to a toxicity / potential-harm criterion, enabling trafficking-tier penalties even on small quantities; signatories warn this could criminalise medicinal users protected under Articles 4 and 8 of Ley 20.000 and under Ley N°21.575 (prescription-based medicinal cultivation).
  • Six constitutional guarantees invoked: right to life and physical/psychological integrity; equality before the law; proportionality; right to private life; honour; inviolability of the home. Signatory blocs include Frente Amplio (majority), Partido Comunista, Partido Socialista, PPD, Partido Liberal and Democracia Cristiana.
• Diario Constitucional subsequently framed the action as protecting medicinal cannabis users, flagging the unresolved conflict between Decreto N°867 (Ministerio del Interior) and Decreto N°84 (Ministerio de Salud) on cannabis classification — Decreto N°867 still listing cannabis among substances with grave toxic effects despite post-2015 sanitary rules permitting cannabis-derived medicines.
  • Petitioners argue that broad, ill-defined criteria such as ‘toxicity’ or ‘potential harm’ would be left to administrative or judicial interpretation, creating arbitrariness risk and breaking penal logic by punishing consumption and trafficking with equal intensity.
  • Procedural status: the TC must first review admissibility (deadline, active legitimation, prior constitutional reservation lodged by Gazmuri on 23 March, impugnable object); if admitted, the plenary may suspend promulgation pending ruling. Treat as filed and pending, not resolved.

The Corte Suprema’s 29 April ruling sits as the counterweight. A divided Second Chamber reclassified 100.3 g of cannabis as personal use, anchoring quantity-plus-context jurisprudence for future microtrafficking defences.

• Poder Judicial de Chile reported the Corte Suprema Second Chamber reclassifying 100.3 g cannabis possession as personal use in causa rol 54.608-2025, overturning a microtrafficking conviction from the Tribunal de Juicio Oral en lo Penal de Viña del Mar.
  • Reasoning: quantity alone (100.3 g, single transparent film wrap, CLP 10,000 cash, no transactions detected, no dosing or distribution implements) is insufficient to configure the Article 4 trafficking presumption — reaffirming SCS Nº2.813-2012 and SCS Nº2.270-2008.
  • Substitute sentence: one Unidad Tributaria Mensual (UTM) fine under Article 50(3); convertible to reclusión at one day per third of UTM if unpaid. Dissent from justices Valderrama and Zepeda on the principal nullity ground; López and Vidal voted to confirm the small-quantities trafficking conviction.
  • Scope: the ruling is operative on the specific case only and does not invalidate Ley 20.000; downstream effect will run through defence strategies in similar microtrafficking cases.

Enforcement track ran at record intensity in parallel. Three multi-tonne or multi-hundred-kilo operations underline the supply-side pressure even as the legal frame is contested.

• The Delegación Presidencial Regional de Antofagasta announced the Carabineros OS7 El Loa seizure in Calama of 4,695.2 kg cannabis plus 136.5 kg liquid ketamine in 648 vials — 4,831.7 kg total, the largest single seizure in Chile since the Reforma Procesal Penal.
  • Concealment via tanker truck bound for central-southern Chile; four detained (three Colombian nationals and one Bolivian linked to ketamine transport), placed in pre-trial detention on drug-trafficking charges.
  • Year-to-date context per General Cristian Montre: ≈20 tonnes of drugs seized in the Antofagasta region with an estimated street value of ≈CLP 200 bn; the regional government frames Antofagasta as the country’s northern barrier against trafficking.
• La Tercera reported the PDI closing the Plan Cannabis 2026 cycle on the programme’s 25th anniversary in Curicó with 111,424 plants seized (≈50 t), ≈58 million doses removed from circulation, and a CLP 290 bn valuation across the Coquimbo–Ñuble band.
• ADN Radio reported the Carabineros OS7 dismantling of a trafficking ring moving 272 kg of cannabis from Atacama to the Metropolitan Region, valued at ≈CLP 3.1 bn, with nine detained.

🇲🇽 Mexico — SCJN Pleno strikes Art. 478 LGS for personal-use cannabis sativa (AR 132/2025) as Senate integral law stays frozen

🔭 On the radar: AR 132/2025 returns to the Primer Tribunal Colegiado del Decimoséptimo Circuito for application; the Senate’s integral cannabis law (Sánchez Cordero vehicle) remains uncalendarised ahead of 2026 FIFA World Cup kick-off; Cofepris permit cadence (~1,000/month) on track to surpass the 12,500 five-year cumulative within 2026 if the amparo-based access route remains unchanged.

🏛️ Regulation — Tribunal Pleno retakes AR 585/2020 doctrine at full-court level while integral law stays frozen and access routes through Cofepris amparos

Mexico’s recreational-cannabis policy splits along a judicial-legislative divergence in April: the SCJN Tribunal Pleno retakes personal-use doctrine at full-court level via AR 132/2025, striking Article 478 of the Ley General de Salud in the porción “en igual o inferior cantidad” exclusively for cannabis sativa, while the Senate‘s integral cannabis law stays frozen and operative access continues to route through Cofepris permits secured by amparo (~12,500 over five years, ~1,000 applications/month).

Tribunal Pleno reaffirms AR 585/2020 doctrine at full-court level, interrupting four jurisprudencias exclusively for cannabis sativa. The Pleno expressly shares and adopts the considerations from AR 585/2020 (extinct Primera Sala, 11 May 2022, non-binding 3-vote majority), elevating the doctrine to Pleno level for the first time.

• SCJN Tribunal Pleno (ponente Min. Giovanni Azael Figueroa Mejía) declared Article 478 LGS unconstitutional in the porción “en igual o inferior cantidad a la prevista en la misma” — exclusively for cannabis sativa.
  • Interrupts jurisprudencias 1a./J. 72/2010, 73/2010, 74/2010 and 1a./J. 43/2012 for cannabis sativa only, under Article 228 Ley de Amparo; all other narcotics remain governed by the Article 479 dosage table.
  • The Ministerio Público may abstain from acción penal when possession above the 5 g threshold is shown to be for personal use; judges must analyse case by case under objective criteria (quantity, time, place, manner) and subjective criteria (farmacodependence, cultural or religious use, professional activity).
• Pleno explicitly disclaims legalisation: Article 477 LGS (simple-possession offence) and Article 479 LGS (dosage table) remain in force; the ruling neither legalises cannabis nor decriminalises possession beyond personal-use cannabis sativa.
  • Process status: remitted to the Primer Tribunal Colegiado del Decimoséptimo Circuito for application to the underlying case; engrose redacts session date pending Semanario Judicial / DOF confirmation.

Senate integral cannabis law stays frozen as civic coalitions deliver formal petition and Mundial 2026 sharpens the pressure. The Sánchez Cordero vehicle — Senate-approved, modified in the Cámara de Diputados and returned to the Senate — remains uncalendarised; civic coalitions frame the inaction as a security, public-health and economic risk ahead of the World Cup.

• 20+ civic organisations — including México Unido Contra la Delincuencia, CEA Justicia Social, Consultoría GEA, Cannabis Libre A.C., Educannabis and Autocultivo Medicinal en México — delivered a formal petition to the Senate on 21 April demanding the integral cannabis bill (use, production, distribution) be retaken.
  • Petition cites the 2018 SCJN libre-desarrollo ruling, three Mexico City tolerance zones and dozens of unregulated cannabis-derivative shops as evidence of structural drift; framed alongside cannabis prevalence at 12.0% (2025) vs 8.6% (2016), a 3.4 pp increase over the decade.
• Diario Jurídico (20 April, Día Internacional de la Marihuana) reports legislators and civil society warning the cannabis law remains stalled ahead of the 2026 FIFA World Cup, contrasting Mexico’s vacuum with Malta (7 g personal possession), Germany, Luxembourg, Switzerland‘s pilot programmes and Uruguay‘s 2013 framework.

Cofepris permits remain the operative access route — ~12,500 over five years, monthly cadence now exceeds the five-year average. Permit issuance continues on an amparo basis, with the regulator denying applications by default and applicants forced into litigation that resolves on SCJN precedent.

• Cofepris has issued ~12,500 personal cannabis-use permits over five years, while Cannabis Libre de Oaxaca records more than 1,000 permit applications per month — the current run-rate exceeds the cumulative five-year average.
  • Cofepris sets cultivation-plant limits discretionally despite the 2021 SCJN declaratoria setting no quantitative cap; Instituto RIA‘s Zara Snapp and 20+ civic groups press Congress for either a Ley General de Salud reform or a dedicated cannabis statute covering production, consumption and sale.
  • Process status: AR 132/2025’s Pleno-level elevation may shorten the amparo path for personal-use cases, but does not alter the Cofepris discretionary regime or establish a regulated commercial supply chain.

🇬🇷 Greece — Draft law lifts THC threshold to 0.3% but bans dried-flower retail; simplifies medical-cannabis export licensing

🔭 On the radar: Public consultation closure and cabinet adoption decision on the draft cannabis-nicotine-tobacco law. If enacted: retail sale, supply, purchase and use of dried cannabis flower banned even within the new 0.3% THC limit; 500 m school-distance rule, regional-administration retail licensing and mandatory digital registry activate; simplified medical-cannabis export-production licensing pathway and reduced fees open; EOF and police enforcement framework with fines up to €100,000 and up to 5 years’ prison comes into force.

🏛️ Regulation — Consultation-stage draft raises THC limit to 0.3%, bans dried-flower retail, eases medical-export licensing

The Greek Health Ministry opened public consultation on a draft cannabis, nicotine and tobacco law that would raise the THC threshold to 0.3% (from 0.2%) while banning retail sale, supply, purchase and use of dried cannabis flower even within the new limit. Cannabis-based foods, cosmetics and supplements would remain permitted under specified conditions. Treat as consultation-stage draft — not enacted.

Medical-cannabis export-production licensing would be simplified with reduced fees; a dedicated retail framework would add a new compliance perimeter. The same draft recasts both the export-oriented production pathway and the domestic retail-licensing regime.

• Medical-cannabis production aimed at export moves onto a simplified licensing pathway with reduced fees, expanding pharmaceutical-export capacity even as the dried-flower retail ban contracts the consumer-flower market.
• Cannabis-product-shop licensing would route through regional administrations under a 500 m school-distance rule and a mandatory digital registry.
• EOF and police run enforcement; penalties for illegal trafficking reach up to €100,000 and up to five years’ imprisonment.

🇲🇰 North Macedonia — BIRN/Balkan Insight investigation extends Feb–Mar 18-licence revocation arc as Skopje prepares EU-aligned legislation

🔭 On the radar: Investigation open: Aleksandar Mijajlovic on the run under international warrant; Ivan Dragnic, Radet and Nebojsa Spasojevic, and Uros Mladenovski in custody. New EU-aligned legislation in preparation per March reporting — no April procedural milestone surfaced. Dragan Krstev trial open in Gevgelija since January 2025. Cross-border cooperation degraded by the replacement of Serbian prosecutor Irina Bjelos.

🏛️ Regulation — BIRN exposes structural oversight failure as Serbian-led scheme uses Alphapharm and Green Life with sub-€15,000 deposits

The 17 April BIRN/Balkan Insight investigation extends the February–March enforcement arc by naming the alleged ringleaders of a cross-border diversion scheme and exposing the structural oversight failure that made it possible — a five-member health-ministry monitoring commission tasked with policing 60+ licensed producers. The Balkan Insight piece casts further doubt on the state’s ability to keep its medicinal cannabis industry in check, ahead of new EU-aligned legislation in preparation.

• Named individuals and process status: Serbian nationals Mijajlovic (international warrant, on the run) and Dragnic (in custody after a Krusevac home search recovered automatic rifles, ammunition and a Zolja RPG); Radet and Nebojsa Spasojevic in custody; Uros Mladenovski arrested in Belgrade with 100 kg of cannabis.
• Mechanics: repeated sub-€15,000 deposits into Alphapharm — below the threshold that triggers suspicious-transaction checks — funnelled licensed Macedonian product into Serbia, where ~5 tonnes were seized near Krusevac (January); the parallel 9-tonne seizure plus 1,300+ bottles of cannabis oil in North Macedonia exposed the supply-side leakage.
• Structural oversight failure: monitoring delegated to a five-member commission under the Ministry of Health; one former member quoted in BIRN’s 2023 investigation: “We are five people; we can’t be everywhere.” No vetting of licence holders in the legal procedure. 2022 Lake Ohrid raids (€5m black-market value) and a 2023 BIRN probe flagged criminal ties without forcing a reckoning.
• Industry context: legalised 2016 under former PM Zoran Zaev, who predicted €250m annual industry value; 60+ licensed producers by 2021. The Krstev case in Gevgelija (under the Law on the Control of Narcotic Drugs and Psychotropic Substances) remains live; he denies wrongdoing.

🇲🇹 Malta — 22 active CHRAs operating under February 2026 tiered stock framework as ARUC–MFA youth-outreach deal draws civil-society scrutiny

🔭 On the radar: ARUC solventless cannabis-resin amendment (CHRAs allowed to produce and distribute resin) — confirmed on 6 May 2026, sits outside the April window and will anchor the May 2026 Malta brief. MCESD employers’ associations and Caritas Malta civil-society pushback on the ARUC–MFA youth-outreach deal — credibility flag rather than rule change. Per-member 7g/day, 50g/month limits and consumption-in-private-spaces rules unchanged.

🏛️ Regulation + 💼 Market — 22 active CHRAs (up from 19) operate under tiered stock rules as ARUC youth-outreach deal draws MCESD and Caritas pushback

Malta’s April footprint is the operating reality of the regulated cannabis harm-reduction association (CHRA) channel under the Feb 2026 amendments to S.L. 628.01/628.02, paired with a credibility flag around ARUC’s public-policy posture. The 🗞️ News DB returned zero April-dated Malta items; the April picture relies on a Phase X-surfaced 12 Apr GrowerIQ recap (operating-reality anchor) and on 31 Mar / 1 Apr civil-society pushback from MCESD and Caritas Malta on the ARUC–Malta Football Association youth-outreach arrangement — surfaced via Phase X gap-scan and positioned as context rather than as canonical April newsroom events.

• Operating reality: 22 active CHRAs as of mid-April (up from 19 in April 2025); under the February 2026 tiered stock rules, 350+ member clubs may now hold 3.5 kg in stock; per-member 7g/day and 50g/month limits unchanged; consumption restricted to private spaces.
• Credibility flag: civil-society and employers’-association pushback on ARUC’s youth-football outreach raises optics questions about the regulator’s harm-reduction education remit — framed as a regulatory-credibility issue rather than a rule change. No enforcement or policy reversal recorded.

🇸🇿 Eswatini — UEDF and police seize 117.13 kg dagga (R700,000) at Boshoek border post (22 Apr) against Q4 2025 cumulative 2,266 kg

🔭 On the radar: No regulatory framework movement documented for Eswatini in April 2026; the picture is enforcement-only and feeds the South Africa-bound smuggling corridor. Eswatini-side regulatory architecture for medical cannabis remains undefined for the purpose of this brief.

🏛️ Regulation — Boshoek border post arrest underlines the structural smuggling corridor into South Africa; UEDF positions itself as the front-line enforcement actor

A 22 April arrest at the Boshoek border post saw UEDF and police detain three individuals — including two Eswatini nationals — in possession of 117.13 kg of dagga valued at R700,000. The event extends a Q4 2025 cumulative UEDF haul of 2,266 kg and positions Boshoek as a recurring smuggling corridor into South Africa.

• Operational frame: single enforcement event, not a regulatory change; no policy reform recorded for the month.

🇰🇪 Kenya — High Court sets 28 May 2026 judgment on Rastafari Society religious-freedom petition against the 1994 NDPSA

🔭 On the radar: High Court judgment date 28 May 2026 on the Rastafari Society petition under Article 32 of the Constitution (freedom of religion); the ruling will set the precedent for whether religious-use exemptions can apply to cannabis under Kenyan law. No regulatory framework movement in April; the country picture is judicial-process-only.

🏛️ Regulation — Rastafari Society petition advances toward 28 May 2026 ruling: first appellate-level test of the 1994 NDPSA on religious-freedom grounds

Kenya’s April footprint is the High Court’s scheduling of a 28 May 2026 judgment on the Rastafari Society religious-freedom petition — a structurally significant May/June 2026 event whose April marker is procedural (court listing) rather than substantive. The petition argues that blanket cannabis criminalisation under the colonial-era Narcotic Drugs and Psychotropic Substances Act (1994) violates Article 32 of the Constitution where the use is religious.

• Process status: hearing date set, judgment pending. Drafting must use forward-looking language and avoid framing as a court ruling or regulatory change.

🇨🇳 China — Zhejiang Gi-biased CB1 agonists in Cell and CsYABBY3↔CsAS1 trichome feedback loop in Advanced Science as bast-fibre imports halve to 44,370 t (-52.2% YoY)

🔭 On the radar: Zhejiang LZD503/505 — IND filings, Phase I, licensing follow-up through 2026. CsYABBY3↔CsAS1 — patent and breeding follow-ups on the engineerable trichome–cannabinoid circuit. Hemp trade quarterly data through 2026; any movement on CBD precursor classification or NMPA cosmetics review. CBD remains banned for domestic use in cosmetics; April produces no domestic regulatory shifts.

🔬 Science — Zhejiang University team publishes Gi-biased CB1 agonists in Cell (LZD503, LZD505) with potent analgesia, no tolerance and no addiction across 7-day dosing in mouse models of acute, inflammatory and neuropathic pain

Zhejiang University’s Li Xiaoming team (with Dong Xiaowu and Zhang Yan) rationally designs CB1 agonists biased toward Gi signalling, decoupling analgesia from the temperature and locomotion side-effects that typically dog non-selective CB1 agonism. The Cell paper00287-4) reports potent analgesia in mouse models of acute, inflammatory and neuropathic pain, with no tolerance, addiction or notable adverse events over 7-day continuous dosing — published in the highest-impact venue for this class of pharmacology.

• Translational read: pre-clinical only; watch for follow-up Phase I/IND filings or licensing announcements through 2026.

A second Chinese-led study in Advanced Science maps a CsYABBY3↔CsAS1 transcriptional feedback loop that couples glandular trichome differentiation to cannabinoid biosynthesis — an engineerable regulatory circuit linking trichome fate to specialised metabolism. The Wiley paper shows CsYABBY3 (FIL/YAB3-family TF) binds a conserved TAATTAA motif in CsPT4 and CsCBDAS promoters; CsAS1 (R2R3-MYB) acts independently and cooperatively; physical association between the two factors is required for full activation.

• Mechanism detail: a single residue (M199 in CsYABBY3) is required for the CsAS1 interaction; comparative evidence suggests broadly conserved FIL/YAB3–AS1 coupling across species.
• Applied read: a practical route to improve cannabinoid yield in cultivars; watch for follow-up patent filings.

💼 Market — China halves bast-fibre imports to 44,370 t in 2025 (-52.16% YoY); France remains dominant supplier at 74.29% share; total bast-fibre exports fall 15.23% to $2.018bn

HempToday’s reading of China’s 2025 bast-fibre trade data signals demand-side weakness in the broader fibre value chain (the category sits wider than pure hemp) even as domestic Chinese planting rose sharply. The HempToday analysis (24 Apr) frames the contraction as volatility in a key global market.

• Trade contour: imports 44,370 t in 2025 vs 92,744 t in 2024 (-52.16% YoY); supplier mix France 74.29% / Belgium 3.26%; US shipments rose 1.75% despite the overall contraction.
• Export side: total Chinese bast-fibre exports fell 15.23% to $2.018bn.
• Caveat: HempToday clarifies the figures sit within a broader bast-fibre category rather than pure hemp; treat the headline as a directional signal on fibre demand rather than a pure-hemp commodity price.

🇦🇹 Austria — BFG overturns customs’ hemp-flower seizure (9 Apr) as 2025 Drug Report flags rising synthetic-cannabinoid contamination

🔭 On the radar: ÖCB (Österreichischer Cannabis-Bundesverband) constitutional challenge to the December 2025 tobacco-monopoly amendment is pending at the Verfassungsgerichtshof (VfGH); transition window for hemp/CBD shops runs to end-2028, with full effect from January 2029. Further BFG/VwGH cases on hemp-flower classification.

🏛️ Regulation — BFG rules vending-machine hemp-flower seizure unlawful, breaking the VwGH line on tobacco-tax treatment

Austria’s April 2026 signal is a judicial brake on the tobacco-monopoly track for smokable hemp: the Bundesfinanzgericht (BFG) overturned a 2025 customs seizure as unlawful, rejecting blanket classification of 0.3% THC hemp under the Tobacco Monopoly Act. The 9 April OTS release frames the decision as reversing momentum from the February 2025 VwGH (Supreme Administrative Court) confirmation that hemp flowers fall under the Tobacco Tax Law (34% tax).

• Industry read: the ruling is cited as central by hemp shops and the ÖCB in challenging the December 2025 amendment that schedules smokable hemp under the tobacco monopoly from January 2029 with a transition window through end-2028. The constitutional challenge is filed at the VfGH.
• Process status: the tobacco-monopoly file is active. Drafting must use forward-looking language on the constitutional challenge (filed, not adjudicated) and on the 2029 effective date (scheduled, with transition).

💼 Market — 2025 Austrian Drug Report frames cannabis as the most-used illicit substance with rising synthetic-cannabinoid contamination on the recreational market

Austria’s 2025 Drug Report anchors the demand-side picture and feeds the harm-reduction angle: 20% lifetime cannabis use, 6% lifetime cocaine, ~39,000 high-risk opioid users, 257 drug deaths in 2024 and 56 Tyrol ICU admissions (2022). The Die Presse coverage flags synthetic-cannabinoid contamination of recreational/illicit cannabis as a rising risk — a public-health concern that connects directly to the BFG / tobacco-monopoly debate (legal-channel quality control vs unregulated supply).

• Cross-DACH+ pairing: the contamination signal pairs naturally with Luxembourg’s MDMB-PINACA finding in vending-machine product (same month) under a Harm reduction / synthetic-cannabinoid contamination sub-cluster in the Monthly Brief.

🇰🇷 South Korea — MAFRA-IPET launches KRW 5.7bn CBD API localisation project as HLB Life Science R&D consortium leads pre-clinical and IND work

🔭 On the radar: HLB Life Science R&D consortium milestones — first IND filings, partner additions, pull-through to KFDA/MFDS-approved products. Quarterly disclosures from HLB Life Science (KOSDAQ: 067630). Whether Korea’s regulator signals any pharmaceutical-CBD lane separate from the consumer-grade narcotic posture over the next 12 months.

🔬 Science — State-backed industrial-policy move: MAFRA-IPET funds CBD-API localisation under the “Agricultural Bio-resource-based National Essential Medicine Raw Material Supply Chain Response Technology Development Project”

South Korea’s April signal is a single, structurally significant move: a national R&D programme to end the country’s import dependency on medical-cannabis raw materials, funded through MAFRA and managed by IPET. The Seoul Economic Daily piece (13 Apr) reports total programme budget KRW 5.7bn (~US$4.2m), with KRW 1.7bn allocated to the HLB Life Science R&D consortium (a subsidiary of HLB Life Science, KOSDAQ: 067630).

• Scope: pre-clinical, CMC and IND work on high-purity CBD APIs; target indications include oncology, anti-inflammatory and dermatology.
• Paradox to preserve: the same Korean regulator that treats CBD as a controlled narcotic for general consumer use is funding pharmaceutical-grade CBD localisation — industrial-policy and pharma signal, not consumer-market liberalisation.

🇱🇺 Luxembourg — MDMB-PINACA detected in vending-machine ‘Silver Haze THCA’ as CBD-shop grey-market retail channel exposes quality-control gap

🔭 On the radar: Health-Ministry follow-up guidance and additional CBD-shop / vending-machine inspections; any move to license retail (today operating in regulatory grey space, distinct from the 2023 personal-cultivation framework). Further synthetic-cannabinoid detections in DACH+ harm-reduction reporting (cross-watch with Austria, Germany, Switzerland).

🏛️ Regulation — MDMB-PINACA coating detected on vending-machine ‘THCA’ product as both THCA and synthetic cannabinoids remain illegal under 2009 narcotics law

Luxembourg’s April signal is a safety-and-quality alarm in the unregulated CBD/”THCA” retail channel: lab tests on a product labelled “Silver Haze THCA” — purchased from a vending machine in a central Luxembourg City CBD shop — revealed it was CBD flower coated with the synthetic cannabinoid MDMB-PINACA, a compound 50–100× stronger than natural THC. The RTL Today report documents the health-ministry’s confirmation that both THCA and synthetic cannabinoids are illegal under Luxembourg law.

• Health risk profile: documented effects of MDMB-PINACA include severe nausea, sudden blood-pressure drops, seizures, panic attacks and acute psychiatric symptoms — well beyond the natural-THC risk envelope and routinely undetectable to consumers expecting a “legal cannabis” product.
• Structural gap exposed: Luxembourg’s 2023 reform legalised personal possession (3 g) and home cultivation (4 plants) but established no licensed retail channel. The THCA-as-grey-market workaround thrives in this regulatory vacuum, and is now the locus of public-health risk rather than the cultivated personal-use channel.
• Cross-section pairing: read alongside the same-month Austrian 2025 Drug Report finding of rising synthetic-cannabinoid contamination, the two member-state datapoints make the DACH+ public-health narrative concrete and warrant a Harm reduction / synthetic-cannabinoid contamination sub-cluster in the April Monthly Brief.
• Follow-up RTL Today framing: subsequent coverage flags the rising European trend, suggesting the Luxembourg detection is one of several rather than an isolated case.

🇧🇪 Belgium — Flanders industrial-hemp area up ~8× over a decade (67.57 → 540.96 ha) as Cretes flags multi-stream design as fibre viability gate

🔭 On the radar: Federal medicines and health-products bill 56K1488 (submitted 23 April 2026) — flagged via Phase X gap-scan, pending textual review for cannabis-relevance before ingestion. Belgian regime remains pharmaceutical-cannabinoid only: medicinal access is restricted to magistral CBD preparations on prescription; HHC is pharmacy-only; recreational remains prohibited.

💼 Market — Hemp acreage acceleration meets supply-side discipline as multi-stream valorisation becomes viability gate

Flemish industrial-hemp acreage scaled from 67.57 ha in 2015 to 540.96 ha in 2025 — roughly an 8× expansion over a decade — with most of the growth landing post-2023 on the back of biodiversity-friendly crop support. The Agentschap Landbouw en Zeevisserij figures frame hemp as agronomically advantageous (deep roots, drought tolerance vs flax) but commercially constrained by marketing/offtake certainty.

• Process changes for 2026: registration moves fully digital via the annual verzamelaanvraag (deadline 31 May); seed-certification submission deadline 30 June; Finola 2 banned after two consecutive THC-threshold exceedances.
• Legal frame: only EU-certified varieties with THC ≤ 0.3% authorised; harvest and harvest residues cannot be used for human consumption without explicit FAGG or FAVV authorisation; cultivation data is shared with federal police.
• Subnational scope: the cultivation series is Flanders-specific; the figures should not be generalised to all of Belgium.

Cretes’ Alex Teodorescu argues fibre projects only become viable when designed from day one for multi-stream valorisation — current few-hundred-kg/h throughputs are insufficient for industrial economics. The HempToday interview reframes hemp’s supply-side maturity gap as one of repeatable consistency, not feasibility: textile-grade quality is achievable in isolated batches but rarely sustained across daily industrial runs.

• Demand-side framing: strongest business cases pair textiles with paper, nonwovens, composites, construction materials and shives valorisation — single-output textile economics rarely close on their own.
• Feedstock discipline as the bottleneck: retting quality, moisture control, baling density and contamination drive line-level outcomes; bales that look identical externally can behave very differently in opening, cleaning and yield.
• European relevance: Cretes’ commentary applies across the bast-fibre value chain rather than to Belgian operators specifically — Flanders expansion (demand) pairs with processing-design discipline (conversion constraint) as a single value-chain narrative.

🇧🇼 Botswana — Cannabis Regulations 2026 gazetted but Act 2025 awaits presidential assent; 500 kg Gantsi seizure underlines enforcement gap

🔭 On the radar: Cannabis Bill 2025 awaiting presidential assent and formal commencement — no published date. Cannabis Regulations 2026 (gazetted 12 January 2026) activation contingent on Act commencement. BITC/NARDI hemp pilot → commercial-scale rollout at Dibete pending pilot completion. Future framework explicitly excludes recreational/adult-use; restricted to medicinal, scientific, research and industrial purposes.

🏛️ Regulation — Illicit Trafficking Act still governs as January 2026 NCCA licensing architecture sits dormant

Botswana’s headline April 2026 development is a process-status correction: the Cannabis Bill 2025, passed by Parliament in August 2025, still awaits presidential assent — the country is not yet legally operating a regulated cannabis industry. The Ngami Times brief (20 Apr, by Bhekinkosi Phiri) clarifies that the Illicit Trafficking and Narcotic Drugs and Psychotropic Substances Act continues to govern, illustrated by the April Gantsi case in which police seized roughly 500 kg of suspected dagga at a farm near Gantsi; a Zimbabwean national was charged at the Gantsi Magistrate Court with unlawful cultivation and possession.

• Once commenced, scope: medicinal, scientific, research and industrial — recreational use will remain prohibited; home growing, casual sale and personal possession outside the licensing system will remain criminal.

The Cannabis Regulations 2026 set out the NCCA licensing architecture in detail: DIS intelligence vetting, Botswana Police Service criminal-record checks, mandatory 24-hour surveillance, enclosed transport compartments and proof-of-funding requirements — preparing a system the Act has not yet activated. The Cannabiz Africa fee analysis frames the cost structure as one of the most tightly regulated and expensive in the region.

• Fee disparity by applicant type: cultivation P3,325/ha for citizens vs P6,981 for joint ventures vs P8,310 for non-citizens; processing/manufacturing P150,000–P400,000/year; transportation P13,000–P56,000/year; import/export P16,000/year for citizens. Breach fines up to P250,000 or five years imprisonment.
• Critique: the cost regime risks favouring well-capitalised multinationals over local applicants — local farmers risk remaining at the bottom of the value chain even after Act commencement.

💼 Market — BITC visit to NARDI hemp pilot marks first commercial-track milestone with Dibete land allocated for scale-up

The Botswana Investment and Trade Centre’s first publicly documented site visit to the NARDI-hosted hemp pilot is the country’s first commercial-track milestone, moving the programme from licensing/policy headlines into operational territory. The Ecofin Agency tour (22 Apr, by Cynthia Ebot Takang) frames hemp as part of Botswana’s diversification beyond diamonds.

• Operational footprint: two BITC-backed companies hold licences and have launched pilots in partnership with NARDI and Botswana University of Agriculture and Natural Resources (BUAN); Dibete land allocated for large-scale cultivation with site preparation ongoing; hemp production cycles ~3 months per cycle.
• Demand backdrop: Ecofin cites industry estimates of the global legal cannabis market projected >US$50bn by 2030, anchored on expanding medical applications and regulatory liberalisation; CBD flagged as a key derivative across pharmaceuticals, food processing and wellness products.
• Investor-pipeline signal: BITC framing itself as facilitator across licensing → land → operations is consistent with its investment-promotion mandate, but the public visibility of cannabis-sector engagement is new. Identity of the two licensees not disclosed in source; Dibete site size, ownership and offtake destination also unspecified.

🇨🇷 Costa Rica — UNED study finds lifetime cannabis use up 2.2pp to 19.9% as 73.7% of seizures stay sub-1 g

🔭 On the radar: Bill 23.383 (Ley de control y regulación del cannabis para uso recreativo) under Asamblea Legislativa debate; Law 10113 medical-cannabis and industrial-hemp regime remains operational with recreational use still prohibited.

🔬 Science — UNED study frames use-without-acceptance tension as enforcement falls on consumers

Costa Rica’s first systematic empirical readout of the consumption side since Law 10113 finds cannabis use rose 2.2 percentage points between 2015 and 2022 (lifetime 19.9%, past-month 4.4%), with 73.7% of police seizures under 1 g — consumption-scale rather than trafficking-scale, yet 74.9% of the population still reject recreational legalisation. The UNED Police Sciences study (Roberto Salas Sánchez, Acontecer UNED, 27 Apr) anchors the demand-side picture feeding the Bill 23.383 debate.

• Demand growth: 19.9% lifetime use, 4.4% past-month; among secondary-school students annual cannabis incidence reached 2.9% in 2021, rising to 8.8% in 12th grade.
• Enforcement geometry: 73.7% of seizures fall in the 0.01–1 g band; Salas Sánchez frames criminalisation as falling on consumers while the illegal market continues to grow; 911 logs 2,000+ drug-related calls per month (~74/day).
• Public-opinion ceiling: 74.9% reject free recreational access; acceptance rises sharply for medical (64.3%) and scientific (61.1%) uses; in 2023 IAFA-authorised NGOs assisted 2,705 people for substance use, of whom only 9.6% for cannabis vs 45% for alcohol.
• Policy framing: UNED’s Karen Jiménez Morales argues regulation does not itself reduce violence (other-drug trafficking persists) but enables product-quality assurance — relevant given documented fentanyl adulteration in regional illicit markets — and earmarks revenue for prevention, treatment and organised-crime enforcement.

🇩🇰 Denmark — Politiken orders cannabis joint via Wolt in 28 minutes, exposing unregulated retail channel

🔭 On the radar: Possible Lægemiddelstyrelsen (DKMA) or consumer-protection response to mainstream-app cannabis listings; clarification on which cannabis-product categories are eligible for delivery platforms; broader Danish policy posture on the unregulated legal-cannabis retail channel.

💼 Market — Mainstream delivery apps normalise unregulated cannabis retail

A Politiken reporter ordered a joint via Wolt in central Copenhagen and received it 28 minutes later from a delivery rider on Rådhuspladsen — turning a long-standing legal grey area into a visible mainstream-app retail channel. The Politiken Edition piece (28 Apr, by Laurits Lauesen Otto) reports experts warning strongly against consumption while Wolt says sales fall within Danish law.

• Near-food-delivery convenience (28 minutes) makes the consumer experience indistinguishable from any other Wolt order — a structural shift even if the underlying legal status is unchanged.
• Expert warnings centre on consumer harm despite the legality claim; the channel’s surfacing exposes gaps in product regulation and quality control rather than a new policy event.

🇮🇷 Iran — Cancer-survivorship meta-analysis (Shiraz-tagged) finds lower past-30-day cannabis use than non-cancer populations

🔭 On the radar: Cannabis remains illegal in Iran (medical and recreational); no April policy event surfaced. Country relevance for this brief is research-of-interest (Shiraz-tagged co-authorship), not domestic programme news. Geopolitical Iran×US-cannabis supply-chain stories from the Hormuz cluster belong in the US brief, not here.

🔬 Science — Springer/BMC meta-analysis finds modestly lower past-30-day use in cancer survivors

A peer-reviewed systematic review and meta-analysis in Archives of Public Health (Springer/BMC) finds cancer survivors use cannabis at rates broadly comparable to non-cancer populations, with modestly lower past-30-day use, and authors call for open, evidence-based counselling on benefits, risks and safe use within survivorship care. The pooled analysis, co-authored with a Shiraz-tagged affiliation (likely Shiraz University of Medical Sciences), is the only Iran-tagged cannabis item in the April window.

• Headline finding: lower odds of past-30-day (recent) cannabis use among cancer survivors vs non-cancer populations.
• Null findings: no statistically significant differences for current, past-year or lifetime cannabis use.
• Clinical implication: authors frame survivorship-care guidance — not legal status — as the next clinical lever, calling for open counselling rather than avoidance.

🇵🇰 Pakistan — Menthol–thymol deep eutectic solvent outperforms conventional solvents for cannabinoid recovery from cannabis leaf

🔭 On the radar: CCRA implementation regulations under the Cannabis Control & Regulatory Authority Act 2024, the cabinet-approved National Cannabis Control & Regulatory Policy 2025, the CCRA Amendment Bill 2026 and KP licence-fee changes — all pre-April milestones, all watched for next-phase Q2/Q3 implementation. No April regulatory or market events surfaced.

🔬 Science — Peer-reviewed MDPI study validates natural deep eutectic solvent for cannabis-leaf valorisation

Researchers report that a hydrophobic deep eutectic solvent built from menthol and thymol (1:1 molar ratio) delivers superior recovery of cannabinoids and phenolic compounds from cannabis leaf compared with conventional organic solvents. The MDPI study (International Journal of Molecular Sciences, April 2026; DOI 10.3390/ijms27072933) frames the result as a practical valorisation route for a leaf-biomass fraction typically composted or discarded.

• Performance signal: HDES-extracted fractions show higher concentrations of target cannabinoids and phenolics — a preferential affinity for lipophilic compound classes vs the reference solvent panel.
• Why it matters for Pakistan’s pipeline: the solvent is built from natural, GRAS-status components (menthol, thymol), so it is compatible with food- and pharma-grade applications — directly usable by the licensed industrial-hemp and medical-cannabis processors that Pakistan’s CCRA framework is set up to authorise.
• Country tagging caveat: Pakistani institutional affiliation among the authors is not explicitly confirmed in the abstract; downstream verification would strengthen the country tag.

🇵🇾 Paraguay — 17 licensed firms (4–5 active) and US$10–15m exports anchor maturing industry as Nueva Alianza 54 destroys 291 t cannabis

🔭 On the radar: CCIP bill to raise the hemp THC limit — in progress, treat as watch-item. DINAVISA medicinal-cannabis tightening (Harbourview, 16 Apr) and lot-recall communications — pending primary-source confirmation. Nueva Alianza 55 timing is the next enforcement watch-item (cadence ~1 major operation per quarter). SUMMIT 420 Edición 2026 ran 22 Apr.

💼 Market — Cámara reports 17 licensed firms, US$10–15m of 2025 exports and Brazil as growth target

Marcelo Demp, president of the Cámara de Cannabis Industrial del Paraguay, used 4/20 to release the first structural readout for the country’s licensed industry: 17 firms on the registry, 4–5 actively operating, 2025 exports of US$10–15m, and 180+ approved products spanning pain creams, sublingual droppers, THC formulations on prescription, cosmetics, foods, supplements, veterinary products and phytotherapeutics. The InfoNegocios interview frames the sector as primarily medical, anchored on Brazil’s adjacent demand.

• Regulatory enabler: DINAVISA‘s December 2025 advance allowing medical cannabis under medical supervision, protocols and sanitary controls — expanded scope beyond CBD to include THC-containing therapeutic formulations with official traceability.
• Brazil thesis: Paraguay’s 2017-vintage regulatory framework gives it a head start over Brazil, which is only now advancing cultivation, genetics and agronomic trials. Demp: “Brazil is just beginning processes Paraguay has already gone through. That lets us position ourselves as legal suppliers of finished products.”
• Foreign-firm interest: Brazilian and at least two Argentine companies are evaluating Paraguayan operations; the attraction is the combination of an active regulatory framework, banking access, legal certainty and export conditions.
• Active vs licensed gap: 17 licensed but only 4–5 active makes Paraguay licensing-rich and execution-constrained.

🏛️ Regulation — Nueva Alianza 54 destroys 291 t cannabis and 95 ha across Canindéyú in 10 days

The 21 April conclusion of Nueva Alianza 54 inflicted an estimated US$43.5m loss on cross-border criminal structures, dismantled seven narco camps in the Morombi Natural Reserve / Pindó / 7 Montes corridor, and incinerated 6,300 kg of processed marijuana destined for the São Paulo–Rio distribution chain. The Rio Times account frames cumulative eradication at 44,000+ tonnes since the 2017 framework launch, with 4,500 t destroyed in 2025 alone across five operational phases.

• Operational architecture: SENAD coordinated with the Polícia Federal do Brasil, Fuerza Aérea Paraguaya (helicopter platform) and Ministerio Público. The valuation is wholesale-cost capital destruction; Brazilian street-value would run roughly three times higher.
• Shared-responsibility framing (producer Paraguay + consumer Brazil) and the Peña administration‘s Plan Paraguay Seguro / Operación Bosques envelope keep the operation politically sustainable across both administrations.
• Illicit-market track, kept separate from the licensed-industry narrative — Paraguay’s legal cannabis footprint is not the source.

🇵🇪 Peru — Futura Farms presses MIDAGRI for Law 32195 hemp rules as Sativa Info shows only 18,837 of 55,000+ medical patients access formal supply

🔭 On the radar: MIDAGRI hemp reglamento for Law 32195 (Dec 2024) — public consultation closed Nov 2025; industry asks for silencio administrativo positivo and a 2027 commercial start. DIGEMID licence base (18 Mar 2026) to monitor: 2 active labs, 44 active pharmacies, 34 importer/distributor licences. 2026 election cycle will set cannabis-policy continuity.

🏛️ Regulation — Hemp reglamento still unpublished as medical track stays blocked by municipal-licence bottleneck

April produced no new published cannabis regulation, licence award or judicial ruling in Peru, but two complementary opinion-analytical pieces sharpened the country’s two-track implementation gap: Raúl Injoque (business-development director, Futura Farms) writing in El Reporte on the unfinished Law 32195 industrial-hemp reglamento, and Jorge Paucar Albino writing in Sativa Info on 4/20 with the first hard official figures on medical-cannabis access under Laws 30681 (2017) and 31312 (2021).

Futura Farms calls on MIDAGRI to issue the Law 32195 implementing reglamento with silencio administrativo positivo so processing CAPEX can land before a 2027 commercial start. The El Reporte op-ed (11 Apr) frames hemp as a multi-output crop — 2 t long fibre, 4 t hurd, ~1 t seed and up to 10 t dry biomass per hectare over a 120-day cycle — with downstream applications in hempcrete, textiles, paper/cellulose, nutrition, cosmetics and phytoremediation.

• Public consultation on the reglamento ran 22 Aug – Nov 2025; constant turnover of MIDAGRI political appointees has stalled publication.
• Adoption of silencio administrativo positivo is the specific procedural ask: deemed-approval after fixed timeframes would eliminate discretionary delay and unlock processing CAPEX.

Sativa Info quantifies the medical-access shortfall: 55,000+ registered patients but only 18,837 (~34%) buying through authorised channels, against a DIGEMID base of just 2 active labs and 44 active pharmacies. The 4/20 column reports DIGEMID’s 18 Mar 2026 licence base: 2 active labs producing derivatives, 1 active artisanal-production association, 45 authorised pharmacies/boticas (44 active), and 34 importer/distributor labs and droguerías concentrated in Lima.

• The binding bottleneck is the municipal operating-licence prerequisite for a Dirandro security certificate (required to advance to the LPA artisanal cultivation route under Law 31312). Municipalities lack recognised technical competence over medical cannabis yet block formalisation; Asociación Ámbar has flagged this in observations to MINSA and MININTER since 2021–2023.
• Continued criminalisation persists despite the MINJUSDH position that self-cultivation for personal use should not be treated as a crime and that hemp below 1% THC is not a controlled substance.
• Carry-over friction from the El Reporte piece: complex import rules, limited DIGEMID institutional-pharmacy supply, and prescriber reluctance route demand away from the legal channel.

🇷🇸 Serbia — BIRN traces Belgrade as cross-border hub for Serbian-led ring diverting Macedonian medical cannabis

🔭 On the radar: Medical and recreational cannabis remain illegal in Serbia; the April story is enforcement/investigative, not policy. Aleksandar Mijajlovic on the run under international warrant; Ivan Dragnic, Radet and Nebojsa Spasojevic, and Uros Mladenovski in custody; cooperation with North Macedonia complicated by the replacement of Serbian prosecutor Irina Bjelos.

🏛️ Regulation — BIRN investigation traces Alphapharm and Green Life as conduits for diverted Macedonian cannabis

A 17 April BIRN/Balkan Insight investigation positions Belgrade as the demand-side endpoint of a regional medical-cannabis diversion ring, with Serbian buyers linked to corporate-fronted leakage from North Macedonia’s licensed industry. The Balkan Insight report by Vlado Apostolov, Jelena Veljkovic and Besar Likmeta documents the mechanics, the named individuals and the structural-oversight failure that made the scheme possible.

• Mechanics: ~€15,000 deposits per diverted shipment into Alphapharm — sub-threshold for suspicious-transaction triggers, and consistent across repeated transactions per North Macedonia’s central business registry.
• Serbia-side seizures: ~5 tonnes of cannabis seized near Krusevac (January 2026); additional 100 kg recovered from Mladenovski’s Belgrade arrest. Weapons cache (automatic rifles, ammunition, a Zolja RPG) recovered from Dragnic’s Krusevac home.
• Regional spillover context: parallel 9-tonne seizure in North Macedonia plus 1,300+ bottles of cannabis oil; the licensed Macedonian industry (~€250m projected by former PM Zoran Zaev, 60+ licensed producers) is leaking into adjacent illegal markets, with Serbia (where medical cannabis remains illegal) the primary endpoint.
• Investigation outlook: Serbian Prosecutor’s Office for Organised Crime tells BIRN that cooperation has been “complicated” by the replacement of prosecutor Irina Bjelos. North Macedonian police have not ruled out activities extending to other European countries.
• Attribution note: the €250m and 60-licence figures belong to North Macedonia, not Serbia, and should be used only as supply-side context.

🇸🇽 Sint Maarten — NNCSXM presents cannabis legalisation framework to CAFAH projecting $25m Y1 revenue and 400+ jobs

🔭 On the radar: CAFAH committee review ongoing; legislation drafting and implementation timing still in scoping under NNCSXM (RFP awarded September 2022). Open design questions: banking-access architecture, EU-GMP export ambition with French Caribbean (St-Martin, St-Barts, Martinique, Guadeloupe) as nearer-term targets, and Caribbean regional export-hub framing.

🏛️ Regulation — NNCSXM proposes illicit-to-regulated transition with licensing, banking compliance and farmer participation

Native Nations Cannabis SXM (NNCSXM) representative Clifton Brown presented the proposed legalisation framework to Parliament’s Committee for Agriculture, Fishing and Animal Husbandry (CAFAH) on 9 April 2026 (reported 13 April), setting out a single bill covering medicinal, scientific, recreational and religious use. The Daily Herald account frames the proposal as capturing existing demand rather than creating new consumption — moving an entrenched illicit market into a controlled, transparent, taxable system.

• Regulatory pillars: licensing; product standards (THC limits, child-resistant packaging, warning labels); public-health education; banking compliance (formal-system operation, AML alignment); farmer participation via land-access and licensing pathways; tax revenue earmarked for mental-health services and substance-abuse programmes.
• Economic projections (NNCSXM estimates, not realised data): ~$25m projected Y1 government revenue / $149m over 5 years; 400+ direct jobs at ~$52k average; 47 business licences including hemp-adjacent verticals (clothing, cosmetics, industrial hemp). Tourism modelled at ~28% of demand; the remainder reflects local consumption transitioning from informal to regulated channels.
• Cultivation model: hybrid approach balancing efficiency with international-grade standards while including small-scale farmers — positioning local agriculture as a core beneficiary rather than a peripheral participant.
• Policy anchoring: the framework stems from the 2020–2024 government programme and economic recovery plan, in which cannabis is listed as one of six targeted tourism export sectors.

🇸🇮 Slovenia — Adult-use bill 2293-IX still in National Assembly procedure as Marihuana Marš revives 2024 referendum mandate

🔭 On the radar: National Assembly progress on adult-use bill 2293-IX (Zakon o konoplji za omejeno osebno uporabo); DZ President’s 13 April procedural letter; JAZMP secondary legislation under the medical act, whose 6-month bylaw deadline fell in February 2026.

🏛️ Regulation — 2024 referendum mandate unimplemented as bill 2293-IX awaits Assembly progress

The 9 June 2024 four-question referendum produced majority support for cannabis reform (51.57% personal use, 67% patient self-cultivation, 52% general adult possession), yet adult-use bill 2293-IX has been in National Assembly procedure since July 2025 with no committee reading outcome in April. DZ President procedural correspondence dated 13 April 2026 is the only public movement, while the annual Marihuana Marš (Ljubljana, 23 April) framed the country as “closer than ever to comprehensive cannabis regulation”.

• Medical track in force: Medical & Scientific Cannabis Act (ZKMZN) entered into force 20 August 2025; the 6-month bylaw window ran out in February 2026 with no commencement milestone surfacing in April.
• Adult-use track stalled: bill 2293-IX remains the procedural vehicle but produced no committee reading outcome in April; civil-society pressure (Marihuana Marš) is the only public lever currently moving.
• European comparator framing: Slovenia is typically grouped with Germany, Czechia, Malta and Luxembourg in personal-use comparators and positioned as a next-likely entrant pending 2293-IX.

🇦🇪 UAE — Hemp framework operational since 1 January 2026; April produces no qualifying cannabis-industry news

🔭 On the radar: Emirates Drug Establishment (EDE) implementing regulations under the Federal Decree-Law on industrial hemp, expected over Q2 2026; first licensed medical-hemp product approvals; any cosmetic-THC-concentration cabinet resolution; cultivation-zone licences; clarifications on hemp-derived medical-product import/export via UAE pharmaceutical channels.

🏛️ Regulation — Hemp framework awaits implementing regulations as April activity stays in narcotics-enforcement lane

The Federal Decree-Law regulating industrial and medical uses of industrial hemp (issued October 2025, in force 1 January 2026) remains the structural anchor for UAE cannabis coverage, but produced no April amendments, implementing regulations or licensing announcements. No qualifying cannabis-industry items appeared in the April window.

• Narcotics-enforcement signal (context, not industry news): UAE authorities reported a Dh3.3m drug plot foiled on 29 April with 13 arrests linked to a Bahrain-based kingpin in a joint UAE–Bahrain–Dubai–Sharjah operation; Daniel Kinahan was arrested in UAE on 17 April in connection with organised crime and drug trafficking.
• Adjacent industry signal (not cannabis-specific): EDE presence at Make it in the Emirates 2026 (29 April) covered the pharmaceutical industry broadly and did not target cannabis.

🇿🇲 Zambia — Cannabis Control Authority offers Ghana help cutting US$45,000/ha licence fees and US$2/km transport surcharges

🔭 On the radar: Whether NACOC (Ghana) formally accepts the Zambian offer; ZCCA institutional build-out as Zambia’s apex cannabis institution. Cannabiz Africa‘s pending “Cannabis integrated into Zambia’s public-health system” piece — if dated in April it would override the current cornerstone; flagged for ingestion. Recreational use remains illegal in Zambia.

🏛️ Regulation — ZCCA’s Dr Prosper Sievu offers Ghana technical assistance on farmer-friendly licensing design

Zambia’s newly formed Cannabis Control Authority used a Cheeba Africa webinar to position itself as a regional regulatory exporter, offering Ghana help redesigning its cannabis licensing regime to be farmer-friendly. The Cannabiz Africa account frames the offer as a response to a plea from Nana Kwaku Agyemang, CEO of the Hempire Association of Ghana (HAG), who argued that Ghana’s cost regime locks out smallholders in favour of multinationals.

• Ghanaian cost barriers the offer targets (per Agyemang): ~US$45,000/ha cultivation licence fee; US$2/km transport surcharge with two armed NACOC guards required per shipment; published January 2026 and now under Supreme Court challenge by farmer Mariam Alhassan on constitutional-beneficiary grounds.
• Zambia’s own model on display: small-scale farmer participation; Zambian Defence Force and traditional leaders pledging land for sustainable hemp farming; a stated pivot from export-only toward domestic medical-cannabis research and integration into the public-health system under Dr Sievu’s stewardship.
• Pan-African endorsements: Lameck Nthlekela (Hemp Innovations Botswana) and Trenton Birch (Cheeba Africa) also pledged support for the Ghanaian initiative.
• South African counterpoint (context): Cian McLelland (SACHIDA / Druids Garden) flagged Africa’s patchwork regulatory framework as the binding obstacle — a hemp superfood co-developed with the CSIR and Gauteng government funding remains blocked from school feeding schemes.
• Process framing: the news is Zambia’s posture toward Ghana, not a Zambian licensing reform announcement; the 2021 Cannabis Act baseline and the 2025 ZNS cultivation authorisation remain context, not April events.